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Cutaneous melanoma is associated with significant morbidity and mortality 
representing the most significant cutaneous malignancy.  As it is known that early 
diagnosis and treatment are the most efficient approaches to cure cutaneous 
melanoma, an improved understanding of the molecular pathogenesis of melanoma 
and exploration of more reliable molecular biomarkers are particularly essential. Two 
different types of molecular biomarker for melanoma have been investigated in this 
thesis. 
 
microRNAs (miRNAs) are single-stranded RNA molecules of 20-23 nucleotides in 
length that are found in both animal and plant cells. miRNAs are involved in the 
RNA interference (RNAi) machinery to regulate gene expression 
posttranscriptionally. miRNAs have important roles in cancer: by controlling the 
expression level of their target genes they can affect cell signalling pathways and 
have been shown to have both prognostic and therapeutic potential. Importantly for 
melanoma research, reproducible miRNA expression profiles from formalin-fixed 
paraffin-embedded (FFPE) tissues can be obtained that are comparable to those from 
fresh-frozen samples.  
 
The aims of the miRNA project were: first, to identify a melanoma-specific miRNA 
expression profile; secondly, to investigate roles of some of the melanoma-specific 
miRNAs identified in melanomagenesis. Using miRNA microarray on FFPE 
samples, I obtained a melanoma-specific miRNA expression profile. 9 of these 
differentially expressed miRNAs between benign naevi and melanomas (7 
downregulated, 2 upregulated in malignancies) were verified by qRT-PCR and the 
functions of four of these miRNAs were studied. Ectopic overexpression of miR-
200c and miR-205 in A375 melanoma cells inhibited colony forming ability in 
methylcellulose, an in vitro surrogate assay for tumourigenicity. Moreover, elevation 
of miR-200c resulted in increased expression levels of E-cadherin through negative 
regulation of the zinc finger E-box-binding homeobox 2 (ZEB2) gene. Ectopic 
overexpression of miR-211 in A375 melanoma cells repressed both colony formation 
 
xv 
in methylcellulose and migratory ability in matrigel, an in vitro surrogate assay for 
invasiveness. These findings indicate that miR-200c, miR-205 and miR-211 act as 
tumour suppressors in melanomagenesis. 
 
The second biomarker investigated, mutated BRAF, has been seen in 50-70% of 
spontaneous cutaneous melanoma. The commonest mutation in melanoma is a 
glutamic acid for valine substitution at position 600 (V600E). Oncogenic BRAF 
controls many aspects of melanoma cell biology. The aim of this part of the work 
was: firstly, to study BRAF V600E mutation status in our melanoma tissue 
microarray (TMA) panel; secondly, to correlate this mutation to various clinico-
pathological features and evaluate its prognostic value through statistical analyses. 
BRAF V600E mutations were seen in 20% of the primary and 69% of the metastatic 
melanomas, respectively. More BRAF V600E mutations were seen in males relative 
to females. The mutation was also related to cell pigmentation, but not to age, 
ulceration or solar elastosis. Melanoma patients with the BRAF V600E mutation 
relapse earlier than patients without this mutation. However, no significant 
association between the BRAF V600E mutation and overall survival and melanoma 
specific survival was found. 
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Chapter 1: Introduction 2 
1.1 Cutaneous melanoma 
 
Melanoma is a malignant tumour of melanocytes, which are pigment producing cells 
found predominantly in skin. Melanoma is one of the rare types of skin cancer, but 
causes the majority of skin cancer related deaths. The underlying mechanism of 
transformation of melanocytes to melanoma is a complex biological process 
involving a large number of genetic and environmental factors.  
 
 
1.1.1 Introduction to melanocytes and effects of ultraviolet radiation 
 
The skin of all mammals is pigmented, and while the intensity and hue of this 
pigmentation may vary with genetic and environmental factors, in all cases it results 
from the accumulation of heterogeneous polycyclic polymers known as melanins. 
The capacity to synthesize these compounds is restricted to ~5% of skin cells that 
have a common embryological origin and a distinct morphology and are thus 
considered to be a unique cell-type: the melanocytes [1]. During embryonic 
development, an epithelial- mesenchymal transition (EMT) involving epithelial cells 
of the neuroectoderm gives rise to migratory neural crest cells [2]. Neural crest cells 
(NCCs) are a transient, multipotent migratory cell population and are unique to 
vertebrates. The premigratory neural crest cells dissociate from the neural folds, 
become motile, and disperse to the different parts of the embryo, where they undergo 
further differentiation that gives rise to diverse cell lineages including melanocytes, 
craniofacial cartilage and bone, smooth muscle, peripheral and enteric neurons and 
glia. Melanocytes differentiate from their precursor cells—melanoblasts within the 
neural crest. By week 8 in utero, human melanocytes begin to migrate first to the 
dermis, and hence, to the stratum basale of the epidermis. Alternative paths also lead 
them to hair follicles or to the uveal tract of the eye and the retina. Melanocytes are 
relatively large, clear, dendritic cells that lack tonofilaments and desmosomes. They 
are distinguishable by their many dense, membrane-bound, spherical or ovoid 
organelles called melanosomes, occurring throughout the cytoplasm and associated 
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with a microtubule network extending into the dendritic arms. In some melanocytes, 
the melanosomes remain static within the cell. In other types of melanocyte, the cell 
can extend its surface as long pseudopodia carrying melanosomes away from the 
centre of the cell and increasing the cell's effectiveness in absorbing light. This 
extension happens slowly in dermal melanocytes in response to ultraviolet radiation 
(UVR) as well as in the production of new melanosomes and increased “donation” of 
melanosomes to adjacent keratinocytes. Keratinocytes may engulf the end of the 
melanocyte pseudopodia, which contains many melanosomes. Cytoplasmic dynein 
will carry the vesicles containing the melanin to the centre of the cell. This causes 
melanosomes to become sequestered around the keratinocyte's nucleus, providing 
optimal protection from UVR. 
 
The skin relies on melanocytes to provide photoprotection and thermoregulation by 
producing melanin. There are two main types of melanin: yellow/red pheomelanin 
and brown/black eumelanin [3]. Both types of melanin derive from a common 
tyrosinase-dependent pathway with the same precursor, tyrosine. Individual 
melanocytes can produce both types of melanin with the ratio dependent on the 
expression of pigment enzymes and the availability of tyrosine and sulphydral-
containing reducing agents in the cell [4]. Eumelanin is found in hair, areola, and 
skin, and colours hair grey, black, and brown. In humans, it is more abundant in 
people with dark skin. Pheomelanin is also found in hair and skin and is present in 
both lighter-skinned and darker skinned humans. Pheomelanin imparts a pink to red 
hue and, is found in particularly large quantities in red hair and freckled populations. 
Eumelanin and pheomelanin differ not only chemically but also in their physical 
properties. Pheomelanin is less efficient at protecting the skin against UVR-induced 
DNA damage. When UV irradiated, pheomelanin also produces more free radicals 
than those produced by eumelanin [5, 6]. Moreover, pheomelanin pigments have 
been suggested to enhance intrinsic DNA damage in cells, particularly in response to 
UVR [7, 8]. Therefore, pheomelanin may actually contribute to UV-induced skin 
damage rather than merely produce less protection against UVR [5, 6].  
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The melanocortin 1 receptor (MC1R), also known as melanocyte-stimulating 
hormone receptor (MSHR), melanin-activating peptide receptor, or melanotropin 
receptor, is a G protein-coupled receptor which binds to a class of pituitary peptide 
hormones known as the melanocortins, which include adrenocorticotropic hormone 
(ACTH) and the different forms of melanocyte-stimulating hormone (MSH). MC1R 
is one of the key proteins involved in regulating mammalian skin and hair colour. It 
is located on the plasma membrane of melanocytes. It works by controlling the type 
of melanin being produced and its activation causes the melanocyte to switch from 
generating the yellow/red pheomelanin by default to the brown/black eumelanin. 
When activated by one of the variants of MSH, typically α-MSH, MC1R initiates a 
complex signalling cascade that leads to the production of the brown/black pigment 
eumelanin. In contrast, the receptor can also be antagonized by agouti signalling 
peptide (ASIP), which reverts the cell back to producing the yellow/red pheomelanin. 
MC1R is a conserved and representative locus and major determinant of pigment 
phenotype [9]. MC1R variants are found related to increased risk of melanoma and 
non-melanoma skin cancer, independently of skin pigment [7, 10].  
 
Although melanin absorbs much UVR, melanocytes can survive considerable 
genotoxic stress from UVR-induced DNA damage through DNA repair, by which a 
cell identifies and corrects damage to the DNA molecules that encode its genome. A 
cell that has accumulated a large amount of DNA damage, or one that no longer 
effectively repairs damage incurred to its DNA, can enter one of three possible 
states: senescence, apoptosis and unregulated cell division—carcinogenesis. 
Absorption of UVR produces two predominant types of DNA damage, cyclobutane 
pyrimidine dimers (CPD) and pyrimidine (6-4) pyrimidone photoproducts (6-4PP). 
Unrepaired UV-induced DNA damage can lead to transition mutations of cytidine-
thymidine (C-T) and CC-TT [11], which are the most frequent mutations of p53 in 
both human and mouse skin cancers [12]. After UV exposure, cells activate p53 and 
stall the cell cycle for repair [13, 14]. If the damage is too severe, the cell will trigger 
apoptosis to get rid of a DNA damaged, potentially mutant cell [15]. The UVB-
induced DNA lesions, CPD and 6-4PP, show differential biological effects with 
respect to the induction of apoptosis and cell cycle arrest. It was suggested that the 6-
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4 PP lesion is more potent in the induction of UV-induced apoptosis while the CPD 
lesion appears to be more potent in the induction of cell cycle arrest [16]. Moreover, 
You et al. have documented that CPD lesions account for the majority of UV-
induced mutations in mammalian cells. The more potent apoptosis-inducing activity 
of 6-4PP lesions may induce apoptosis and eradicate the damaged cell, thus 
removing its carcinogenic potential [17]. 
 
Nucleotide excision repair (NER) is one of the major repair systems for removal of 
DNA lesions. The NER pathway mainly repairs UV-induced DNA damage, and is 
also active against a broad range of endogenously generated oxidative lesions [18, 
19]. Physiologically, the NER pathway excises damaged nucleotides, along with 
adjacent undamaged DNA. Studies on the human inherited disease, xeroderma 
pigmentosum (XP) identified NER deficiency as a dramatic genetic risk factor for 
melanoma [20], and NER-deficient XP patients develop numerous skin cancers 
under UV exposure, including a 2000-fold higher incidence of melanoma and non-
melanoma skin cancer as compared to repair-proficient individuals [21, 22]. 
 
UVR causes genetic changes in the skin, impairs cutaneous immune function, 
increases the local production of growth factors, and induces the formation of DNA-
damaging reactive oxygen species that influence keratinocytes and melanocytes [23, 
24]. The initial detection of genomic damage that occurs within the melanocytes is 
termed direct sensitivity to DNA damage, while a response that is elicited from the 
melanocyte via paracrine messaging is indirect sensitivity. In response to UVR, 
keratinocytes produce larger amounts of endothelin-1 (ET1), α-MSH, and nitric 
oxide (NO). The first stimulates nearby melanocytes to proliferate, and all three 
stimulate melanogenesis [25-27]. NO also reduces the adhesion of melanocytes to 
the extracellular matrix, an effect that may bear on the increased dendriticity seen, 
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1.1.2 Melanoma epidemiology, classification, aetiology, and prevention  
 
The incidence of cutaneous melanoma has continued to increase over the last 30 
years in most white populations [29, 30]. In the UK in 2008, almost 11,800 cases of 
malignant melanoma were diagnosed and melanoma is the 6th most common cancer 
overall in the UK [31]. Within the UK, Scotland has the highest melanoma 
incidence, surpassing incidence rates in the US. Unlike most cancers, melanoma has 
a tendency for presentation at younger ages and is now the second most common 
malignancy in young people aged 15-34 in the UK [32]. 
 
The mean age of presentation with melanoma is about 55 years, but this may vary 
according to melanoma thickness and histological subtype [33]. Cutaneous 
melanoma is usually divided into four clinico-pathological subtypes: Acral 
melanoma (AM), Lentigo maligna melanoma (LMM), Nodular melanoma (NM) and 
Superficial spreading melanoma (SSM) [34]. AM tends to be found on the palms of 
the hands, the soles of the feet and in the nail bed and is not associated with UV 
exposure. NM and LMM tend to affect older individuals, whereas SSM, is by far the 
commonest form, is usually thinner and seen in younger individuals. The most 
common sites for women and men are the legs and the trunk, respectively. Site 
differences according to sex are likely to reflect genetic differences as naevi are also 
differently distributed between boys and girls from an early age [35]. 
 
The major risks for cutaneous melanoma are thought to be the interplay between the 
key environmental factor—sun exposure and genetic factors. To date, the risk factors 
have been identified as: history and pattern of sun exposure, hair and skin colour, 
multiple naevi, family history and hormonal factors.  
 
Sunlight exposure represents the key environmental factor as described by the higher 
incidence of melanoma in Australia and other sunny parts of the US and Europe [30]. 
Interestingly, a meta-analysis of melanoma case-control studies found low relative 
risks associated with various measures of exposure to UVR, and the relation to 
sunshine was not dose dependent [36]. In contrast to non-melanoma skin cancer 
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which is linked to total lifetime sun exposure, melanoma development is most 
closely associated with intense, intermittent sun exposure [37]. Epidemiologic 
observations suggest that chronic or low-grade exposures to UV induce protection 
against DNA damage, whereas intense and intermittent exposures cause genetic 
damage [24]. Moreover, the incidence of sunburn during early childhood is 
particularly important [36]. Likewise, the link between sunbed usage and melanoma 
is controversial [38-41]. However, it is recommended to avoid sunbed use to protect 
against premature skin aging [41].  
 
Light-skinned and red haired individuals exhibit higher risk of developing melanoma 
than those with darker skin and hair. Polymorphisms in the MC1R gene have been 
linked to fair skin and red hair and have been associated with an increased risk of 
melanoma [42, 43].   
 
Moreover, it is found that an individual who has more than 100 common naevi or 
more than two atypical naevi has a 5-fold to 20-fold increased risk of melanoma [44], 
indicating that a most powerful genetic risk factor for melanoma is the number of 
naevi. 5% to 10% of melanoma patients have family history [45] and about 25%-
40% of all families with melanoma have been linked to mutations in the cyclin-
dependent kinase inhibitor, CDKN2A, gene on chromosome 9p21 [46].  
 
Interestingly, women usually have thinner tumours and survive melanoma better than 
men even after adjustment for Breslow thickness (also Breslow depth, see Page 8) 
ulceration, and body site, which suggests that there may be X linked variable gene 
expression or hormonal factors affecting melanoma survival [45].  
 
In the 1980’s, health education campaigns aimed at primary prevention for 
melanoma by reducing sun exposure to people commenced in Australia and were 
soon adopted worldwide. There is as yet no direct evidence showing that reducing 
sun exposure has an effect on melanoma incidence. On the contrary, drastic 
reduction of sun exposure may be detrimental since it can prevent synthesis of 
adequate levels of vitamin D in the skin, which protects against inflammation, 
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cancer, psychiatric and autoimmune diseases [45]. So an important message for 
preventing melanoma would be to avoid sunburn and excessive sun exposure without 
protection instead of keeping away from the sun altogether. More importantly, 
secondary prevention—early identification and treatment, is a more efficient way, as 
tumours are highly visible with a good prognosis if detected early [45]. 
 
 
1.1.3 Melanoma diagnosis and staging 
 
Guidelines written by Roberts et al. suggested that suspicious melanocytic lesions 
should be excised completely, with a clinical margin of 2mm of normal skin and a 
cuff of fat [47] so that accurate pathological diagnosis can be made from the 
examination of the entire lesion.  
 
Primary melanoma staging is based on the histological features of the lesion. 
Accurate staging allows more precise classification, determines more appropriate 
treatment and improves the accuracy of predicting the likely prognosis and outcomes 
for melanoma patients. The updated American Joint Committee of Cancer (AJCC) 
staging (2010, 7th edition) for cutaneous melanoma (Table 1.1) considers localized 
melanoma, tumour thickness, the microscopic ulceration and rate of mitoses [48]. 
Breslow depth, used for describing tumour thickness, is used as a prognostic factor in 
melanoma of the skin (Also discussed in Chapter 1.1.4). It is a description of how 
deeply tumour cells have invaded. It is one of the cornerstones of the current AJCC 
TNM staging of malignant melanoma. A large study validated the importance of 
Breslow depth as one of the three most important prognostic factors in melanoma 
(the others being T stage and ulceration) [49]. Breslow depth is also used to predict 
the risk for lymph node metastasis, with deeper tumours being more likely to involve 
the nodes [50]. Ulceration is found in 20-25% of all melanomas and is more 
commonly seen in male patients. Mitotic rate was examined for the first time in the 
new staging system [48]. The Melanoma Staging Committee recommended that 
mitotic rate be determined by the “hot spot” approach and expressed as the number 
of mitoses per mm2 of primary tumour [48].  
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Classification Breslow Thickness Ulceration Status/Mitoses 
T   
   Tis N/A N/A 
   T1 ≤ 1.00 a: without ulceration and mitosis < 1/mm2 
b: with ulceration or mitosis ≥ 1/mm2 
   T2 1.01-2.00 a: without ulceration 
b: with ulceration 
   T3 2.01-4.00 a: without ulceration 
b: with ulceration 
   T4 > 4.00 a: without ulceration 
b: with ulceration 
N No. of  Metastatic Nodes Nodal  Metastatic Burden 
   N0 0 N/A 
   N1 1 a: Micrometastasis 
b: Macrometastasis 
   N2 2-3 a: Micrometastasis 
b: Macrometastasis 
c: In transit metastases 
/satellites with metastatic nodes 
   N3 
 
4+ metastatic nodes,  
Matted nodes,  
In transit metastases 
/satellites with metastatic nodes 
 
M Site Serum LDH 
   M0 No distant metastases N/A 




   M1b Lung metastases Normal 
   M1c All other visceral metastases 
Any distant metastases 
Normal 
Elevated 
Table 1.1 AJCC TNM staging system 7th edition (2010): TNM categories. N/A: Not applicable. 
Micrometastasis: Diagnosed after sentinel lymph node biopsy. Macrometastasis: Defined as clinically 
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There are some differences between the 6th (2002) edition and the 7th (2010) edition 
of the melanoma staging system. Comparisons in staging for localized melanoma 
(Stage I/ II), recommendations for using primary melanoma thickness and primary 
tumour ulceration in TNM categories and stage groupings in the 7th edition remain 
unchanged. Mitotic rate is first used in the new staging system. Multiple thresholds 
of mitotic rate were identified and the most significant correlation with survival was 
at a threshold of at least 1/mm2 [48]. Data from the AJCC Melanoma Staging 
Database showed a highly significant correlation between increasing mitotic rate and 
declining survival rates. In a multifactorial analysis of 10,233 patients with clinically 
localized melanoma, mitotic rate was the second most powerful predictor of survival, 
after tumour thickness [48]. In staging for regional metastatic melanoma (stage III), 
immunohistochemical (IHC) detection of micrometastases is included in the new 
system as it is considered acceptable to classify nodal metastases solely on the basis 
of IHC staining of melanoma-associated markers (HMB-45, Melan-A/MART1). 
Finally, in staging for distant metastatic melanoma (stage IV), the updated AJCC 
staging system demonstrated that an elevated serum lactate dehydrogenase (LDH) 
level is an independent and highly significant outcome predictor for stage IV disease. 
A precise staging system is very important in melanoma diagnosis and prognosis 
since it determines any following treatment. The current overall survival rates for 
melanoma patients at the different TNM stages are shown in Table 1.2. 
	  
Stage TNM Classification 5 Year OS (%) 10 Year OS (%) 


























IV Any T any N M1a-1c 9.5 6.0 
 
Table 1.2 AJCC TNM stages with 5 year and 10 year overall survival rates of melanoma 
patients.  OS: Overall survival. Adapted from [49, 51]. 
 
 
1.1.4 Diagnostic and prognostic markers in melanoma  
 
Histological examination of skin biopsies is still the gold standard for melanoma 
diagnosis [52]. However, it is a challenging task largely due to the wide 
morphological spectrum of cutaneous melanocytic tumours and lack of firm 
diagnostic criteria. In a recent study, there was only 55% agreement for difficult 
melanocytic lesions between two experts with significant, high level disagreement in 
25% cases [53]. Under or over diagnosis can result in therapy failure or unnecessary 
melanoma treatment and large medical expenses.  
 
The clinical prognostic markers identified so far include anatomical site, gender and 
age. Tumours located on the trunk, head or neck tend to be thicker indicating poorer 
outcomes. Survival rates are generally higher for females and the young. These 
clinical markers offer only rough prognostic estimation. The histological markers 
include depth of invasion and ulceration. Depth of invasion (Clark level) and tumour 
thickness (Breslow depth) are the most important parameters in melanoma prognosis. 
The Clark level describes how far a melanoma has penetrated into the skin. The 
Clark level of a melanoma uses a scale of I to V (with higher numbers indicating a 
deeper melanoma). The Breslow system is divided into four thickness integers: < 
1mm, 1-2mm, 2-4mm, >4mm. Generally, the lower the Clark level and the thinner 
the melanoma is, the better the prognosis. It is found that much of the rise in 
melanoma incidence can be attributed to very thin melanoma lesions or melanomas 
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in situ, neither of which are easily diagnosed [45]. Moreover, the Clark level is no 
longer recommended as a staging criterion in the 7th AJCC staging system and has 
prognostic significance only in patients with very thin (Breslow depth <1 mm) 
melanomas [48]. No molecular biomarker is used in the 7th edition staging system. 
 
Few biomarkers have been proven to have clinical significance in melanoma. 
Proliferation markers, such as Mindbomb homolog 1 (MIB-1) and Cyclin D1 
(CCND1), and tumour suppressors, such as p16INK4A and p53, as well as anti-
apoptotic proteins, such as Bcl-2, have been applied in the clinical setting [52]. 
However, these biomarkers have prognostic value rather than diagnostic benefit as 
abnormalities of these proteins are seen only in a subset of melanomas and are most 
pronounced only in advanced melanoma. Moreover, although most recently, the 
presence of specific gene copy number changes or mutations have proved useful in 
distinguishing between certain benign lesions and their malignant equivalents (e.g. 
Spitz naevi from spitzoid melanoma by 7p gain and HRAS mutation), no single 
genetic change has been informative over a wide range of lesion types [54]. 
Moreover, studies with such techniques are limited in their clinical application as 
they are technically challenging, costly and reliable interpretation requires 
experience and skill. 
 
There is an urgent need for molecular biomarkers to assist histological diagnosis and 
provide accurate prognosis. To be clinically useful, these markers need to be 
technically easy and readily available for use on formalin-fixed and paraffin-
embedded (FFPE) tissue using routine methods, such as immunohistochemistry 
(IHC) or in situ hybridization (ISH), which allow high throughput analysis.  
 
 
1.1.5 Melanoma management 
 
1.1.5.1 Sentinel lymph node biopsy 
 
Sentinel lymph node biopsy is used in the staging of certain types of cancer to see if 
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they have spread to any lymph nodes, since lymph node metastasis is one of the most 
important prognostic signs. The procedure offers powerful prognostic information. 
Microscopic lymph node involvement is becoming an integral part of the AJCC 
staging system [55]. The AJCC Melanoma Staging Committee recommends that 
sentinel lymph node biopsy be performed as a staging procedure in patients for 
whom the information will be useful in planning subsequent treatments and follow-
up regimens [48].  
 
 
1.1.5.2 Current treatment 
 
Treatment of melanoma that has not spread beyond the original area of growth 
(especially if it is thin and has not invaded the primary dermis) is highly effective, 
and most of these cancers can be cured mainly by surgery. However, therapy for 
distant metastatic melanoma is usually unsatisfactory, reinforcing the importance of 
early diagnosis and therapy. 
 
By bearing in mind the clinical examination rules: Asymmetry of a lesion, Border 
irregularity, Colour change and Diameter greater than 6mm, also called the ABCD 
system of diagnosis [56], most melanomas can be identified from normal moles. 
Standard treatment for early melanoma (Stage I) patients is to remove the tumour 
tissue locally with or without wide local excision depending on the substage. 
 
For medium melanoma (Stage II and III) patients with high risk of recurrence and 
distant metastatic potential, adjuvant treatments, a combination of surgery, 
chemo/radiotherapy and biological treatment, increase the chance of cure. However, 
the only drug that has been shown reproducibly to have some effect on patient 
outcome in large randomised trials is high dose intravenous interferon-α [57]. 
Preliminary results of the European Organisation for Research and Treatment of 
Cancer (EORTC) showed a significant improvement in relapse-free survival but not 
in distant metastasis-free survival or overall survival by interferon-α treatment for 
stage III melanoma patients [58]. There is currently no accepted standard adjuvant 
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treatment in the UK including high dose of interferon, so melanoma patients are 
referred instead to enter into clinical trials [59].  
 
In the UK, only 7 to 19% patients whose melanoma has spread to distant lymph 
nodes or other parts of the body will live for more than 5 years [60]. Patients with 
metastases have a median survival of 6-9 months [55]. The treatment for these 
advanced melanoma (Stage IV) patients is inefficient. So far, no intervention has 
been shown to have significant effect on overall survival for these metastatic 
melanoma patients. Darcarbazine and high dose interleukin-2 (HD-IL2) are the only 
drugs approved by the Food and Drug Administration (FDA) in treating metastatic 
melanoma patients [61]. However, the clinical response rates are only ~10% and 
~16%, respectively and both have high toxicity [62, 63]. The combinatorial 
approaches, including multiagent chemotherapy and bio/chemotherapy regimens, 
have failed to improve outcomes for advanced melanoma patients [64]. Surgery is 
used for treatment of local recurrences and for metastatic disease in regional lymph 
nodes and can also be helpful for patients with surgically resectable disease in up to 3 
visceral sites. 
 
Advances in understanding the molecular pathology of melanoma and in 
immunotherapeutics therefore provide hope for future enhancements in the treatment 




1.1.6 Genetic and environmental interactions in melanoma progression 
 
Although the tanning response to UVR appears dose-dependent, the nature of the 
exposure is also a factor that is relevant to induction of cutaneous melanoma. It has 
been interpreted that chronic and low-grade exposures to UVR induce protection 
against DNA damage, whereas intense, intermittent exposures causes genetic 
changes in melanoma pathogenesis [24].  The Clark model describes the histological 
changes that accompany the progression from normal melanocytes to malignant 
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melanoma [65], although it is losing its prognostic value. To better illustrate the 
alterations in molecular and environmental interactions, I show the Clark model 
along with the phenotypic and relevant molecular changes (Figure 1.1). Through 
Figure 1.1 it is clear that different biological activities and several key genetic 
changes occur relative to individual phases of the Clark model. The following 
discussions will focus on some of the key genes involved and their signalling 
pathways. Figure 1.3 (see Page 24) is a simple map of the key regulators and 
signalling pathways involved in melanomagenesis that offers a guide to the 
signalling networks of melanoma. 
 
 
1.1.6.1 Mutations in the MAPK pathway 
 
In the Clark model, the first phenotypic alteration in melanocytes is the development 
of benign naevi (Figure 1.1). The growth control in this stage is disrupted but growth 
of naevi is also limited—a naevus rarely develops to cancer [65]. Most naevi are 
growth arrested and express many markers of senescence. BRAF mutations (see next 
paragraphs) are often already present in benign naevi. These activated oncogenes are 
thought to trigger senescence (oncogene-induced senescence) [66]. The oncogene-
induced senescence is probably the reason for the absence of progression from 
naevus to melanoma [67].  
 
The RAS/RAF/MEK/ERK (the mitogen-activated protein kinase, MAPK) pathway 
regulates most important biological programmes, including proliferation, 
differentiation, angiogenesis and cell survival. In physiological situations, the MAPK 
pathway is stimulated after the interaction of growth factors with surface receptors 
and the transmission of these signals through the small GTPase, RAS [68]. RAS 
activates a number of downstream effectors, one of which is the RAF family of 
serine/threonine kinases. There are three isoforms of RAF, namely, ARAF, BRAF 
and CRAF. Once activated, RAF stimulates the MAPK cascade, resulting in the 
sequential activation of MEK1 and MEK2, which in turn activate ERK1 and ERK2 
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[69, 70]. The activated ERKs finally stimulate cytoplasmic targets or migrate to the 
nucleus, where they phosphorylate transcription factors. 
 
In most melanoma cells, the situation is different. It has been shown that >90% of 
melanoma specimens have continuous hyperactivity of the MAPK pathway [71]. It is 
activated mainly by oncogenic mutations, although factors such as other autocrine 
growth factor stimulation [72], or N-cadherin (Neural-cadherin)-based homotypic 
cell-cell adhesion [73] can also be involved. The first such oncogenic mutation found 
to activate the MAPK pathway in melanoma was in NRAS [74]. Mutations have 
been identified in 15-25% of all melanomas [75] and most commonly result from 
substitution of leucine to glutamine at position 61 [76, 77]. The most common 
mutation to be reported in melanoma is in BRAF [77]. Although the reported 
frequency of the mutation varies in different studies, it seems that at least 60% of all 
melanomas harbour the BRAF mutation, which activates the MAPK pathway [78]. It 
has been identified that there are over 50 distinct mutations in BRAF [79]. Of these, 
the BRAF V600E mutation, a valine to glutamic acid substitution, is the most 
common and accounts for 80% of all reported BRAF mutations [77, 80].  
 
Unlimited proliferation and apoptosis resistance are the two best-characterized roles 
for MAPK signalling in melanoma (Figure 1.2, Page 19). Constitutive MAPK 
activity enhances cyclin D1 and downregulates p27 expression in melanoma cells 
[81]. A pharmacological study showed that inhibition of either MEK or BRAF in 
melanoma cell lines led to a profound G1-phase cell cycle arrest. Moreover, 
constitutive MAPK activation can suppress apoptosis through the release of 
Smac/DIABLO from mitochondria [82] and through the ribosomal S6 kinase-
mediated inactivation of the pro-apoptotic protein BAD [83]. More recent 
experiments have shown that the BRAF V600E mutation can decrease the levels of 
the pro-apoptotic Bcl-2 family member, BIM through a MAPK-mediated mechanism 
[84].  
 
The constitutive MAPK activity is also involved in melanoma cell metastasis through 
activation of angiogenesis, adhesion disruption and immunosuppression. The 
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activated MAPK pathway may regulate angiogenesis through the control of hypoxia 
inducible factor -1α (HIF-1α) expression [85]. In addition, downregulation of V600E 
BRAF with small-interfering RNA (siRNA) resulted in significant reduction of 
vascular endothelial growth factor (VEGF) produced by melanoma cells, implicating 
that melanoma-associated angiogenesis is partially mediated by the MAPK pathway. 
There is also evidence that BRAF/MAPK signalling activity may contribute to 
metastasis of melanoma through regulating ß3 integrins and matrix metalloproteinase 
expression [86-89]. Finally, it has also been suggested that BRAF/MAPK may allow 
melanoma cells to escape from immune surveillance through suppression of their 
highly immunogenic melanocytic antigens, including Melan-A/Melanoma antigen 
recognised by T cells (MART-1), gp-100 and tyrosinase [90].  
 
 
Figure 1.1 The Clark model along with the relevant biological events and molecular changes in 
melanoma progression. CDKN2A: Cyclin-dependent kinase inhibitor 2A. PTEN: Phosphatase and 
tensin homologue. CD1: Cluster of differentiation 1. MMP-2: Matrix metalloproteinase 2. TRPM1: 
Melastatin 1. Adapted from [91].  
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1.1.6.2 PI3K/AKT pathway 
 
Besides activation of the MAPK pathway, other signalling pathways may be equally 
important in melanoma progression. The phosphoinositide 3-kinase (PI3K)/ protein 
kinase B (PKB/AKT) pathway is one of the widely explored signalling pathways [92, 
93]. PI3K plays a crucial role in effecting alterations in a broad range of cellular 
functions in response to extracellular signals. A key downstream effector of PI3K is 
the serine-threonine kinase AKT, which in response to PI3K activation, 
phosphorylates and regulates the activity of a number of targets including kinases, 
transcription factors and other regulatory molecules. Activation of the PI3K/AKT 
pathway in melanoma is induced through either paracrine/autocrine growth factors, 
or the loss of expression and/or mutation of negative pathway regulators. This 
subsequently affects cell proliferation and apoptosis and intersects with the MAPK 
pathway [78] (Figure 1.2). For example, the insulin-like growth factor-1 is known to 
stimulate growth of early-stage melanoma cells, at least partially through activating 
PI3K/AKT pathway.  
 
One of the most vital regulators of AKT is the phosphatase and tensin homolog 
(PTEN). The PTEN locus on chromosome 10 is a second chromosomal region that is 
frequently affected by homozygous deletion in melanoma and other cancers [94-96]. 
In physiological situations, PTEN can prevent AKT activation through degrading the 
products of PI3K. Although how the PI3K pathway is activated in melanoma is not 
fully understood, loss of expression and function of PTEN and PTEN mutation 
activate AKT. Loss of PTEN expression occurs in up to 30% of melanoma cell lines 
and 10% of melanoma tissues [97].  
 
There are three AKT members, AKT1-3 [98]. Different AKT members exhibit 
different expression levels dependent on the cell type. 43-50% of melanomas have 
selective constitutive activity of AKT3 [92]. AKT has critical roles in cancer 
development in regulating apoptosis through the inhibition of BAD (pro-apoptotic 
protein) and increasing cell proliferation by elevating CCND1 expression, and 
activating the mammalian target of rapamycin (mTOR) pathway [78, 99, 100]. 
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Stimulation of the mTOR pathway leads to increased protein translation and cell 
proliferation [78]. Moreover, AKT effects many other pathways including the 
stimulation of ribosomal S6 kinase, the suppression of forkhead signalling, and 
inhibition of glycogen synthase kinase-3 (GSK3) [101, 102]. Other studies 
demonstrated that AKT transformed melanocytes under hypoxic conditions through 
the Notch signalling [103, 104]. 
 
A                                                                     B 
       
Figure 1.2 Intersected functions of MAPK and PI3K signalling pathways. A, In regulating cell 
proliferation; B, In regulating apoptosis. Adapted from [78]. 
 
 
1.1.6.3 MITF and melanocyte differentiation 
 
Clark proposed that many naevi could regress through differentiation and that the 
failure of this differentiation is necessary for dysplasia [65]. The microphthalmia-
associated transcription factor (MITF) is the key regulator in the development and 
differentiation of melanocytes [105] and maintains melanocyte progenitor cells in 
adults [106, 107]. However, the relationship between MITF and melanoma 
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development is complex. 
 
On the one hand, MITF contributes to melanocyte differentiation by triggering cell 
cycle exit through induction of the cell cycle inhibitors p16INK4a and p21Cip [108, 
109]. High levels of MITF have differentiation and anti-proliferation functions in 
melanoma cells, while low levels of MITF are found in invasive melanoma cells 
[110, 111]. All the above evidence suggests that MITF must be downregulated for 
melanoma progression. 
	  
On the other hand, MITF contributes to melanocyte survival by increasing the 
expression of an anti-apoptotic gene, Bcl-2 [112] and cyclin-dependent kinase 2 
(CDK2) [113]. In animal models, deficiencies of both MITF and Bcl-2 caused grey 
hair because of a loss of differentiated melanocytes. The loss of melanocytes is due 
to the apoptosis of melanocyte progenitor cells in the hair follicles [106]. In a 
melanoma cell study, it was found that survival of malignant melanocytes was 
dependent on Bcl-2 as decreased Bcl-2 induced cell death. Moreover, MITF also 
functions in melanocyte pigmentation. α-MSH induced intracellular signalling via 
MC1R subsequently elevates MITF expression, which in turn increases the 
transcription of genes underlying melanin synthesis [114]. Furthermore, the MITF 
gene is amplified in 10–15% of melanomas in which BRAF is mutated and 
overexpression of both MITF and BRAF could transform primary cultures of human 
melanocytes, indicating that MITF is an oncogene [115]. These studies support the 
view that continued expression of MITF is essential in melanoma cells. 
 
Marais’ group proposed that in melanoma cells oncogenic BRAF exerts exquisite 
control over MITF on two levels: oncogenic BRAF downregulates MITF protein by 
targeting it for degradation in an ERK-dependent manner and then counteracts this 
by elevating MITF transcription through an octamer-binding transcription factor 
BRN2-dependent manner [116]. Through these opposing mechanisms, oncogenic 
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1.1.6.4 Cell adhesion and invasion 
 
In the Clark model, invasion commences in the vertical-growth phase when 
melanoma cells grow intradermally as an expanding nodule (Figure 1.1). Whereas, 
when tumour cells dissociate from the primary lesion, migrate through the 
surrounding stroma, and invade blood vessels and lymphatics to form a tumour at a 
distant site, the tumour is then called metastatic melanoma [117]. Apparently, the 
formation of metastatic melanoma is also related to environmental alterations 
surrounding primary melanoma cells. Cell adhesion is one of the major 
environmental processes. Normally, it controls cell migration, tissue organization, 
and organogenesis [118]. Disturbances in cell adhesion contribute to tumour 
invasion, tumour-stroma interactions and tumour-cell signalling. Cadherins and 
integrins are the most important structural protein superfamilies involved in cell 
adhesion.  
 
Cadherins (named for "calcium-dependent adhesion") are a class of type-1 
transmembrane proteins that sustain cell-to cell contacts, form connections with the 
actin cytoskeleton, and influence intracellular signalling. The extracellular domain of 
cadherins binds to like cadherins on other cells in regions of cell contact called 
adhesion junctions. There are three subtypes of cadherins, N-cadherin (Neural-
cadherin), E-cadherin (Epithelial-cadherin) and P-cadherin (Placental-cadherin). The 
intracellular domain is associated with a larger protein complex that includes ß-
catenin and forms structural links with bundles of actin filaments. Progression from 
radial-growth phase to vertical-growth phase of melanoma is marked by the loss of 
E-cadherin and presence of N-cadherin [119, 120]. Additionally, besides the changes 
in cell adhesion, decreased E-cadherin expression and aberrant N-cadherin 
expression increase the survival of melanoma cells by stimulating ß-catenin 
signalling [73, 121, 122].  
 
The integrins are the cell membrane receptors of extracellular matrix (ECM) proteins. 
Transition from radial to vertical-growth of melanoma is related to the expression of 
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αVß3 integrin [123], which induces expression of matrix metalloproteinase 2, an 
enzyme that degrades the collagen in basement membrane [124-126]. 
 
 
1.1.6.5 Other genes and signalling networks involved in melanoma 
 
CDKN2A (also called p16) is a tumour suppressor protein, which in humans is 
encoded by the CDKN2A gene. CDKN2A plays an important role in regulating the 
cell cycle, and mutations in CDKN2A increase the risk of developing a variety of 
cancers, especially melanoma. This gene generates several transcript variants, which 
differ in their first exons. Alternative splicing of various exons within CDKN2A 
produces two distinct tumour suppressors: INK4A and alternate reading frame 
protein (ARF, also called p14). These tumour suppressor proteins p16INK4A and 
p14ARF are encoded by overlapping frames at the CDKN2A locus on chromosome 
9p21. p16INK4A (an inhibitor of CDK4) blocks the cell cycle at the G1-S checkpoint 
by inhibiting cyclin-dependent kinases, suppressing the proliferation of cells with 
damaged DNA or activated oncogenes [127]. p14ARF acts as a tumour suppressor by 
restraining the cell cycle or promoting cell death after DNA damage or aberrant 
proliferation stimulated by various oncogenes. ARF participates in the key regulatory 
process that controls the p53 protein level. Moreover, the studies done in vitro and in 
vivo also suggest the low frequency of p53 mutations observed in melanoma is a 
consequence of the frequent loss of CDKN2A (and ARF) [128-130], which 
inactivates the p53 pathway [127]. 
 
In some melanoma samples with a low prevalence of BRAF mutation, DNA copy 
number gains and mutations in c-KIT gene were characterized [131]. c-KIT, a 
transmembrane tyrosine growth factor receptor, acts on a downstream signalling 
cascade leading to key intracellular signals that control cellular proliferation and 
survival. Three crucial pathways, MAPK, PI3K and STAT signalling, were initiated 
by KIT activation [132]. c-KIT mutation frequency is very high in gastrointestinal 
stromal tumours (GIST). In melanoma, c-KIT mutations were identified in 17% of 
chronic sun-damaged cutaneous, 11% of acral and 21% of mucosal melanomas 
 
Chapter 1: Introduction 23 
[131]. In addition, KIT gene amplification was found in 6% of chronic sun-damaged, 
7% of acral lentiginous and 8% of mucosal melanomas. In vitro studies demonstrated 
that point mutations of c-KIT resulted in activation of c-KIT protein in melanoma 
cells and therefore stimulated downstream proliferation and pro-survival signalling 
pathways [132, 133]. 
 
Melanomas also exhibit constitutive activity in multiple other pathways, including 
nuclear factor kappa B (NF- κB), Src, Janus kinase/signal transducer and activator of 
transcription (JAK/STAT3), Wnt, Hedgehog and Notch [134-137]. Although most 
studies have focused on the role of individual signalling pathways, these different 
pathways in melanoma comprise a highly interconnected network. Multiple feedback 
loops in the intercrossed network would increase the difficulty in treatment of 
melanoma as inhibition of one pathway may activate a parallel pathway. For 
example, inhibition of mTOR leads to a rebound increase in the MAPK pathway 
through a PI3K-mediated mechanism [138]. These reciprocal interactions between 
the signalling pathways active in melanoma require strongly combined targeted 
therapy strategies. 
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1.1.7 Prospects for new therapies 
 
Given the continuous rising incidence of cutaneous melanoma and inefficient 
conventional treatments, especially for advanced and recurrent melanoma patients, a 
wide range of studies are trying to find better molecular biomarkers and novel 
therapeutic strategies. Cancer treatment is entering into a “targeted therapy” era and 
this approach has shown extraordinary clinical benefits in several cancers. Specific 
kinase inhibitors are now used as the standard treatments for chronic myelogenous 
leukaemia, HER2/neu-amplified breast cancer, clear-cell renal cell carcinoma and 
GIST [139]. However, the precondition to the success of using these approaches is 
dependent on the identification of genetic aberrations in these diseases. 
Accumulating evidence showed melanoma harbours genetic changes in key protein 
kinase signalling pathways.   
 
Sorafenib is a small molecule inhibitor of tyrosine kinase receptors, including wild 
type BRAF, V600E BRAF and CRAF. Sorafenib inhibited the growth and survival 
of BRAF-mutant human melanoma cells and slowed down the growth of melanoma 
xenografts [140]. However, a randomized Phase III trial of sorafenib did not increase 
the clinical response or disease control rate achieved by the chemotherapy agents 
alone [141], although a nonrandomized trial of sorafenib in combination with 
paclitaxel and carboplatin showed promising activity, with 26% clinical response rate 
[142]. More excitingly, a V600E-mutant-specific BRAF inhibitor, PLX4032, shows 
great effects on BRAF V600E positive melanoma patients. In the dose escalation 
portion of the Phase I clinical trial in metastatic melanoma, 56% of patients with the 
BRAF V600E mutation had a partial response and an additional 31% had a minor 
response. No responses were seen in patients without a BRAF V600E mutation 
[142]. Preliminary results from a dose expansion cohort of an extra 31 patients with 
V600E-mutant BRAF reported that 70% achieved a clinical response [143].  
 
There are also several case reports of individual melanoma patients with c-KIT 
mutations who have achieved remarkable clinical responses to c-KIT small molecule 
inhibitors, such as imatinib, sorafenib and dasatinib [144-147].  For example, 
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imatinib showed a 50% clinical response rate among 10 melanoma patients with c-
KIT mutations, but in none of the 10 patients with c-KIT amplification of the wild 
type gene [143].  
 
The promising results with PLX4032 and c-KIT inhibitors in melanoma patients with 
BRAF and c-KIT mutations, respectively, add to the growing list of successful 
clinical strategies targeting specific activating genetic events in cancer. Although 
such studies to date have focused on the treatment of advanced melanoma, in the 
future these molecular insights may lead to improved early diagnosis of the disease. 
Personalized strategies of targeted therapies are likely the hope for melanoma 
patients. Moreover, a novel class of non-coding genes—microRNAs (miRNAs), are 
becoming a “hotspot” for cancer research including melanoma (Chapter 1.2). 
Numerous studies have shown their potential not only act as biomarkers, but they 
also play an important role in cancer therapy, including anti-drug resistance which is 





1.2.1 General introduction to non-coding genes 
 
Over the past decade an explosion in the number of genome-wide studies has 
challenged the traditional view that most genes are protein-coding. Although 
counter-intuitive it is now clear that the number of protein-coding genes of humans 
and mice are close to those in the 1mm long Caenorhabditis elegans (C. elegans), 
and that all multicellular organisms have fewer protein-coding genes than some 
simple unicellar eukaryotes [148]. An explanation for the apparent paradox involves 
non-protein-coding genes: whilst only 2% of the mammalian genome encodes 
mRNAs the vast majority of the genome is transcribed as short and long non-coding 
RNAs (ncRNAs) which contribute to biological complexity [149]. In the expanding 
RNA world, the importance of thousands of regulatory ncRNAs including miRNAs, 
small interfering RNAs (siRNAs), PIWI-interacting RNAs (piRNAs, PIWI originally 
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from P-element induced wimpy testis in Drosophila) [150] and various classes of 
long ncRNAs (lncRNAs) is being increasingly recognized while new short 
transcripts, such as promoter-associated small RNAs (PASRs) and transcription 
initiation RNAs (tiRNAs) have recently been described [151, 152]  .  
 
The earliest demonstration of fundamental and general functions for regulatory RNA 
in eukaryotic biology was the finding that double-stranded RNA (dsRNA) introduced 
into C. elegans is cleaved into ~22 nucleotide (nt) small RNAs which cause 
widespread and heritable gene silencing [153-155]. Although it was originally 
thought to be restricted to exogenous dsRNAs, it is now clear that plants and animals 
produce endogenous siRNAs, miRNAs and piRNAs [156-161]. Small regulatory 
RNAs (siRNAs, miRNAs and piRNAs) guide effector Argonaute proteins to 
genomic loci or target RNAs in a sequence specific manner. Unlike siRNAs and 
miRNAs which are found ubiquitously, the longest small RNA class, piRNAs, which 
are 25-30nt in length, are first produced by successive waves of Argonaute-cleavage 
of long-non-coding transcripts arising from a Dicer-independent pathway and are 
largely restricted to the germline [157, 158, 162]. For lncRNAs, it is known that at 
least 80% of the transcription in the mammalian genome is exclusively in association 
with lncRNAs [151]. They are frequently long, spliced and contain canonical 
polyadenylation signals. lncRNA promoters are bound and regulated by transcription 
factors, including octamer-binding transcription factor 3/4 (Oct3/4), cAMP response 
element-binding (CREB), c-MYC, sex determining region Y-box 2 (Sox2), NF- κB, 
p53 [163-166]. Interestingly, ncRNAs are pervasive in all complex genetic 
phenomena in the eukaryotes (See Table 1.2). ncRNAs facilitate normal 
development and physiology and, when dysfunctional, underpin disease. Many 
intergenic regions associated with complex diseases express ncRNAs. Despite their 
potential use as diagnostic markers and therapeutic targets, and although there has 
been a near-exponential growth of manuscripts devoted to regulatory RNAs, their 
precise mechanisms of biogenesis and roles in signalling are not fully understood 
because of their natural complexity and diversification. Within the existing ncRNAs, 
the miRNA family is the best-characterized class both in terms of its biogenesis and 
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function. In my thesis the introduction to non-coding genes mainly focuses on 
miRNAs, since they are the main subjects of my project. 
 
 Length VD TR Post-TR GI/TD EM 
endo-siRNA ~21-22nt √ √ √ √  
miRNA ~22nt √ √ √   
piRNA ~26-30nt    √ √ 
snoRNA ND   √   
sdRNA ND   √   
tiRNA ND  √   √ 
lncRNA >~200nt     √ 
 
Table 1.3 Summary of simplified representation of regulatory ncRNAs and their roles VD: Viral 
defence, TR: Transcriptional regulation, GI: Genome integrity, TD: Transposon defence, EM: 
Epigenetic modification; endo-siRNA: Endogenous siRNA, miRNA: microRNA, piRNA: PIWI RNA, 
snoRNA: Small nucleolar RNA, sdRNA: sno-derived RNA, tiRNA: Transcription initiation RNA, 




1.2.2 History and biogenesis of microRNAs 
 
The first miRNA to be discovered, lin-4 was found in 1993 in the nematode C. 
elegans and functioned as a regulator in development [168]. The exact nature of this 
RNA was a mystery at that time, though there was evidence showing that lin-4 
negatively regulated lin-14 protein expression by a novel antisense mechanism. In 
2000, the second miRNA, let-7, was discovered [169]. let-7 was evolutionarily 
conserved among animal species including vertebrates, ascidian, hemichordate and 
mollusk, indicating that these small molecules are important to many biological and 
pathological processes [169]. let-7 targets well-established cell-cycle regulators, such 
as CDK6 and RAS [170, 171]. Since the first two miRNAs were identified, the 
miRNA field has grown tremendously and has become an integral component of the 
way we think gene expression is regulated. Many other miRNA genes have been 
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discovered in different species. In the latest release of miRBase 16, more than 1,100 
mature miRNAs have been confirmed in human [172].  
 
During the past few years studies on basic mechanisms of miRNA biogenesis and 
functions have seen some surprising new discoveries in miRNA processing and post-
transcriptional regulation and the different processes between plants and animals. 
Mammalian miRNAs are short and highly conserved molecules [173, 174] that seem 
to have evolved independently of plant miRNAs as their sequences and biogenesis 
pathways differ substantially [175]. The introduction to the biogenesis of miRNA 
here focuses predominantly on the mammalian system and related information is also 
cited from model systems, including the fruitfly Drosophila melanogaster and 
nematode C. elegans. 
 
Biogenesis can be divided into two major steps: miRNA processing in the nucleus 
and subsequent miRNA maturation in the cytoplasm (Figure 1.4, Page 32). 
 
1. miRNA processing in the nucleus (Figure 1.4-A) 
1) Transcription of the pri-miRNA  
A miRNA is processed from a primary miRNA (pri-miRNA), which is either 
transcribed by RNA polymerase II or RNA polymerase III [176-178]. Because both 
polymerases are regulated differently and can recognize specific promoters and 
terminators, there exists a wide range of regulatory options [179]. Furthermore, each 
miRNA located in the same genomic cluster can be transcribed and regulated 
independently [180]. An average human pri-miRNA is usually composed of a 33 
base pair (bp) hairpin stem, a terminal loop, and two single-stranded (ss) flanking 
regions of several kilobases [181].  
 
2) pri-miRNA cleavage by the Drosha-DGCR8 microprocessor complex 
After transcription, the nuclear microprocessor complex formed by the RNase III 
enzyme Drosha (RNASEN) and the DGCR8 (DiGeorge critical region 8, also known 
as Pasha, Partner of Drosha) protein cut the pri-miRNA. 5' and 3' arms of the pri-
miRNA hairpin are cleaved by the two RNase domains of Drosha [182], whereas 
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Pasha interacts with the pri-miRNA and acts as a molecular ruler to determine the 
precise cleavage site [183] that is located ~11bp away from the ssRNA/dsRNA 
junction at the base of the hairpin stem. The resulting pre-miRNA (precursor 
miRNA) is now generated comprising of a ~22bp stem and a terminal loop. 
 
3) Pre-miRNA export mediated by Exportin-5-Ran-GTP   
Thereafter, Exportin-5 (XPO5), a Ran-GTP-dependent dsRNA-binding protein, 
transports the pre-miRNA from nucleus into cytoplasm [184]. XPO5 can also protect 
the pre-miRNAs against nuclear degradation because knockdown of XPO5 only 
induces a decrease of mature miRNAs but not nuclear accumulation of pre-miRNAs 
[184-186]. XPO5 binding to a defined length of double-stranded stem and the 3' 
overhangs ensures the export of only correctly processed pre-miRNAs [186-188]. 
 
2. miRNA maturation in the cytoplasm (Figure 1.4-B) 
1) The RISC loading complex (RLC): Dicer, TRBP and PACT join Ago2 
Prior to Dicer cleavage, the RISC (RNA-induced silencing complex) loading 
complex (RLC) needs to be generated to provide a platform for RISC assembly and 
cytoplasmic processing. RLC is composed of the RNase Dicer, the double-stranded 
RNA-binding domain proteins TRBP (Tar RNA binding protein) and PACT (protein 
activator of PKR) and associates to form a complex that is subsequently replenished 
by the core component Argonaute-2 (Ago2) [189-193]. RISC contains a single- 
stranded miRNA guiding it to its target mRNA while Ago2 also mediates RISC 
effects on mRNA targets. Neither TRBP nor PACT is essential for Dicer-mediated 
cleavage of pre-miRNA but they enhance RISC formation and participate in the 
recruitment of Ago2 [191-193]. 
 
2) Two fates after nuclear export: Ago-2-mediated ac-pre-miRNA cleavage and 
Dicer-mediated pre-miRNA cleavage 
An additional endonucleolytic cleavage step occurs before Dicer-mediated cleavage: 
for some highly complementary miRNAs, Ago2 cuts the 3' arm in the middle of the 
hairpin to generate a nicked hairpin termed the ac-pre-miRNA, also regarded as the 
prospective passenger strand [194]. Dicer can process this precursor as efficiently as 
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noncleaved pre-miRNAs. This additional step might explain the early association of 
Ago2 with RLC, even before pre-miRNA [189-193]. Once the RLC is formed, the 
RNase III Dicer cleaves off the loop of the pre-miRNA or the nicked ac-pre-miRNA 
and generates a roughly ~22nt miRNA duplex [195]. One mature miRNA end in the 
duplex is already determined by Drosha, Dicer cleavage defines the other mature 
miRNA end with 2nt protruding overhangs [196, 197].  
 
3) Unwinding the miRNA duplex into guide and passenger strand 
Following Dicer cleavage, the miRNA duplex is separated into the functional guide 
strand and the subsequently degraded passenger strand, while the ternary complex of 
Dicer, TRBP and Ago2 dissociates [190]. 
 
4) Guide strand selection and passenger strand degradation 
Both strands of the miRNA duplex could have given rise to two different mature 
miRNAs. In fact, in a similar manner to siRNA duplexes, only one strand is usually 
incorporated into the RISC and the other is degraded [198]. In mammals, 
thermodynamic stability of the two terminal base pairs determines the functional 
asymmetry: the miRNA strand with the less stable base pair at its 5' end in the duplex 
is loaded into RISC, whereas the miRNA strand with the more stable base pair is 
typically degraded [198, 199].  
 
5) Silencing the target gene with help from Argonaute proteins 
Finally, the mature miRNA incorporated into RISC triggers the target gene silencing 
step with help from Argonaute proteins. At least three independent mechanisms of 
miRNA-mediated mRNA silencing have been discovered so far: target cleavage, 
translation repression, and mRNA decay [200, 201]. In situations of perfect 
complementarity between mature miRNA and its target transcripts, the Ago2-RISC 
cleaves the mRNA [202]. Translational inhibition is achieved via various 
mechanisms: CAP structure dissociation with elongation factor, translation-
elongation blockage, or ribosome drop-off promoting premature dissociation of the 
mRNA [203-205]. In addition, miRNAs trigger deadenylation and subsequent 
decapping to initiate degradation of the mRNA target. 
 








Figure 1.4 Biogenesis of miRNAs. The figure describes the key steps of microRNA biogenesis. 
Adapted from [179].  
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1.2.3 Regulation of microRNAs 
 
As described above, biogenesis of miRNA has been intensively studied and well 
described. However, the regulation of miRNA expression remains largely unclear. In 
early studies, promoter regions had been determined for only a small portion of 
miRNAs [206]. Most of the predicted miRNA promoters were not confirmed in wet-
laboratory experiments [172], although several in silico studies predicted the 
promoter regions of miRNAs [207-209]. According to whether the miRNA is 
localized in a transcribed genome region (for a protein coding gene) or not, miRNAs 
can be classified as ‘intragenic’ and ‘intergenic’. Localization of promoters for 
intergenic and inversely-directed intragenic miRNAs is largely unknown, whereas 
promoters for overlapping primary genes are considered to be promoters for the 
intragenic miRNAs that are localized in the same direction as the primary gene. 
However, the means by which miRNA expression is regulated appears complicated 
and needs to be answered. 
 
There is no single pathway universal to mature miRNA processing and it actually 
appears to be a well-organized and regulated process. There are many common or 
specific regulatory mechanisms operating throughout the whole activity to facilitate 
and supervise the processing of individual miRNAs by regulation in both 
transcriptional and posttranscriptional pathways. Here I discuss some common 
regulatory mechanisms including miRNA editing, miRNA-related single nucleotide 
polymorphism (SNP) and epigenetic regulation.  
 
 
1.2.3.1 microRNA editing  
 
RNA editing is an important process defined as a post-transcriptional change of RNA 
sequences by deamination of adenosine (A) to inosine (I). It takes place either in the 
nucleus or in the cytoplasm. The A to I editing of primary transcripts by ADARs 
(adenosine deaminases acting on RNAs) was first described for miR-22 [210], 
followed by a lot of other miRNAs such as miR-151, miR-197, mi-223, miR-376a, 
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miR-142 and miR-143 [211, 212]. Many pri-miRNAs and pre-miRNAs are targeted 
by ADARs at different stages in their processing, and the modifications can affect 
both Drosha-mediated and Dicer-mediated cleavage, and also prevent the export of 
pre-miRNAs. For instance, in pri-miR-142, A to I editing inhibits its cleavage by 
Drosha and contributes to its degradation by the nuclease Tudor-SN, which has 
affinity for dsRNA containing inosine-uracil pairs [213]. For another example, 
editing of pre-miR-151 prevents Dicer processing in the cytoplasm and results in 
accumulation of pre-miR-151 [214]. However, whether miRNA editing is 
predominantly in the nucleus (on the pri-miRNAs) or in the cytoplasm (on the pre-
miRNAs) needs to be established. In addition to alterations of miRNA processing, 
miRNA editing can also have impact on miRNA target specificity. A single A to I 
change in the seed sequence of miR-376-5p precursor redirects the mature miRNA to 
a new target, resulting in altered protein expression in mice [215]. 
 
 
1.2.3.2 microRNA and SNPs 
 
The first miRNA related SNP was found in the miR-189 binding site of SLIT and 
NTRK-like protein 1 (SLITRK1), which was associated with Tourette’s syndrome 
[216]. Since then, several other studies have identified SNPs in miRNA genes (pri-
miRNA, pre-miRNA and mature miRNA) using systematic sequencing and in silico 
methods. Catalogues of SNPs in miRNAs have been created and made public [217-
219]. An example, a G-U SNP in miR-125a results in processing blockage and 
consequently reduces the levels of mature miR-125a [218]. Most studies have tried to 
associate SNP occurrence with susceptibility to cancer. (More information about 
miRNAs and SNPs in cancer is discussed later in this Chapter—section 1.2.7.2.) 
 
 
1.2.3.3 microRNA and epigenetics 
 
Recently, many studies have focused on identification of the relationship between 
regulation of miRNAs and epigenetics. The first study of this type established that 
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the expression of miR-127 is regulated epigenetically. In this study, pharmacological 
unmasking of epigenetically silenced miRNAs activated 17 of 313 miRNAs 
investigated in the bladder cancer cell line T24 and the normal fibroblast cell line 
LD419 [220]. DNA methylation level and histone modification status at identified 
promoter regions of miR-127 correlated significantly with mature miR-127 
expression. Subsequent to this initial report, studies on the epigenetic regulation of 
miRNAs have increased dramatically. Epigenetic mechanisms, including DNA 
methylation and histone modification, not only regulate the expression of protein-
encoding genes, but also miRNAs. Conversely, another subset of miRNAs controls 
the expression of important epigenetic regulators, including DNA 
methyltransferases, histone deacetylases and polycomb group genes. This 
complicated network of feedback between miRNAs and epigenetic pathways appears 
to form an epigenetics–miRNA regulatory circuit (Figure 1.4), and to organize the 
whole gene expression profile [172]. When this regulatory circuit is disrupted, 
normal physiological functions are interfered with, contributing to various disease 
processes. (More information about miRNAs and epigenetics in cancer is discussed 
later in this Chapter—section 1.2.7.3.)  
 
 
Figure 1.5 Epigenetic-microRNA regulatory circuit. PABP: poly (A) binding proteins. TF: 
Transcriptional factors. TRBP: Tar binding protein. Adapted from [172]. 
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1.2.4 Functions of microRNAs 
 
Besides perfectly matched sequence complementarity only between the “seed” 
region of the miRNA (~2-7nt of mature sequence) and its target gene, the miRNA 
binds to the 3' UTR of its targets through imperfect base pairing [221]. Depending on 
the precise nature of the binding, this induces degradation, destabilization, or 
translational repression of the mRNA and consequently silences gene expression 
[200]. Additionally, because of the imperfect complementarity of binding, a single 
miRNA can influence a broad range of mRNAs and a whole miRNA family may 
regulate thousands of target genes [222, 223]. The estimation that more than 30% of 
protein-coding genes are regulated by miRNAs at the posttranscriptional or 
translational level [224] indicates that almost all cellular pathways are directly or 
indirectly affected by miRNAs. So far miRNAs are reported to have been involved in 
94 diseases [225], ranging from psychiatric disorders [226], through diabetes [227], 
to cancer [228] (More miRNA functions related to cancer are discussed in this 
Chapter—section 1.2.7.).  
 
Notably, there was a unique study that defined a novel role for miRNA that can 
upregulate mRNA translation [229]. AU-rich elements (AREs) bind specific proteins 
to regulate mRNA stability or translation in response to external and internal stimuli. 
In a previous study, the same authors had already demonstrated that upon cell cycle 
arrest, the ARE in the tumour necrosis factor-α (TNF-α) mRNA is transformed by 
serum starvation into a translation activation signal, recruiting Ago and fragile X 
mental retardation—related protein1 (FXR1). They found that the expression of miR-
369-3 is necessary for translation up-regulation of the ARE-containing reporter. A 
siRNA directed against the loop region of pre-miR-369-3 prevented this translation 
up-regulation under serum-starved conditions. The knockdown cell line was rescued 
with synthetic miR-369-3 resistant to siRNA and the translation efficiency of the 
ARE-containing receptor was increased five-fold. All the above results indicate that 
miR-369-3 is specifically required for TNF-α ARE-mediated translation activation 
under growth arrest conditions. Similarly, they also found let-7 and a synthetic 
miRNA miRcxcr4 induced translation upregulation of target mRNAs on cell arrest, 
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although they repressed translation in proliferating cells. Therefore, they thought that 
there is miRNA oscillation between repression and activation in coordination with 
the cell cycle: in proliferating cells they repress translation, whereas in G1/G0 arrest 
they activate translation.  
 
 
1.2.5 Detection of microRNAs 
 
The first method to quantify miRNA was northern blotting. However, it requires a 
relatively large amount of RNA and is insensitive, especially for those miRNAs with 
low expression levels. Thereafter, reflecting the need for greater precision and higher 
throughput, miRNA real-time RT-PCR and miRNA microarray methods are 
commonly used.  
The real-time RT-PCR makes use of a stem loop reverse transcription primer to 
generate cDNA templates, which are then amplified using specific primers and tested 
with specific fluorescent probes. Currently four different chemistries, TaqMan®, 
Molecular Beacons, Scorpions® and SYBR® Green, are available for real-time 
PCR. All of these chemistries allow detection of PCR products via the generation of 
a fluorescent signal. TaqMan probes, Molecular Beacons and Scorpions depend on 
Förster Resonance Energy Transfer (FRET) to generate the fluorescence signal via 
the coupling of a fluorogenic dye molecule and a quencher moiety to the same or 
different oligonucleotide substrates. SYBR Green is a fluorogenic dye that exhibits 
little fluorescence when in solution, but emits a strong fluorescent signal upon 
binding to double-stranded DNA. The choice should be made according to individual 
situation as each different chemistry method has its own advantages and 
disadvantages.  
 
Microarray for quantifying miRNA is optimal for the simultaneous analysis of 
hundreds of miRNAs present in one sample or multiple samples. Recently, for better 
understanding of miRNA roles in different diseases, determination of miRNA 
expression in FFPE tissues has become of interest to researchers. Therefore, methods 
have been developed to profile miRNAs from FFPE specimens and to localize 
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miRNA expression at the cellular and subcellular levels by in situ hybridization 
(ISH). Although it is challenging to perform ISH with miRNAs because of their very 
small size, introduction of locked nucleic acid (LNA) probes has greatly improved 
the performance of this technique. For specific detection of miRNA the use of the 
nucleic acid analogues LNA, in which the ribose ring is locked into a C3' -endo 
conformation by a 2' -O, 4' -C methylene bridge (Figure 1.5), have shown great 
advantages for ISH [230]. LNA exhibits higher base pairing affinity than DNA and 
RNA as measured by UV melting analyses [231], and as also observed by ISH [230]. 
In addition, the design of LNA oligos can be optimized to enable increased mis-
match discrimination and thereby enable specific identification of highly similar 
sequences such as miRNA family members [231] and single mutations [232]. 
Several groups have used this technique successfully for different miRNAs on both 
tissues and cells [233, 234]. 
 
Figure 1.6 Structure of locked nucleic acid. The black arrow indicates the bridge.  
 
 
1.2.6 Identification of microRNA targets 
 
Precise target prediction of miRNAs is a challenging task in miRNA research, 
especially for those newly identified miRNAs implicated in specific diseases but 
with little help from previous literature. To assist this task a variety of computer-
aided prediction algorithms have become available. These algorithms are trained by 
well known miRNA-mRNA interaction rules gained from microarray data in order to 
identify novel miRNA targets. Among algorithms, miRanda [235] is one of the most 
popular and others include TargetScan [236], PicTar [237], PITA [238] and RNA22 
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[239]. However, most of them suffer from either high false positive or false negative 
rates due to insufficient specificity and sensitivity. To overcome these disadvantages, 
other approaches have been developed. DIANA-microT [240] and DIANA-miRPath 
[241] are gene set analysis based approaches. DIANA-miRPath software performs an 
enriched analysis of multiple miRNA target genes comparing each set of miRNA 
targets to all known Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways 
[242, 243] and therefore it becomes a valuable tool for interpreting targets which are 
affected by deregulated miRNAs. Since the prediction algorithms do not always offer 
identical targets, using the intersected target lists from multiple algorithms serves to 
narrow down the candidate targets with higher confidence. However, 
computationally predicted targets still need to be verified through biochemical 
identification to understand the mode of action of miRNAs and their functions. 
 
  
1.2.7 microRNA and cancer 
  
Given the fundamental role of miRNAs, it is no surprise that miRNAs have been 
shown to be involved in a great spectrum of diseases, including cardiovascular [244], 
infectious [245], neurologic [246] and metabolic diseases [247, 248]. Equally 
interesting, miRNAs have been found important in tumourigenesis with more than 
3,000 publications associating miRNAs with cancer to date. To further understanding 
of the miRNA functions in malignancies, the following sections focus on miRNAs in 




1.2.7.1 Association with genomic alterations 
 
Approximately 50% of annotated miRNA genes are located in cancer-associated 
regions or fragile sites [249-251]. For example, the miRNA cluster 15a/16-1 is 
located on 13q14, a frequently deleted genomic locus in chronic B cell lymphocytic 
leukaemia (B-CLL) [249]. Other examples include deletion of let-7g/miR-135-1 in a 
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variety of human malignancies [250], amplification of the miR-17-92 cluster in 
lymphoma [252], translocation of miR-17-92 in T cell acute lymphoblastic 
leukaemia  (T-ALL) [253] and amplification of miR-26a in glioblastoma [254]. In a 
study with higher genomic resolution, 283 miRNA genes in 227 human ovarian, 
breast, and melanoma cancer specimens were analyzed for copy number changes 
[255]. Of all the analyzed miRNAs, 37.1% in ovarian cancer, 72.8% in breast cancer 
and 85.9% in melanoma were located in genomic regions with gene copy number 
changes. In all three cancers, the copy number of 26 particular miRNA genes 
increased, whereas 15 decreased. This indicates that some miRNAs participate in the 




1.2.7.2 microRNA related SNPs  
 
miRNA related SNPs can occur in miRNA genes (specifically in “seed regions”) , 
miRNA binding sites of target genes and in miRNA-processing machinery.  
 
SNPs in miRNA genes are thought to influence miRNA functions through the 
transcription of primary transcript, through pri-miRNA and pre-miRNA processing, 
and thirdly through effects on miRNA-mRNA interactions [256]. The first evidence 
that point mutation in miRNA genes can have a functional effect and confer cancer 
susceptibility comes from a seminal study by Carlo Croce’s group. A germline 
mutation (C to T) in pri-miR-16-1 was found in familial chronic lymphocytic 
leukaemia (CLL) and resulted in decreased miR-16-1 expression. A SNP in the 
terminal loop of pre-miR-27a was associated with lessened advanced breast cancer 
risk in families with a history of non-BRCA-related disease [257]. A unique example 
of a functional miRNA SNP in pre-miR-146a (C to G), led to altered processing, 
lower expression of mature sequence and susceptibility to papillary thyroid 
carcinoma [258].  Individuals with a heterozygous genotype have a higher risk of 
developing papillary thyroid carcinoma than homozygous populations.  
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The disruptive action of SNPs in the miRNA binding site of target mRNAs is similar 
to seed region SNPs for altered gene expression in cancer. let-7 binds to the 3' UTR 
of KRAS and negatively regulates KRAS’s expression [171]. Very low expression of 
let-7 and elevated KRAS were found in lung cancer. Chin et al. sequenced the 3' 
UTR of KRAS and identified ten let-7 complementarity sites. A new SNP (T to G) in 
LCS6 was present in 20% of lung cancer cases and 5% of the control populations 
[259]. 
 
Recent studies suggest that SNPs in the biogenesis machinery are also associated 
with cancer risk, drug response and prognosis [256]. Low level of Drosha was related 
to poor ovarian cancer survival [260]. XPO5 was decreased in bronchioloalveolar 




1.2.7.3 In epigenetics 
 
Genetic lesions cannot solely explain the complexity of the abnormalities that arise 
in a cancer cell. Epigenetics offers an additional and equally important explanation 
that, along with genetics, contributes to a better understanding of the whole 
malignant process. It is now defined as the inheritance of changes in gene activity 
that is independent of DNA sequence [263]. DNA methylation and histone 
modifications are the two major events of epigenetics. Likewise for miRNA, not only 
genetic alterations might cause the deregulation of subsets of miRNAs, but 
epigenetic changes can also have an effect on miRNA expression.  
 
It was hypothesized that miRNA genes with tumour suppressor features could be 
hypermethylated in cancer in the same way as classic protein-coding genes [264, 
265]. Two tumour-suppressor miRNAs, miR-127 and miR-124a that negatively 
regulate the expression of oncogenes CDK6 and Bcl-6 were methylated in various 
cancers [220, 265]. Some recent papers have demonstrated that the presence of CpG 
island hypermethylation of miRNA genes is a widespread phenomenon in cancer, as 
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shown for miR-9-1, miR-193a, miR-137, miR-342, miR-203, miR-34b/c and miR-1 
[266]. In addition, global DNA hypomethylation events can also affect miRNAs. The 
human let-7a-3 gene is located on chromosome 22q13.31 and is embedded in a CpG 
island. let-7a-3 was found hypomethylated in lung cancer cells relative to normal 
lung cells [267]. For miRNA genes with histone modifications, DNA 
hypermethylation interacts with histone modifications through precise crosstalk 
mediated by the transcriptional repressor methyl-CpG-binding domain proteins 
(MeCP/MBDs) [268]. miR-124 silencing by DNA methylation was accompanied by 
the presence of the transcriptional repressors MeCP2 and MBD2, and absence of 
active histone marks, such as acetylation of histone H3 and H4 [265]. 
 
Since more hypermethylated protein-coding genes and miRNA genes have been 
discovered in cancer that are involved in invasion and metastasis, novel therapeutic 
opportunities targeting such hypermethylation will present themselves in the future. 
 
 
1.2.7.4 Dysregulation in tumourigenic pathways 
 
Expression changes in miRNAs could drive tumourigenesis, through their roles as 
tumour suppressors or oncogenes. Upregulated or downregulated miRNAs involved 
in malignancies are respectively referred to as oncogenic miRNAs (also called 
“oncomiRs”) or tumour-suppressor miRNAs. Functional studies performed in cancer 
cell lines or mouse models of various cancers through overexpression or knockdown 
of miRNAs have supported these different roles for miRNAs in tumourigenesis. For 
example, the expression cluster miR-17-92 was increased in lung cancer, especially 
in small-cell lung cancer [269]. Lung cancer cell growth was also increased by miR-
17-92 expression. In contrast to miR-17-92, Takamizawa et al. found that expression 
levels of let-7 were often reduced in both in vivo and in vitro lung cancer studies 
[270]. They also observed that overexpression of let-7 in A549 lung adenocarcinoma 
cell lines inhibited cell growth. let-7 negatively regulates its target genes: RAS and 
MYC [171]. It was also shown that lung tumour tissues display decreased levels of 
let-7 and increased levels of RAS protein relative to normal lung tissue.  
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In both solid and haematological malignancies, many other miRNAs have expression 
changes indicating that they function as oncogenes or tumour suppressors. The MYC 
oncoprotein family has crucial roles in the pathogenesis of many human neoplastic 
diseases through deregulating both cell growth and death check points and, in a 
permissive environment, rapidly accelerating the affected clone through the 
carcinogenic process. miR-155 expression has been correlated to MYC over-
expression in B-cell cancers, suggesting it may be playing a role in the regulation of 
this oncogene [271]. Other studies showed that expression of miR-155 was 
upregulated in pediatric Burkitt’s lymphoma, in Hodgkin’s lymphoma and large B-cell 
lymphomas [272, 273] and also in breast, lung, colon, and thyroid cancers [274, 275]. 
The oncomiR, miR-221 is increased in glioblastoma [276], and tumour suppressors 
like the miR-34 family in breast cancer [277], and miR-143/145 in colorectal neoplasia 
are reduced relative to normal tissues [278].  
 
Additionally, some miRNAs have been regarded as metastasis-related miRNAs (also 
termed as “metastamiRs”) through cell line and xenograft experiments. For instance, 
breast cancer related examples include miR-10b, miR-9, miR-31 and miR-335, either 
as pro-metastatic regulators (the former two), or anti-metastatic effectors (the latter 
two) [279].  
 
The observed global deregulation of miRNA expression on tumour initiation, 
maintenance or metastasis can be explained through studying miRNA targeted genes 
and the pathways that they regulate. It is difficult to assign an individual miRNA or 
miRNA cluster to a single or a certain type of tumourigenic pathway because there 
are many hundreds of miRNAs and each miRNA can have hundreds of targets and 
there are also signalling crosslinks between different pathways. As noted, miRNA 
regulation is pervasive in almost all biological transductions in tumour-stromal 
ecosystems involving cell adhesion, angiogenesis, proteolysis and cell signalling.  
 
Metastasis of malignancies requires the loss of expression or function of E-cadherin. 
E-cadherin regulates the actin cytoskeleton via its association with ß-catenin, which 
is also a transcription factor involved in the Wnt signalling pathway. The E-cadherin/ 
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ß-catenin system acts as a tumour suppressor of invasion and low E-cadherin 
expression level is correlated to inverse patient survival and advanced histological 
grade in colorectal cancer [280]. Interestingly, both E-cadherin and ß-catenin 
mRNAs contain potential miRNA binding sites: miR-9 in E-cadherin and miR-139 
and miR-200a in ß-catenin. Upregulated miR-9 has been reported in breast cancer 
relative to normal tissues [281]. Integrins perform essential roles in cell adhesion to 
the ECM. αVß3 integrin is upregulated in tumour cells at the invasion front as well 
as acting as a marker of neovessels following activation of the angiogenic switch 
[282]. The mRNAs for both integrin αV and ß3 subunits contain binding sites for 
miRNA, such as miR-32 for integrin αV and let-7/miR-98 for integrin ß3 [283]. As 
mentioned above altered expression of let-7 might contribute to the development of 
lung cancer through regulating RAS [171]. Moreover, integrin ß1 was downregulated 
on overexpression of miR-124 [284]. Similar to integrins, transcripts encoding the 
cytoskeletal proteins paxillin and focal adhesion kinase (FAK) that are 
downregulated in cancer have potential miRNA binding sites [285]. For FAK, miR-
32/92 binding sites are present, just as in integrins αV and α5. FAK also shares a 
miR-199 site in common with fibronectin. Lysyl oxidase (LOX), involved in the 
crosslinking of collagen and elastin, is one of the important regulators in the tumour 
cell microenvironment. Elevated LOX expression is related to poor survival and 
promotes tumour cell invasion via increased formation of focal adhesions. LOX 
contains a binding site for miR-145, which is reduced in many cancers and has been 
reported to be deleted in prostate cancer [281]. 
 
Tumour angiogenesis requires tumour cell factors, such as VEGF and is driven by 
multiple mechanisms. The four tissue inhibitor of metalloproteinases (TIMPs) are 
intriguing molecules for their having both pro- and anti-tumourigenic functions 
[286]. TIMP3 is also antiangiogenic by blocking VEGF binding to VEGFR2 [287]. 
TIMP3 mRNA contains a large number of potential target sites for miRNA, 
including miR-21 and miR-17/20/106 that are upregulated and strongly related to a 
poor prognosis signature [275, 288]. Moreover, TIMP3 also has a site for miR-
221/222, which are upregulated in papillary thyroid cancer. All the above evidence 
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indicates deregulated miRNA expression could influence both angiogenesis and 
proteolysis pathways, resulting in dysregulation in tumour invasion and metastasis. 
 
 
1.2.7.5 In stem cell activation 
 
Several studies have shown miRNAs are associated with the self-renewal of stem 
cells. In mice and zebrafish, the absence of Dicer-1 results in lethality early in 
development and loss of stem cell populations [289, 290]. Shcherbata et al reported 
that in Drosophila melanogaster, the Dicer-1 mutation affects germline stem cells 
showing delay in the G1 to S transition and indicating an important role of miRNAs 
in the division of stem cells [291]. This suggests that miRNAs might be involved in 
stem cell activation. However, which set of miRNAs are the crucial players for 
normal stem cell maintenance and whether they are involved in cancer stem cells 
needs to be elucidated. 
 
 
1.2.7.6 Clinical applications  
 
The miRNA family can be very useful in clinical applications since their expression 
is specifically altered in different cancers, or between normal and malignant tissues. 
miRNA expression profiling studies suggest miRNAs are superior biomarkers for 
cancer subtype classification and prognostication [292-294]. On the other hand, 
changing miRNA expression back to normal could be a potential therapeutic 
strategy. 
 
Two of the earliest reports have shown the utility of miRNAs expression profiles to 
distinguish tumour from normal samples, identify tissue of origin for tumours of 
unknown origin or in poorly differentiated tumours and to distinguish different 
types/subtypes of tumours [295, 296]. Moreover, it is also elucidated that certain 
alterations of miRNAs occur in patients at an early stage of cancer and thus may be 
helpful for early detection. The availability of FFPE specimens for miRNA detection 
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[297] makes it feasible to use miRNAs for diagnostic purposes as biomarkers. More 
excitingly, some new studies have also shown that miRNAs can be detected in serum 
[298, 299]. Beyond the realm of diagnosis, a series of publications has shown that 
miRNAs can act as useful indicators of clinical outcome [283, 300, 301] and can be 
used for estimation of treatment efficiency [302]. 
 
General therapeutic strategies involving antisense-mediated inhibition of oncogenic 
miRNAs and miRNA replacements with miRNA mimics or viral vector-encoded 
miRNAs have been generated.  
 
Application of 2'-O-methyl anti-miRNA oligonucleotides (AMOs) targeting the 
oncomiR, miR-21 has been found to inhibit glioblastoma and breast cancer cell 
growth in vitro and in an MCF-7 breast cancer xenograft mouse model [288, 303]. In 
another AMO application, modified AMOs conjugated with cholesterol termed 
“antagomiRs” were systematically delivered through intravenous injection to target 
the liver-specific miR-122 in mice [247, 248]. Other miRNA reduction strategies 
include miRNA sponges and construction of lentiviral vectors as anti-miRNA decoys 
[304].  
 
For overexpressing miRNA, viral or liposomal delivery mechanisms have been used 
[305, 306]. Using adenovirus-associated virus in a hepatocellular carcinoma (HCC) 
animal model, a successful elevation of a tumour suppressive miRNA, miR-26 in 
HCC occurred and resulted in inhibition of cell proliferation and tumour-specific 
apoptosis [307]. It is also thought that cationic liposomes or polymer-based 
nanoparticle formulations can be developed to achieve the delivery of miRNA 
mimics and tested for therapeutic efficacy [308]. Absence of vector-based toxicity is 
the advantage of these mimics, indicating that these approaches might be promising 
tools for future tumour therapy. 
 
Finally, it has been reported that miRNA therapy can also enhance the response and 
suppress resistance to anticancer chemo-/radio-therapy. miR-200c levels were 
extremely low in poorly differentiated cancer cells and restoration of miR-200c 
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increases their sensitivity to microtubule-targeting agents by 85% [309]. Weidhaas et 
al. showed that the let-7 family can radiosensitize A549 lung cancer cells, while 
reducing let-7 levels causes radioresistance [310].  
 
 
1.3 Summary and aims 
 
Cutaneous melanoma is likely to become an increasingly important public issue due 
to its continuous increase of incidence over the last 30 years. Inaccurate diagnosis 
and prognosis, and extremely low efficiencies for therapy of metastatic melanoma 
constitute the major barriers to curing melanoma. The objective of the studies in this 
thesis is to lower these barriers by identifying key non-coding genes and coding 
genes involved in melanomagenesis. 
 
As has been explained miRNAs are crucial factors in almost all biological progresses 
such as development, cell differentiation, proliferation, apoptosis and chemo-
resistance, so that any abnormality of functional miRNAs may affect the 
development of organisms, lead to disease and influence therapeutic efficiency. 
Moreover, miRNA analysis has a number of advantages compared to conventional 
mRNA analysis. First, owing to its small size, it is less susceptible to degradation and 
has been successfully extracted from 10 years old FFPE specimens [311]. Secondly, 
the quality of miRNA expression data from FFPE specimens is equivalent to that 
from fresh frozen ones [312]. Furthermore, an indication of the potential of miRNAs 
in cancer diagnosis demonstrated that miRNA expression profiles can distinguish 
between tumour and normal tissue and can also define the tissue of origin in tumours 
of diagnostic uncertainty [313].  
 
Given the unsolved issues of melanoma and the importance and advantages of 
miRNA analysis, the objectives of Chapter 3 and Chapter 4 are:  
1) To identify melanoma-specific miRNA diagnostic and prognostic markers. 
2) To establish functional miRNAs in melanomagenesis and by connecting to their 
downstream signalling pathways to begin to identify potential miRNA treatments. 
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Oncogenic BRAF mutations are frequent in cutaneous melanoma occurring at sites 
with little or moderate, as opposed to high levels of sun-induced damage. BRAF is a 
vital coding-gene in the MAPK pathway and a mutant BRAF inhibitor has shown 
effective therapeutic function in melanoma. In our group we have melanoma Tissue 
Microarray (TMA) samples available with full clinical records, from both sun-
exposed and non-exposed sites and at all pathological stages from naevus to 
metastasis, as well as a mature method to genotype the V600E BRAF mutation. 
Therefore, the aims of Chapter 5 are:  
1) To genotype BRAF V600E mutation status in melanoma TMA samples.  
2) To investigate possible correlation between BRAF mutation status and 
clinicopathological features.  
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Chapter 2: Materials and Methods 
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2.1 Materials 
 
2.1.1 General reagents and plastic consumables  
 
General laboratory chemicals were purchased from Fisher Scientific (absolute 
alcohol, methanol, phenol, isopropanol, chloroform, xylene, Na2EDTA, isoamyl 
alcohol, potassium acetate, sodium hydroxide, glycerol). Some commonly used 
solutions were obtained from Medical Research Council, Human Genetics Unit stock, 
including Dulbecco PBS, dH2O, 1M Tris pH7.5 and pH8.0, 5M NaCl, 20x TBE, 
0.5M EDTA, 5M NaOH. All the general reagents were stored at room temperature 
unless otherwise indicated. 
 
General plastic consumables were purchased from Greiner Bio One. 
 
 
2.1.2 DNA isolation reagents  
 
For mammalian cells: 
Tail buffer: 10mM Tris-HCl pH8.0, 400mM NaCl, 3mM Na2EDTA, 1% (w/v) SDS. 
Stored at 4°C. 
Proteinase K stock solution: 2mg/ml proteinase K (Sigma-Aldrich, P2308), 100mM 
Na2EDTA, pH 7.5, 2% (w/v) SDS. Stored at -20°C. 
PCA: 25 parts redistilled phenol, 24 parts chloroform, 1 part isoamyl alcohol. Stored 
at 4°C. 
CA: 24 parts chloroform, 1 part isoamyl alcohol. Stored at 4°C. 
 
For FFPE samples: 
QIAamp® DNA Micro isolation kit and QIAamp Mini Elute column (QIAGEN, 
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2.1.3 RNA isolation reagents 
 
For mammalian cells: 
RNA-Bee (AMSBIO, CS-1048-100ml). Stored at 4°C.  
 
For formalin fixed paraffin embedded (FFPE) samples: 
RecoverAll™ Total Nucleic Acid Isolation Kit (Applied Biosystems, AM1975). 
Stored at room temperature/4°C. 
 
 
2.1.4 PCR reagents and oligonucleotides 
 
Nested PCR and restriction digestion reagents  
 
Polymerase chain reaction (PCR) stock reagents: 5x Clear PCR buffer (Promega, 
M890A), 25mM MgCl2 (Promega, A351H), 100mM dNTP set (GE Healthcare, 27-
203501), GoTaq Flexi DNA Polymerase (Promega, M8305). 5x Green GoTaq® 




PCR Primers for genotyping BRAF V600E mutation 
 
Custom oligonucleotides were purchased from Sigma-Genosys. Lyophilised 
oligonucleotides were resuspended in sterile dH2O to 100pmol/ul stock solution and 
stored at -20 °C. Working stocks were diluted to 25pmol/ul and stored at -20 °C. 
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First round PCR forward primer 
BRAF Rev5 
 
CTGATTTTTGTGAATACTGGGAA      
           










Nested PCR reverse primer 
 
 
TaqMan® real time reverse transcription-PCR (real time RT-PCR)  
 
For RT-PCR: 
TaqMan® MicroRNA Reverse Transcription Kit (Applied Biosystems, 
PN4366596/4366597). Stored at -20°C. 
 
High Capacity RNA to cDNA Master Mix (Applied Biosystems, 
PN4390712/4390713). Stored at -20°C. 
 
For real time PCR: 
TaqMan® 2X Universal PCR Master Mix, No AmpErase® UNG (Applied 
Biosystems, PN4324018). Stored at 4°C. 
 
 
TaqMan® microRNA expression assays and gene expression assays 
 
All the human microRNA expression assays and gene expression assays were 
purchased from Applied Biosystems. The details are shown in the following table. 
 






miR-92 00430 UAUUGCACUUGUCCCGGCCUG 
RNU6B 001093 CGCAAGGATGACACGCAAATTCGTGAAGCG 
TTCCATATTTTT 
miR-200a 000502 UAACACUGUCUGGUAACGAUGU 
miR-200b 002251 UAAUACUGCCUGGUAAUGAUGA 
miR-200c 002300 UAAUACUGCCGGGUAAUGAUGGA 
miR-141 000463 UAACACUGUCUGGUAAAGAUGG 
miR-205 000509 UCCUUCAUUCCACCGGAGUCUG 
miR-203 000507 GUGAAAUGUUUAGGACCACUAG 
miR-20b 001014 CAAAGUGCUCAUAGUGCAGGUAG 
miR-675 002005 UGGUGCGGAGAGGGCCCACAGUG 
miR-211 000514 UUCCCUUUGUCAUCCUUCGCCU 
miR-10b 002218 UACCCUGUAGAACCGAAUUUGUG 
miR-214 002306 ACAGCAGGCACAGACAGGCAGU 
miR-373 000561 GAAGUGCUUCGAUUUUGGGGUGU 
miR-137 000593 UAUUGCUUAAGAAUACGCGUAG 
miR-335 000546 UCAAGAGCAAUAACGAAAAAUGU 
miR-199a 000498 CCCAGUGUUCAGACUACCUGUUC 
let-7b 002619 UGAGGUAGUAGGUUGUGUGGUU 
ß-actin 4352935 N/A 
E-cadherin Hs01023894_m1 N/A 
Zeb2 Hs00207691_m1 N/A 
 
N/A: Not applicable. 
 
 
2.1.5 Gel electrophoresis reagents 
 
TBE buffer: 90mM Tris-HCl, 90mM boric acid, 2mM Na2EDTA, pH8.3. 
 
TBE gel: 3% (w/v) agarose gel, 0.5x TBE buffer, 0.5ug/ml ethidium bromide. 
 
HyperLadder I/V (Bioline, BIO-33025/33031). Stored at 4°C. 
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2.1.6 Illumina microRNA microarray  
 
Illumina microRNA microarray (Illumina, Catalog # MI 501-1001, Part # 11297743). 
 
 
2.1.7 Protein detection reagents and antibodies 
 
RIPA buffer: 150mM NaCl, 25mM Tris-HCl pH7.2, 0.1% SDS, 1% Triton X-100, 
1% deoxycholate, 1mM Na2EDTA, 1x Protease inhibitor cocktail tablet (Roche 
Complete)/25-50ml, 20mM NaF, 100uM orthovanadate.  
 
Bicinchoninic acid (BCA) Assay Kit (Pierce Biotechnology, 23227). 
 
Resolving buffer: 390mM Tris-HCl pH 8.8. 
 
Resolving gel (8-12%): 8-12% acrylamide (40% stock, Severn Biotech Ltd, 2-2400-
05. Stored at 4°C.), 1x resolving buffer, 0.1% SDS (20% stock, National 
Diagnostics, EC-874), 0.1% Ammonium persulphate (APS) (Sigma-Aldrich, 3678), 
0.08% TEMED (Sigma-Aldrich, T2281-25ML). Prepared immediately prior to use. 
 
Stacking buffer: 123mM Tris-HCl pH6.8. 
 
Stacking gel (4-8%): 5% acrylamide, 1x stacking buffer, 0.1% SDS, 0.1% APS, 
0.1% TEMED. Prepared immediately prior to use. 
 
Running buffer: 192mM Glycine, 25mM Tris, 0.1% SDS pH8.3. 
 
Transfer buffer: 192mM Glycine, 25mM Tris, pH 8.3. 
 
5x Protein Sample buffer: 225mM Tris-HCl pH6.8, 5% SDS, 20% Glycerol, 0.05% 
(w/v) Bromophenol Blue (Sigma-Aldrich, B-5525).  
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Dithiothreitol (DTT) (Sigma-Aldrich, D0632). Stored at -20 °C. 
 
TBS: 5mM Tris-HCl, 75mM NaCl, pH7.4. 
 
TBST: 5mM Tris-HCl, 75mM NaCl, 0.05-0.1% (v/v) Tween-20, pH7.4. 
Blocking buffer: 5% (w/v) dried skimmed milk, 1x TBST. 
 
Immobilon-P PVDF transfer membrane (Millipore, Billerica, Massachusetts). 
 
Page Ruler™ Plus Prestained Protein Ladder (Fermentas, SM1811), stored at -20°C. 
 
Enhanced chemiluminescence Plus solution (Amersham Biosciences, 





Primary antibody Secondary antibody 





















2.1.8 Mammalian cell lines and cell culture reagents  
   
Mammalian cell lines 
 
Human immortalised melanocyte lines: Hermes1 and Hermes4a immortalised with a 
telomerase expressing retrovirus [314]. 
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Human malignant melanoma cell lines: A375, C32, G361 and WM115 were obtained 
from the European Collection of Cell Cultures (ECACC). HBL was obtained from 
Gentaur (Brussels, Belgium). EDMEL3 was isolated by Ewan Brown from a 
metastasis removed from a melanoma patient. EDMEL3 early passage cell line 
(passage 2) and four EDMEL3 subclones and two EDMEL3 xenograft cell lines 
were obtained and cultured in David Melton’s group.  
 
Human ovarian cancer cell lines: PEA2, PEO1, PEO14 and PEO23 were donated by 
Dr Grant Sellar, Cancer Research Centre, the University of Edinburgh. PEA2: 
Cisplatin-resistant derivative of human ovarian cancer cell line—PEA1. PEO1: 
Human ovarian cancer cell line. PEO14: Human ovarian cancer cell line. PEO23: 
Cisplatin-resistant derivative of PEO14 [315].  
 
 
General Mammalian cell culture media and reagents 
 
Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, GIBCO®, 41965). 
Stored at 4°C. 
 
Fetal Calf Serum (FCS) (Invitrogen, GIBCO®, 16170) 
 
100x Non Essential Amino Acid (NEAA) (Invitrogen, GIBCO®, 11140). Stored at 
4°C. 
 
100mM Sodium Pyruvate (Invitrogen, GIBCO®, 11360). Stored at 4°C. 
 
Penicillin-Streptomycin (P/S) liquid (Invitrogen, GIBCO®, 15070-063). Working 
solution: 50U/ml Penicillin and 50ug/ml Streptomycin. Stored at -20°C. 
 
200mM L-glutamine (100x) (Invitrogen, GIBCO®, 21051-040). Stored at -20°C.   
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The working media were made according to the requirement of the specific 
experiments. 
 
PBS: 140mM NaCl, 3mM KCl, 2mM KH2PO4, 10nM Na2HPO4 pH7.4. 
 
Trypsin-EDTA: 10x trypsin-EDTA (Invitrogen) diluted in PBS to 0.25% (w/v) 
trypsin, 1mM Na2EDTA. Stored at -20°C. 
 
 
Reverse transfection reagents  
 
Opti-MEM® I Reduced Serum Medium (Invitrogen, GIBCO®, 31985-054). Stored 
at 4°C. 
 
siPORT™ NeoFX™ (Applied Biosystems, AM4510/4511). Stored at 4°C. 
 
Ambion® Pre-miR™ microRNA precursors: hsa-miR-205 (Applied Biosystems, 
PM11015), hsa-miR-200c (Applied Biosystems, PM11714), hsa-miR-211 (Applied 
Biosystems, PM10168). Stored at -20°C. 
 
Ambion® Anti-miR™ microRNA inhibitor: hsa-miR-20b (Applied Biosystems, 
AM10975). Stored at -20°C. 
 
FAM™ dye-labeled Anti-miR™ Negative Control #1 (Applied Biosystems, 
AM17012). Stored at -70°C. 
 
FAM™ dye-labeled Pre-miR™ Negative Control #1 (Applied Biosystems, 
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Cell cycle assay reagents 
 
Citrate buffer stock solution: 2000mg trisodium citrate (BDH Laboratory Supplies, 
301287F), 121mg Tris Base (Sigma-Aldrich, T1378), 1044mg spermine 
tetrahydrochloride (Sigma-Aldrich, S2876), and 2ml nonidet NP40 (Sigma-Aldrich, 
N3516), pH 7.6, in 2000ml dH2O. Stored at 4°C. 
 
Solution A: 10mg trypsin type IX-S (Sigma-Aldrich, T0303) in 500ml dH2O, pH7.6. 
Stored at 4°C. 
 
Solution B: 250mg trypsin inhibitor (Sigma-Aldrich, T9253) and 50mg RNase A 
(Sigma-Aldrich, R4875) in 500ml dH2O, pH 7.6. Stored at 4°C. 
 
Solution C: 208mg propidium iodide (Sigma-Aldrich, 81845) and 500mg spermine 
tetrahydrochloride (Sigma-Aldrich, S2876) in 500ml dH2O, pH 7.6. Stored at 4°C. 
 
 
Sulforhodamine B (SRB) assay reagents 
 
25% Trichloracetic acid (TCA) solution: by dilution of 100% TCA solution (Sigma-
Aldrich, T4885-500G). Stored at 4°C. 
 
1% acetic acid solution: by dilution of 20ml of Glacial Acetic Acid (BDH, 10001 6x) 
into distilled water to a final volume of 2 litre. 
 
0.4% SRB solution: by dissolution of 2g of SRB (Sigma-Aldrich, S9012-5G) in 1% 
acetic acid solution to a final volume of 500ml. Stored at 4°C. 
 
10mM Tris solution pH 10.5: by dissolution of 1.21g of Tris base in water to a final 
volume of 1 litre with addition of HCl to pH 10.5. Stored at 4°C. 
 
Cisplatin (Faulding DBL, 100mg/100ml). 
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Transwell migration assay materials 
 
Matrigel™ Basement Membrane Matrix (BD Biosciences, 354234). Stored at -20°C. 
 
Transwell inserts (Corning Inc, 3422). 
 
Calcein-AM (Biotium, 30026). Stored at -20°C. 
 
 
Colony formation assay reagents 
 
2x Minimum Essential Medium (MEM) (Invitrogen, GIBCO®, 21935). Stored at 
4°C. 
 
2.8% (w/v) Methylcellulose (RD system, HSC001).  Stored at -20°C. 
 
UltraPure™ Agarose (Invitrogen, 15510-027). 
 
 
2.1.9 Human tissue samples 
 
For Chapter 3, 18 benign naevi (archived between 2005 and 2006) and 21 metastatic 
melanoma samples (archived between 1993-1997) were cored (∅2mm cores) from 
Formalin Fixed Paraffin Embedded (FFPE) blocks by Bob Morris. Primary 
melanoma tissues (archived between 1992-1997) were obtained from 
macrodissection of 10µm sections of FFPE blocks. All the tissue blocks were marked 
by pathologist, Thomas Brenn. 
 
For Chapter 5, 115 primary and 29 metastatic melanoma FFPE samples with 
complete clinical records were obtained from Ewan Brown’s tissue microarray 
(TMA) panel. Cores from the above sample blocks are ∅0.6mm.  
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Clinicopathological data were collected using the Scottish Melanoma Group (SMG) 
database. FFPE benign naevi, primary and metastatic melanoma specimens were 
obtained with local ethics committee approval from the Pathology Department, 
Royal Infirmary, Edinburgh. 
 
 
2.1.10 Macrodissection reagents and materials 
 
Plain glass slides without any charge or adhesive (VWR International). 
 
Nuclear Fast Red stain (Sigma-Aldrich, N3030-100ml, 0.1% solution in 5% 
aluminium sulphate). 
 
Razor blades (Swann-Morton, Ref 0505). 
 
RNaseZap (Applied Biosystems, AM-9780/9784). 
 
Digestion buffer (Applied Biosystems, AM1975).  
 
 




Bio-Rad PCR Thermal Cycler DNA Engine TETRAD2. 
 
Stuart Orbital Shaker SSL1. 
 
Whirlmixer™ Fisons SGP-202-010J.  
 
Sanyo CO2 Incubator MCO-17A. 
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Centrifuges: Eppendorf Germany 5415R and 5702, Hettich Mikro 20, Heraeus 
Multifuge 3S-R,  Sorvall® Microspin 24S. 
 
Labtech Thermo Nanodrop 2000 spectrophotometer. 
 
Grant Instrument (Cambridge) Ltd. Water Bath, TYPE JB1. 
 
Grant Instrument (Cambridge) Ltd. Heat block, BT3.  
  
Microscope: Leica TYPE 090-135.001 (Cell culture), Nikon Eclipse Ti. 
 
HYBAID Oven, MINI 10. 
 
SCIE-PLAS Electrophoresis system. 
 
Bio-Rad Gel Doc 2000. 
 
Bio-Rad Protein Mini-PROTEAN3™ electrophoresis system. 
 
Beckman Coulter Counter Z series.  
 
Thermo ELECTRON CORPORATION  Multiskan Spectrum. 
 
Fisher Scientific Bio-TEK plate reader, synergy HT. 
 
Applied Biosystems HT7900. 
 
Confocal Leica SP5 with Laser lines: 488nm, Objectives: 10x 0.4 N.A (ECRC). 
 
GE Image Quant LAS 4000. 
 
Heraeus HERAsafe Biological Safety Cabinet HS 12. 
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Software 
 
SDS 2.3/RQ manager 1.2 for real time PCR data analysis. 
 
GenomeStudioTM Gene Expression Module v1.0 and R 2.9.2 for microarray data 
analysis. 
 
Cluster 3.0/TreeView for Hierarchical Clustering analysis. 
 
Flow Jo 7.6.1 for cell cycle analysis. 
 
Image J 1.43u for methylcellulose assay, transwell migration assay and western 
immunoblotting quantification. 
  





2.2.1 DNA isolation and DNA based experiments 
 
DNA isolation from mammalian cell lines  
 
Genomic DNA of all cultured mammalian cells was isolated using the same method. 
Cells were plated in a 60-100mm dish prior to DNA isolation. When cells were ready, 
the medium was discarded and cells were washed once with 10ml of PBS. Cells were 
scraped from the dish in another 3ml of PBS and were transferred to two 2ml-
eppendorf tubes and cells were pelleted. Then 750ul of tail buffer and 15ul of 
proteinase K (20mg/ml) were added to each tube and the mixture was incubated 
overnight at 37°C. Protein and lipid were removed from the DNA solution by two 
extractions with 750ul PCA, followed by a 750ul CA extraction. In each case the 
phases were mixed by vigorous shaking, separated by centrifugation and the aqueous 
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phase was transferred to a fresh tube without disturbing the interphase. The genomic 
DNA was precipitated by adding 750ul of isopropanol and centrifuged at top speed 
for 6 minutes. The DNA pellet was then washed twice with 70% ethanol, air-dried, 
resuspended in sterile dH2O and stored at -20°C. 
 
 
DNA isolation from FFPE samples  
 
Primary and metastatic melanoma FFPE sample cores (2-3 cores/tube) were de-
paraffinised with 1ml xylene. Following centrifugation, the xylene was discarded and 
the samples were washed with absolute alcohol and air-dried. DNA was extracted 
from the deparaffinised tissue using the QIAamp® DNA Micro isolation kit and 
following the manufacturer’s protocol. Briefly, samples were resuspended in 15ul 
ATL (a buffer with proteinase K to lyse samples) buffer and 10ul proteinase K 
solution supplied from the kit, mixed thoroughly and incubated at 56°C overnight. 
25ul of ATL and 50ul of buffer AL (a buffer to allow optimal binding of DNA to the 
membrane), followed with 50ul of absolute alcohol were added and after incubation 
at room temperature for 5 minutes the samples were added to QIAamp MiniElute 
columns and centrifuged at 6,000g for 60 seconds. The columns were washed by 
500ul AW1 (washing buffer 1 for clean up of genomic DNA) and 500ul AW2 
(washing buffer 2 for clean up of genomic DNA) buffers respectively and 
centrifuged at 6,000g for 60 seconds again. DNA was eluted in 25ul sterile dH2O by 




Measurement of DNA concentration 
 
DNA samples were measured using the Thermo Nanodrop spectrophotometer. 
Sterile dH2O was used to blank the Nanodrop spectrophotometer and the DNA50 
parameter was chosen. Then 1.5-2.0ul of each sample was added to the Nanodrop 
spectrophotometer and the software gave the concentration of each sample and the 
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OD260/280 ratio. The OD260/280 ratio provides a measure of the purity of nucleic 
acid solutions and the extent of protein contamination. Ratios between 1.75 and 1.9 
are regarded as acceptable for DNA. DNA50: for double stranded DNA, when 
OD260=1, DNA concentration is 50ug/ml. 
 
 
Nested  PCR and restriction digestion for genotyping BRAF V600E mutation 
 
Routine PCRs were prepared in a 50ul volume containing 5x PCR buffer, 25mM 
MgCl2, 5mM dNTP, 1U Taq DNA polymerase, 25pmol/ul forward and reverse 
primers and ~100ng genomic DNA template. A negative control containing no DNA 
template was present each time. Nested PCR is a modification of the basic PCR 
procedure intended to reduce the contamination in low abundance products due to 
the amplification of unexpected primer binding sites. The specific nested PCR 
programmes were as follows: 
 
            First round                                      Second Round (nested)  
Step1:  1x 94°C 4 minutes                   1x         94°C 4 minutes 
Step2:  35x 94°C 30seconds                  35x       94°C 30seconds 
             61°C 30seconds                               58°C 30seconds 
             72°C 30seconds                               72°C 30seconds 
Step3:  1x 72°C 5minutes                    1x         72°C 5minutes 
Step4:              10°C ∞                                             10°C ∞ 




XbaI restriction fragment length polymorphism (RFLP) analysis 
 
Restriction digests contained 2-4U restriction enzyme per 1ug DNA and the XbaI 
reaction buffer supplemented with 100ug/ml BSA. Restriction digests were 
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Cut control                                                   Uncut  control 
PCR DNA        15ul                                     PCR DNA         15ul 
10X Buffer         3ul                                     10X Buffer          3ul 
XbaI     2ul                                     dH2O                  12ul 
dH2O              10ul 
 
Incubate at 37°C for 2 hours 
Product: 105bp if BRAF V600E mutation is present. 
 
Digests, cut control (positive control) and uncut control (negative control) samples 
were loaded onto a 2-3% agarose gel. 
 
 
Assessment of sensitivity of genotyping method 
 
A heterozygous BRAF V600E mutation positive melanoma cell line—G361 (mutant) 
and a BRAF mutation negative ovarian cancer cell line—PEO1 (wild type) were 
used to test the sensitivity of the assay. First, 1, 2 and 3ul of the two genomic DNAs 
were run on a gel to confirm their relative DNA concentrations. Secondly, DNA 
solutions of the two cell lines were diluted until they were at a similar concentration 
to the DNA concentrations of the FFPE samples. Thirdly, different amount of DNA 
from the BRAF V600E wild type cell line and from thr BRAF mutant cell line were 
mixed in ratios 100:0, 90:10, 80:20, 50:50, 0:100 so that the total amount of DNA in 
each mixture was the same. Finally, the nested PCR and restriction digestion assays 
were run to see what was the lowest ratio of BRAF V600E containing DNA that 





DNA fragments were separated on 2-3% (w/v) agarose gels containing 0.5ug/ml 
ethidium bromide and 0.5x TBE. DNA samples were mixed with sample buffer prior 
to loading. Electrophoresis was carried out at 30-100V in 0.5x TBE buffer. DNA was 
visualized by UV illumination and Hyperladder I/VTM was used as a size marker. 
 
Chapter 2: Materials and Methods 66 
2.2.2 RNA isolation and RNA based experiments 
 
RNA isolation from mammalian cell lines  
 
Prior to total RNA isolation, cells in plates/dishes were washed with PBS twice. 
Total RNA was then isolated from cultured mammalian cell lines using the reagent 
RNAzolTMB. Cultured cells were lysed directly in the culture dish by the addition of 
RNAzolTMB (0.2ml/106 cells) and lysate was mixed by pipetting several times. The 
RNA was extracted by the addition of 0.2ml chloroform/ml of RNAzolTMB followed 
by vigorous shaking of the mixture for 30 seconds. The emulsion was then 
centrifuged at 12,000g for 15 minutes at 4°C. The aqueous phase was transferred to a 
fresh tube and an equal volume of isopropanol was added. RNA was allowed to 
precipitate at room temperature for 10 minutes and was then pelleted by 
centrifugation at 12,000g for 5 minutes. The RNA pellet was then washed in 70% 
ethanol and centrifuged at 7500g for 5 minutes. The pellet was allowed to air dry 
before being resuspended in 100-150ul of sterile dH2O for storage either at -20°C in 





All the sections for macrodissection were cut, mounted and stained by Helen 
Caldwell. The first three 3um sections were discarded from each block. Then 15 
10um sections were cut with a 3um section between every three 10um sections. The 
3um sections were used for H&E staining. 10um sections were stained using Nuclear 
Fast Red for dissection. After sections were cut and mounted on glass slides and 
stained either using H&E or Nuclear Fast Red, all slides were dried in an oven. 
 
The specific area for dissection was marked by Thomas Brenn on the H&E slides. 
The Nuclear Fast Red stained slides were placed on the microscope stage and the 
melanocytic cells were scraped with a razor blade that had been slightly moistened 
with Digestion buffer.  Non-tumour elements, such as lymphocytes, blood vessels 
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and connective tissues were avoided. The scrapings were removed with a fine sterile 
pipette tip, and placed in a microfuge tube containing 100-200ul Digestion buffer. 
The above scraping steps were repeated from additional 10um sections until the 
Digestion buffer in the tube became pink in colour with the stained scrapings. 
 
 
RNA isolation from melanocytic tissue samples 
 
Melanocytic FFPE samples were isolated using the RecoverAll™ Total Nucleic Acid 
Isolation Kit with the guidance of the protocol. The recovered nucleic acids with this 
kit are suitable for downstream applications such as microarray analysis, quantitative 
real-time RT-PCR, and mutation screening. Briefly, the FFPE samples (3-4 cores or 
scrapings from 15 sections per tube) were de-paraffinised with 1ml 100% xylene, 
mixed and incubated at 50°C for 3 minutes. Xylene was then discarded after 
centrifugation at top speed for 2 minutes. The sample pellet was washed twice with 
1ml absolute alcohol and air-dried. Digestion buffer and protease were added to the 
pellet and incubated at 50°C for 15 minutes and then 80°C for 15 minutes. Isolation 
additive/ethanol mixture was then added and mixed. The whole mixture was passed 
through a Filter Cartridge and washed with 700ul of Wash1 and 500ul of Wash2/3. 
After centrifugation to remove residual fluid, DNase solution was added to each 
Filter Cartridge and incubated for 30 minutes at room temperature. The Cartridge 
was then washed with Wash1 and Wash2/3 again and RNA was eluted in sterile 
dH2O for storage either at -20°C in the short term, or at -70°C for longer periods. 
 
 
Measurement of RNA concentration 
 
RNA samples were measured using the Thermo Nanodrop spectrophotometer. Sterile 
dH2O was used to blank the Nanodrop spectrophotometer and the RNA40 parameter 
was chosen. Then 1.5-2.0ul of each sample was added to the Nanodrop 
spectrophotometer and the software gave the concentration of each sample and the 
OD260/280 ratio. The OD260/280 ratio provides a measure of the purity of nucleic 
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acid solutions and the extent of protein contamination. Ratios between 1.8 and 2.0 
are regarded as acceptable for RNA. RNA40: for single stranded RNA, when 
OD260=1, RNA concentration is 40ug/ml. 
 
 
TaqMan real time reverse transcription PCR (real time RT-PCR) 
 
I used 10-100ng of total RNA per 15ul RT Reaction. All kit components and RNA 
samples were allowed to thaw on ice.  
 
1) RT-PCR 
Each 15ul reaction consists of 7ul RT master mix (including 0.15ul dNTP, 1.00ul 
reverse transcriptase, 1.50ul reverse transcriptase buffer, 0.19ul RNase inhibitor, 
4.16ul Nuclease-free water), 3ul primer, and 5ul RNA sample. After the above 
components were added into a 0.2ml polypropylene tube, the tube was sealed and 
mixed gently. The solution was spun down to the bottom of the tube. Then the tube 
was incubated on ice for 5mins and kept on ice until it was ready to load the thermal 
cycler. The RT-PCR programme was as follows: 
 
Step1: 16°C 30 minutes 
Step2: 42°C 30 minutes 
Step3: 85°C 5 minutes 
Step4: 4°C ∞ 
 
2) Real time PCR  
Each 20ul mixture consists of 1.00ul 20X TaqMan® MicroRNA and mRNA Assay, 
1.33ul of RT product, 10.00ul of TaqMan® 2X Universal PCR Master Mix-No 
AmpErase® UNG, 7.67ul of Nuclease-free water. To avoid pipetting many small 
amount of components, a master mix sufficient for triplicate assays on all samples 
was prepared, including 10% extra volume to account for pipetting losses, in the 
same tube. The solution was mixed gently and centrifuged to the bottom of the tube. 
Then the whole mixture, including primer and RT products, was added into a plate 
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and sealed with an optical adhesive cover (Bio-Rad Microseal® ‘B’ Film, 
MSO1001) followed with brief centrifugation of the plate and elimination of any air 
bubbles. The plate was then loaded onto the real time PCR instrument (Applied 
Biosystems HT7900). The real time PCR programme was as follows: 
 
Step1:   1x 95°C 10 minutes 
Step2: 40x 95°C 15 seconds 
                  60°C 1 minutes  
 
 
qPCR quantification method 
 
There are two major methods to quantify changes in RNA levels using real time 
PCR. One is absolute quantification and the other is relative quantification. The 
former is better to accurately determine an unknown gene’s absolute amount. 
Relative quantification is more suitable to compare expression of the same gene 
between different samples.  
 
In relative quantification, the standard curve method and comparative Ct method 
(ΔΔCt method) are two commonly used strategies. In relative quantification, for 
quantification normalized to an endogenous control, standard curves are prepared for 
both the target and the endogenous reference. For each experimental sample, the 
amount of target and endogenous reference is determined from the appropriate 
standard curve. Then, the target amount is divided by the endogenous reference 
amount to obtain a normalized target value. Again, one of the experimental samples 
is the calibrator. Each of the normalized target values is divided by the calibrator 
normalized target value to generate the relative expression levels. The standard curve 
method is a time-consuming process and dilution must be accurate.  
 
The comparative Ct method, another quantification approach, involves comparing 
the Ct values of the samples of interest with a control or calibrator such as a non-
treated sample or RNA from normal tissue. The Ct values of both the calibrator and 
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the samples of interest are normalized to an appropriate endogenous housekeeping 
gene. The comparative Ct method is also known as the 2-ΔΔCt method, where ΔΔCt = 
ΔCt sample - ΔCt reference. Here, ΔCt sample is the Ct value for any sample normalized to 
the endogenous housekeeping gene and ΔCt reference is the Ct value for the calibrator 
also normalized to the endogenous housekeeping gene.  
 
 
Validation of amplification efficiency for the ΔΔCt calculation  
 
For the ΔΔCt calculation to be valid, the amplification efficiencies of the target and 
the endogenous reference must be approximately equal. This can be established by 
looking at how ΔCt varies with template dilution. If the plot of cDNA dilution versus 
delta Ct is close to zero, it implies that the efficiencies of the target and endogenous 
control genes are very similar. A slope in the plot of log input amount (RNA/DNA 
dilution factor) versus ΔCt <0.1 passes this equivalent efficiency test [316]. This 
method increases throughput and eliminates dilution errors. However, if an 
endogenous control gene cannot be found whose amplification efficiency is similar 
to the target, then the standard curve method is preferred. 
 
In my study, amplification efficiency of various target miRNAs and mRNAs were 




Illumina microRNA microarray 
 
The microRNA microarray was done in the Genetics Core of the Wellcome Trust 
Clinical Research Facility, Western General Hospital by Lee Murphy. A brief 
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2.2.3 Protein extraction and protein detection 
 
Protein extraction  
 
Cells were first washed with cold PBS and then scraped into 1ml of cold PBS in a 
1.5ml eppendorf tube, followed by centrifugation at 3,000rpm for 3 minutes to form 
a pellet. The cell pellet was resuspended in 50-200ul RIPA lysis buffer and 
maintained on ice for 15-30 minutes. The suspension was centrifuged at 13,000rpm 
for 15 minutes at 4°C and the supernatant was collected and stored at -70°C.  
 
 
Measurement of protein concentration 
 
Protein concentrations were determined using the BCA™ Assay Kit in a 96-well 
plate. The original lysates were diluted 10-fold in dH2O to a final volume of 25ul. 
dH2O was used as a blank control. 200ul of working reagent from the kit was added 
to each sample and incubated at 37°C for 30 minutes. The plate was then scanned 
using a plate Spectrophotometer at 562nm. Concentrations of samples were 
calculated using the standard curve generated from known BSA standards and the 
dilution factor.  
 
 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Proteins with different molecular weight were separated by discontinuous SDS-
PAGE. The concentration of polyacrylamide in the resolving gel was determined by 
the molecular weight of proteins. First, a 10-12% resolving gel (used for protein 
weights between 30kDa-200kDa) was made to separate the proteins. The resolving 
gel was overlaid with isopropanol to remove air bubbles and give an even gel surface 
prior to polymerisation at room temperature. After the isopropanol was discarded the 
stacking gel was added and a comb was inserted. The comb was removed after the 
stacking gel was set and the gel cassette was assembled into the Mini-PROTEAN3™ 
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electrophoresis module and immersed in the running buffer. Appropriate amounts of 
protein samples were mixed with 4x sample buffer and were heated at 95°C for 5 
minutes before loading onto the gel along with a Prestained Protein Ladder. Proteins 






Proteins were electrophoretically transferred onto an Immobilon-P PVDF transfer 
membrane in transfer buffer according to the method of Towbin [317]. The transfer 
was completed by using a Mini Trans-Blot system (Bio-Rad) at 100V, constant 
voltage at 4°C with an ice block for 1 hour. Then the membrane was taken out and 
rinsed in TBST for 5 minutes and subsequently was blocked in the blocking buffer 
for 1 hour. The membrane was incubated overnight at 4°C with primary antibody 
that had been diluted in the blocking buffer. After washing 3 times (5-10 
minutes/wash) in TBST, the filter was incubated with secondary antibody at room 
temperature for 1 hour. Unbound antibodies were washed away by 3 TBST rinses. 
Finally, the membrane was overlaid with ECL Plus for 1 minute. Immunoreactive 
bands were visualized either by autoradiography or using the ImageQuant LAS 4000 
system (GE, ImageQuant) to make an electronic record. 
 
 
2.2.4 Cell culture and cell based experiments 
 
General culture conditions for mammalian cell lines  
 
The cell culture medium was pre-warmed to 37°C before frozen stocks of 
mammalian cells were defrosted. The frozen cell stock was then quickly thawed in a 
37°C water bath. 5ml medium was added and mixed with a cell suspension. A cell 
pellet was then formed by centrifugation at 1,300 rpm for 5 minutes. A single cell 
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suspension was prepared in fresh medium and transferred to appropriate flasks for 
culture. Flasks were incubated at 37°C in 5% CO2. 
 
When the cells were confluent, the medium was removed and trypsin-EDTA was 
added to the flasks (1ml/25cm2 flask) for 5 minutes. Trypsin is a serine protease that 
can make adhesive cells detach from the culture surface. 4ml fresh medium was 
added to the cell-trypsin suspension and the mixture was then centrifuged at 1,300 
rpm for 5 minutes to form a cell pellet. The cell pellet was resuspended in an 
appropriate volume of fresh medium, either for a future culture or for downstream 
work. As commonly used mammalian adherent cell lines divide approximately once 
every 24 hours, the cells were passaged to 12.5-25% confluency. Passaging was 
routinely carried out once every 2-4 days. 
 
 
Cryopreservation of cell lines 
 
Cells were trypsinised and a cell pellet was made by centrifugation at 1,300 rpm for 
5 minutes and was then resuspended in cell culture medium containing 10% (v/v) 
DMSO and 20% FCS (cells from a 10cm diameter area were resuspended in 1ml 
total volume). The use of DMSO increases the survival of cells during freezing and 
thawing by minimising the formation of ice crystals within the cells. Prior to 
transferring cell stocks to a liquid N2 cryostore for indefinite storage, the cell stocks 





Cells were diluted 1:100 in isoton (Coulter Isoton® II dilents) and counted using the 
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Lipid-based reverse transfection 
 
In traditional transfection of adherent cells, the amount of exposed cell surface, and 
not the number of transfection complexes, is the limiting factor to transfection 
efficiency [318]. Reverse transfection is believed to increase cell exposure to 
transfection complexes, often leading to greater transfection efficiency. 
 
Reverse transfection (also called Neofection), developed by Ambion, is a more 
streamlined transfection method. Reverse transfection involves simultaneously 
transfecting and plating cells, much like products used for transfecting suspension 
cells. siPORT NeoFX Transfection Agent and RNA are mixed, incubated, distributed 
to culture wells, and overlaid with cells. The method produces equivalent or 
improved transfection efficiency over the standard pre-plated method for many of the 
cell types tested and saves an entire day in the process [318]. siPORT NeoFX 
Transfection Agent is a lipid-based formulation that provides extremely high levels 
of transfection without inducing cellular stresses common to other transfection 
agents. 
 
Prior to the specific experiments, the best transfection efficiency was assessed using 
mixtures of different volumes of siPORT NeoFX and the negative control small 
RNA. Assessment of transfection efficiency is described in the next section.  
 
The brief procedure for the specific transfections in my project was as follows: I used 
two types of tissue culture plate for transfection, 12-well and 6-well. First, melanoma 
cells were trypsinised and diluted in normal growth medium to 105 cells/ml. Cells 
were set aside at 37°C in the incubator while the transfection complexes were 
prepared. Appropriate volumes of siPORT NeoFX were diluted in OPTI-MEM I 
medium and incubated for 10 minutes at room temperature. Then appropriate 
amounts of small RNAs (precursors and inhibitors of specific microRNAs) were 
diluted into OPTI-MEM I medium. Diluted siPORT NeoFX and diluted small RNA 
were mixed and incubated for 10 minutes at room temperature and dispensed into a 
culture plate. Finally, the prepared cell suspensions were placed onto the siPORT 
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NeoFX/small RNA complexes and the plates were put into the incubator. The 
medium in each well was replaced daily with fresh normal culture medium. 
 
 
Assessment of transfection efficiency  
 
FAM™ dye-labeled Pre-miR™ Negative Control is a carboxyfluorescein (FAM™)-
labeled double-stranded RNA oligonucleotide designed for monitoring uptake of Pre-
miR™ microRNA precursors by fluorescence microscopy or flow cytometry.  
 
FAM™ dye-labeled Anti-miR™ Negative Control is a carboxyfluorescein (FAM™)-
labeled RNA oligonucleotide designed for monitoring uptake of Anti- miR™ 
microRNA inhibitors by fluorescence microscopy or flow cytometry. 
 
Different volumes for siPORT NeoFX and FAM dye negative control were 
sequentially mixed and transfected to melanoma cells. Cells were examined using 
Fluorescence-activated Cell Sorting (FACS) at several times (24-hour, 48-hour and 
72-hour) after transfection to obtain the best match of siPORT NeoFX and small 
RNA that produced the highest transfection efficiency. Results are shown in Chapter 
4.2.1. 
 
Final concentration of the small RNA used: 30nM for precursors, 150nM for 
inhibitors. Final volumes of siPORT NeoFX: 8ul/well in 12-well plates, 16ul/well in 
6-well plates. 
 
Cells were transfected with small RNAs for 16-18 hours prior to the downstream 
experiments, including cell proliferation, cisplatin sensitivity, methylcellulose 
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Cell cycle 
 
Cells were trypsinised and harvested as described above. The cell pellet was washed 
with PBS and centrifuged. The new cell pellet was then resuspended in 100ul citrate 
buffer and stored at -20°C until the day of the FACS assay. Prior to doing FACS, the 
cell suspension in citrate buffer was first treated with an appropriate volume of 
solution A for 2 minutes to lyse the cell membrane and then treated with an 
appropriate volume of solution B for 10 minutes to stop the effect of solution A. 
After a further 10 minutes of solution C treatment, the samples were ready for flow 
cytometry. All the FACS assays were done by Elizabeth Freyer and I analysed the 
data using Flow Jo software. 24-hour, 48-hour and 72-hour time courses were 
examined after transfection. 
 
 
Cell proliferation (SRB assay) 
 
Cells were plated at a density of 1,000-1,500 cells/well in 96-well plates in normal 
growth medium. Each experimental group had 16 replicates. The plates were assayed 
over four days at 24-hour, 48-hour, 72-hour and 96-hour. For the assay, 50ul of 25% 
(v/v) TCA was added to each well of the plates and incubated at 4°C for at least 1 
hour. Plates were washed with slow-running tap water for 10 times and air-dried. 
Then 50ul of 0.057% (w/v) SRB solution was added to the plates and incubated at 
room temperature for 30 minutes, and then rinsed for four times with 1% (v/v) 150ul 
of acetic acid to remove unbound dye and air-dried. 150ul of 10mM Tris solution 
(pH 10.5) was then added to each well and the plates were incubated at room 
temperature for 60 minutes with agitation to solubilise the protein-bound dye. Plates 
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Cisplatin sensitivity assay (SRB assay) 
 
Prior to seeding cells to 96-well plates, different amounts of cisplatin were prepared 
to make final concentrations at 0uM, 0.1uM, 0.3uM, 0.6uM, 1uM and 3uM. The 
following procedures were the same as described in the cell proliferation SRB assay. 
Cells were fixed at Day 5. 
 
 
Transwell migration assay 
 
An inverse invasion assay was used to test cell migration ability. The method is a 
modified version of the one devised [319] by Margaret Frame’s group at the 
Edinburgh Cancer Research Centre. In brief, an aliquot of Matrigel was thawed 
slowly on ice. Ice-cold PBS and the Matrigel were mixed 1:1 and 100ul of the 
mixture was added to each Transwell that was later inserted into a 24-well plate. The 
plate was incubated for at least 30 minutes at 37°C to allow the Matrigel to set. 
During this time, 105-4x105/ml cell suspensions were prepared in their normal 
growth medium. When the Matrigel was set, the Transwells were inverted on the lid 
of the plate and 100ul of cell suspension were added onto the underside of the filter 
of the each Transwell. The Transwells were carefully covered with the base of the 
plate such that it contacted the droplet of the cell suspension. The inverted plate was 
put into the incubator for 2-4 hours to allow the cells to attach to the filter. The plate 
was turned right-side-up after incubation. Each Transwell was dipped sequentially 
into 3x1ml serum free medium to wash away the unattached cells. The Transwells 
were left in the third change of serum free medium and 100ul of normal growth 
medium with serum were added into each Transwell on top of the Matrigel. (In this 
case, there was DMEM with serum only in the Transwell not in the well-chamber. 
Therefore, cells should migrate through the Matrigel towards the serum.) The plate 
was then put back to the incubator for 5 days.  
 
After 5 days of incubation, fixation and staining of the Transwells were done prior to 
confocal microscope scanning. The procedure was as follows: For n Transwells,  
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(n+1) ml of serum free medium was put into a universal and (n+1) ul of Calcein-AM 
was added [320]. 0.5ml of this mixed solution was added to each of the n wells of the 
plate. The n Transwells were put into the n wells of the plate. Another 0.5ml of the 
mixture was then added into the top of each Transwell. The plate was put into the 
incubator for at least 1 hour and then examined immediately on the confocal 
microscope.  
 
Horizontal z-sections through the Matrigel were examined at 10-15µm intervals 
using a Leica confocal microscope to assess how far the cells had migrated from the 
bottom layer of the Matrigel towards the top layer (Figure 2.1). The bottom layer is 
adjacent to the filter of the Transwell. Therefore, it contains the most cells and has 
the brightest fluorescence. The middle layer contains less cells compared to the 
bottom layer so that it has less fluorescence. The top layer indicates the layer that has 
no cells and so no fluorescence. The further and the more cells that migrate, the 
stronger the invasive ability the cells have. For each Transwell, 3-5 different fields at 
each layer were randomly picked and scanned as replicates of each group. Data were 
analysed using Image J to quantify cell invasive ability through both distance of 
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Figure 2.1 The 3D confocal microscope scanning model. The cube represents a Transwell. X, Y, Z 
represent the three dimensions respectively. The green round circles represent cells at different layers. 
Bottom layer: lots of fluorescent cells; Middle layer: reduced number of fluorescent cells; Top layer: 
very few fluorescent cells. Black arrow represents the scanning direction from bottom to top.  
 
 
Colony formation assay  
 
The methylcellulose assay was used to test the colony formation ability of tumour 
cells. This is a recognised in vitro surrogate assay for in vivo tumourigenicity and has 
been described to support colony formation of various human tumours [321]. In brief, 
1.8% (w/v) agarose solution was made and boiled. The melted agarose solution was 
diluted 1:1 in fresh 2x MEM medium supplemented with 10% FCS, NEAA, Sodium 
Pyruvate, P/S and L-glutamine. 2ml of the mixture was then quickly poured into each 
well of a 6-well plate and left aside until solid. During this time, 2.8% 
Methylcellulose solution was prepared in MEM medium using 2x MEM with the 
same supplements. An appropriate number of cells were mixed with the 
methylcellulose solution and 2ml of the mixture was poured onto the bottom agarose 
base. 5x103-104 cells were seeded in each well. The 6-well tissue culture plates were 
incubated at 37°C in 5% CO2 for 9-12 days.  
 
Images of colonies were taken at Day1, Day3, Day6, Day9, Day12. About 30 
colonies of each experimental group were used in calculation of colony size. Data 
were analysed using Image J. Images of entire wells were also taken on the Gel Doc 





All the statistical analysis was done using Prism except for analysis of microarray 
results. T-test and One-way ANOVA for Chapters 3 and 4. Chi-square, Fisher’s 
exact and Kaplan Meier survival for Chapter 5. P=0.05 was used as the significance 
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level, except where the Bonferroni correction was applied. All the statistical tests are 
two-sided. 
 
Data analysis of microarray was done using R language and Cluster 3.0 and 
TreeView. More information on statistical analysis of the microarray data is 
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A study by Rosenfeld et al. showed that microRNAs (miRNAs) can accurately 
identify cancer tissue origin [322], indicating that miRNA profiling in cancer 
diagnosis may be superior to mRNA gene signatures. Besides its diagnostic 
advantages, the miRNA expression profile is found to correlate with survival in 
cancer patients. Given the tremendous regulatory potential of miRNAs and their 
often tissue-specific and disease-specific expression patterns [295, 323], several 
unique miRNA expression profiles have been found to be associated with bio-
molecular and prognostic characteristics of human lung cancer, chronic lymphocytic 
leukemia and ovarian cancer [283, 293, 324], indicating that miRNA signatures 
could be used to define biological or clinical features of human cancers.  
 
When this study started there were only a very limited number of studies 
investigating melanoma-specific miRNA expression patterns and their role in 
cutaneous melanoma. The first two expression profiling studies identified a set of 17 
miRNAs that were expressed significantly differently in eight melanoma cell lines 
compared to other cancer cell lines [325, 326]. A following microarray-based 
miRNA profiling studied, carried out only on melanocytes and melanoma cell lines 
derived from either primary or metastatic melanomas, discovered a number of 
miRNAs differentially expressed in melanoma cells compared to melanocytes [327]. 
However, the above differentially expressed miRNAs from the literature were 
obtained from cell-based microarray, not from tissue profiling. Moreover, there was 
no miRNA expression profile available based on tissue samples to interpret the roles 
of these miRNAs in the progression of melanoma systematically and investigate their 
prognostic value using different stages of melanocytic lesions. Therefore, the main 
aims of this chapter are: first, to identify a melanoma-specific miRNA expression 
profile on tissues; secondly, to obtain miRNA candidates as biomarkers of 
melanoma; thirdly, to pinpoint potential miRNAs which might be acting in the key 
regulatory pathways in the pathogenesis of cutaneous melanoma. 
 
What is the best way to detect miRNA expression? What type of samples can bring 
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the most benefits for this study? These are the initial questions to be answered.  As 
described in Chapter 1, there are different methods to detect miRNA expression such 
as northern blotting, quantitative RT-PCR (qRT-PCR or real time RT-PCR), and 
microarray. Microarray has the advantage in detecting expression of thousands of 
miRNAs in multiple samples, making it ideal for large screening experiments. The 
Illumina miRNA expression profiling assay uses human- and mouse- specific panels 
containing the most current content for profiling miRNA expression in a highly 
multiplexed assay with flexible multi-sample readout formats. It has several 
advantages, such as its high sensitivity, low sample input (100-200ng of total RNA 
which is very important due to the low harvest of total RNA from FFPE samples), 
robust nature and high specificity. The human miRNA panel contains 1,146 assays 
including seven types of built-in control probes, for detecting more than 97% of the 
miRNAs described in the miRBase database [328]. This assay takes advantage of 
enzymatic primer extension in addition to hybridization to achieve high mismatch 
discrimination. It has been reported that the Illumina BeadArray platform has the 
highest built-in feature redundancy of any currently available array, which further 
increases reproducibility and improves the signal-to-noise ratio [329]. The 
methodology of the Illumina Beadarray panel is a modification of an assay 
developed previously for high-throughput gene expression profiling, the DASL_ 
Assay (cDNA-mediated annealing, selection, extension and ligation) [329]. This 
assay could distinguish between individual miRNAs within families and could 
analyze the expression of 735 human miRNAs from the miRBase. The 735 target 
miRNAs included 470 well-annotated human miRNA sequences (miRBase: 
http://microrna.sanger.ac.uk/, version 9.1, February 2007 Release) and 265 miRNAs 
identified later [330, 331]. Expression profiles obtained by the method are highly 
comparable to that obtained by qRT-PCR and direct sequencing [332]. Finally, this 
method, in conjunction with the 96-sample array matrix should prove useful for high-
throughput expression profiling of miRNAs in large numbers of tissue samples 
simultaneously [332].  
 
However, microarray technology is only semi-quantitative and cannot distinguish 
between highly homologous mature miRNAs within a family accurately because of 
 
Chapter 3: Expression screen for melanoma-specific microRNAs 
 in FFPE tissues 
84 
its inability to optimize hybridization conditions for all miRNAs [333], although the 
use of locked nucleic acid-modified [334] probes has improved specificity [335]. 
qRT-PCR is the “gold standard” for validating microarray data and is an invaluable 
tool for highly sensitive and accurate profiling of miRNA population subsets. 
TaqMan MicroRNA Assays offer several distinct advantages over conventional 
miRNA-detection methods:  
 
High-quality quantitative data – the assays can detect and quantify miRNA over 
more than six logs of dynamic range.  
 
Sensitivity – the assays can detect miRNAs in as little as 1 to 10ng of total RNA, 
allowing conservation of limited samples.  
High specificity – the assays claim to detect only mature miRNA, not its precursor, 
with single-base discrimination.  
 
Fast and simple methodology – the two-step protocol takes less than four hours.  
 
The real time RT-PCR for determining miRNA expression uses a stem-loop reverse 
transcription primer to generate cDNA templates, which are then amplified using 
specific primers and detected with specific fluorescent probes (Figure 3.1). In 
TaqMan real-time PCR assays, the assay probe carries a fluorogenic reporter dye at 
its 5' end and a quencher at its 3' end. The quencher absorbs the fluorescence 
emission of the reporter while the two are close to each other as part of the probe, 
which means there is no fluorescent signal detected. During each cycle of PCR, the 
physical separation of the reporter and quencher dyes caused by the action of Taq 
DNA polymerase results in an increase in fluorescent signal. The Ct (cycle threshold) 
value is defined as the number of cycles required for the fluorescent signal to cross 
the threshold (ie exceed background level). Ct levels are inversely proportional to the 
amount of target nucleic acid in the sample (ie the lower the Ct level the greater the 
amount of target nucleic acid in the sample). Generally, when real time assays 
undergo 40 cycles of amplification, Cts < 29 are strong positive reactions indicative 
of abundant target nucleic acid in the sample, Cts of 30-37 are positive reactions 
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indicative of moderate amounts of target nucleic acid, Cts of 38-40 are weak 
reactions indicative of minimal amounts of target nucleic acid which could represent 
environmental contamination. Whether the Ct value is high or low mainly depends 







             
              Step 1 Polymerization                                                Step 2 Strand Displacement 
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             Step 3 Cleavage                                                   Step 4 Completion of Polymerization 
 
Figure 3.1 The workflow of TaqMan qRT-PCR. (A) Two-step RT-PCR. (B) TaqMan MGB Probes 
and their detection system in Real Time RT-PCR. Adapted from [336]. 
 
Fresh-frozen tissue has traditionally been the standard source for miRNA expression 
profiling studies. Given the enormous amount of physiological information stored in 
archived FFPE tissue and the abundance of clinical data retrievable in association 
with it, it will prove invaluable if miRNA expression levels could be routinely and 
systematically analyzed in FFPE tissues. Moreover, unlike the situation in other 
tumours, the study of the molecular biology of melanomagenesis has been 
constrained by a combination of small tumour specimens and unavailability of fresh 
tissue. Numerous studies have documented that it is feasible and informative to 
characterize miRNA from FFPE samples with qRT-PCR [311, 312], as well as 
microarrays [322, 337, 338]. For melanocytic lesions, a study by Glud et al. showed 
that high-quality miRNA can be extracted from FFPE naevi and that reproducible 
and comparable miRNA expression profiles can be obtained from FFPE and fresh 
frozen samples [339].  
 
Taken together, Illumina miRNA Expression Profiling Human microarray (Version2) 
and TaqMan MicroRNA Real Time PCR Assays were chosen to detect miRNA 
expression in both cultured cells and FFPE samples. It was expected that the miRNA 
candidates from archival FFPE tissues rather than cultured melanoma cells would be 
the better source of miRNA biomarkers and miRNAs involved in melanomagenesis.  
 
In melanoma research, morphological separation is particularly difficult for certain 
types of melanocytic lesion such as dysplastic naevus, naevus of special sites, naevus 
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with dermal regression, recurrent naevus and Spitz naevus, as well as for specific 
types of melanoma. Blue naevus and Spitz naevus are two types of melanocytic 
naevus, which are uncommon and generally benign. Dysplastic naevus is an atypical 
melanocytic naevus, a mole whose appearance is different from that of common 
moles. Generally, it is believed that individuals with multiple dysplastic naevi are at 
much higher risk for developing melanomas. However, whether the dysplastic 
naevus represents a transition between benign naevus and melanoma is still 
controversial.  
 
The most difficult diagnostic problems in separating naevi from melanomas are 
benign naevi showing clinical and/or histological features of malignancy and 
melanomas mimicking benign naevi [340-342]. Superficial spreading melanoma is 
the commonest melanoma subtype in adults, but it has significant clinical as well as 
histological overlap with dysplastic naevi. Therefore, reliable separation is difficult 
to make and is impossible in some cases. Benign acquired melanocytic naevi may 
also show specific changes more classically associated with melanoma. Spitz naevi 
are characterized by distinct cytological features, as well as atypia and mitotic 
activity more usually associated with melanoma and distinction from melanoma is 
notoriously difficult. These tumours most frequently present in childhood and 
adolescence and misdiagnosis as childhood melanoma or underdiagnosis can result 
in disastrous consequences for the patient. Similarly, naevi at special anatomical sites 
may show an atypical clinical presentation and share many histological features with 
invasive melanoma despite their benign behaviour. The most important sites include 
the vulva, acral locations as well as the ear, areas where extensive surgery is difficult 
and potentially mutilating. Finally, naevoid melanoma is characterized by 
histological features reminiscent of a banal melanocytic naevus. This represents one 
of the most challenging diagnoses in Dermatopathology and most cited cases have 
only been diagnosed retrospectively following melanoma recurrence [342]. In 
conclusion, there is an urgent need for adjuvant molecular markers to precisely 
separate benign from malignant melanocytic disease.  
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In this Chapter, I obtained a melanoma-specific miRNA expression profile based on 
FFPE samples by using miRNA microarray. 23 miRNAs with higher functional 
potential were selected as candidates from more than two hundred differentially 
expressed miRNAs between benign naevi and malignancies.  Furthermore, nine 
specific miRNAs from the 23 candidates were verified by qRT-PCR and some of 
them were taken on into functional assays, which are described in Chapter 4. Finally, 
expression of five miRNAs from the nine verified miRNAs was determined using 
qRT-PCR in additional melanocytic lesions, including Blue naevus, Spitz naevus and 
dysplastic naevus FFPE samples. 
 
 
3.2        Results 
 
 
3.2.1 Pilot qRT-PCR in cultured cells and FFPE tissues 
 
 
In order to test the feasibility of quantifying expression of miRNAs in melanoma 
FFPE samples by TaqMan qRT-PCR and look for appropriate endogenous control 
RNAs for the assay, a series of pilot experiments were first carried out in both human 
cell lines and FFPE samples. 
 
Ten miRNAs were selected and their expression was determined in seven human cell 
lines including two immortalized melanocytes (HER1 and HER4), four malignant 
melanoma cell lines (EDMEL3, G361, C32 and A375) and one ovarian cancer cell 
line (PEO1) by TaqMan qRT-PCR (Table 3.1). RNU6B is commonly used as an 
endogenous control in qRT-PCR assays. However, from my results I considered it 
unsuitable for this purpose since the amount of RNU6B was low in each sample (the 
majority of Ct values were higher than 29) and there were considerable variations 
between the cell lines. miR-92 was a better endogenous control and was chosen 
instead since it was abundant in all cell lines and its Ct value was much more 
constant between cell lines than that of RNU6B. The remaining eight miRNAs were 
selected from unpublished and published reports describing their relevance to 
melanoma [325, 326, 343-345]. Expression of all eight miRNAs was detected in 
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melanocytes or melanoma cell lines (Table 3.1). There were variations in both the 
level of the same miRNA between cell lines and of the different miRNAs in the same 
cell line. In general, expression of miR-211, miR-10b and let-7b was much more 
abundant compared to miR-214, miR-373, miR-335, miR-199a and miR-137. More 
interestingly, expression of miR-211 was much lower (103-4-fold) in all tumour cell 
lines (except G361) than in the immortalized melanocytes. 
	  
In FFPE specimens, using the same input amount of total RNA (10ng), expression of 
three miRNAs in six old primary melanoma tissues was quantified by the same qRT-
PCR assays used on the cultured cells (Table 3.2).  All three miRNAs were 
successfully detected in the FFPE samples, although the Ct values for the miR-92 
control were around five cycles higher than in cultured cells and showed more 
variation between samples. Ct values for miR-214 were actually smaller in FFPE 
tissues than in most of the cultured cell samples. I conclude that it is realistic to 
investigate miRNA levels in FFPE melanoma tissues. 
 
 
Table 3.1 Expression of microRNAs in cultured cells. Expression of 10 small RNAs was 
determined by TaqMan qRT-PCR on seven human cell lines: two immortalized melanocytes (HER1 
and HER4), four malignant melanoma cell lines (EDMEL3, G361, C32 and A375) and one ovarian 
cancer cell line (PEO1). Results represent average Ct values ± STDEV of once in a triplicate repeat 




miRNA HER1 HER4 EDMEL3 G361 C32 A375 PEO1 
miR-92 22.6±0.3 22.8±0.2 21.6±0.2 22.1±0.1 22.6±0.2 22.2±0.2 21.6±0.2 
RNU6B 30.0±0.4 29.6±0.2 32.8±0.5 30.5±0.7 31.2±0.5 34.9±0.3 31.2±0.2 
miR-211 22.2±0.5 23.6±0.3 32.3±0.1 24.8±0.1 32.6±0.1 36.2±0.5 37.9±0.7 
miR-10b 26.6±0.5 26.7±0.4 27.0±0.4 27.8±0.5 27.1±0.3 31.4±0.3 28.0±0.5 
miR-214 35.5±0.5 37.5±0.2 23.1±0.2 35.6±0.1 36.4±0.4 34.6±0.3 34.5±0.6 
let-7b 25.8±0.2 26.3±0.2 23.1±0.3 25.4±0.5 24.0±0.2 26.9±0.1 22.6±0.3 
miR-373 37.7±0.7 N/A 38.3±0.2 37.7±0.7 N/A 38.3±0.5 N/A 
miR-335 35.3±0.1 N/A 31.4±0.6 N/A N/A 36.9±0.4 30.8±0.1 
miR-199a N/A N/A 29.3±0.5 N/A N/A N/A N/A 
miR-137 N/A N/A N/A 34.7±0.6 37.8±0.2 37.5±0.7 N/A 
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miRNA 
No.4 No.5 No.6 No.7 No.8 No.9 
miR-92 25.7±0.1 26.3±0.6 26.0±0.3 28.5±0.4 26.3±0.3 29.2±0.4 
miR-211 31.7±0.2 31.6±0.2 30.1±0.6 32.4±0.4 32.4±0.6 34.9±0.3 
miR-214 30.6±0.4 32.5±0.4 33.0±0.6 33.3±0.5 34.3±0.2 33.8±0.4 
 
Table 3.2 Expression of microRNAs in primary FFPE melanoma tissues. Expression of miR-92, -
211 and -214 was determined by TaqMan qRT-PCR in six primary FFPE melanoma tissues (No.4-9). 




3.2.2 High throughput screen of melanoma-specific microRNAs  
 
3.2.2.1 Sample preparation and processing of Illumina microRNA microarray 
 
My array contained 80 samples, including 19 cell lines and 61 FFPE tissues. There 
were two immortalized human melanocytes (HER1 and HER4), 13 human melanoma 
cells (A375, C32, G361, WM115, HBL and the EDMEL3 series) and four ovarian 
cancer cell lines (PEA2, PEO1, PEO14 and PEO23). The EDMEL3 malignant 
melanoma cell line was isolated from a late-recurring distal metastasis of a primary 
melanoma. Early and late passage samples of the cell line, as well as subclones with 
different morphologies (epithelial, spindle cell, mixed) were available. In addition 
cells retrieved back into culture from successful xenografts of EDMEL3 into mice 
were also included. For FFPE tissues, there were 11 benign naevi (archived between 
2005 and 2006), 29 primary (15 recurrent and 14 non-recurrent age and sex-matched 
pairs) and 21 metastatic archival cutaneous melanoma tissues (archived between 
1993-1997). Samples of benign naevi and metastatic melanomas were obtained from 
∅2mm cores of FFPE blocks by Bob Morris. For the much smaller primary 
melanomas, tumour samples were separated from adjacent non-tumour tissues by 
macrodissection of 10µm sections of FFPE blocks. Suitable areas on all the tissue 
blocks were marked by the pathologist, Thomas Brenn. 
 
To perform Illumina miRNA Microarray, 100-200ng of total RNA were required. 
Total RNA of FFPE samples were isolated using RecoverAll™ Total Nucleic Acid 
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Isolation Kit specialised for FFPE. Up to four 10um sections, or up to 35 mg of 
unsectioned core samples, can be processed per reaction. It is optimized for isolation 
of total nucleic acids, including miRNAs from FFPE tissue. Recovered nucleic acids 
are suitable for qRT-PCR and microarray analyses. The yields of total RNA of the 
FFPE samples were between 400ng and 9,000ng.	   The 260/280 ratios were 1.58-2.07. 
The full total RNA yields and the ratio of 260/280 are shown in Appendix 1.   
 
80 total RNA (200ng) samples were sent to the Genetics Core of the Wellcome Trust 
Clinical Research Facility, Western General Hospital. Illumina miRNA microarrays 
were performed using the Illumina 96-sample Universal Array Matrix by Lee 
Murphy. This involves a 3-day programme, containing several steps. First, the assay 
starts by polyadenylating 200ng total RNA with a Poly-A-Polymerase (PAP). The 
polyadenylated RNA is converted to cDNA using a biotinylated oligo-dT primer 
with a universal PCR sequence at its 5'-end. The miRNA assay monitors miRNA 
expression by targeting sequences with chimeric oligos containing universal PCR 
amplification primer sites. One miRNA-specific oligo is used to assay each miRNA. 
In this process, the biotinylated cDNA is annealed to the query oligos (microRNA 
specific oligos, MSOs). The mixture is bound to streptavidin-conjugated 
paramagnetic particles (SA-PMPs) to select the cDNA/oligo complexes. cDNA 
templates are hybridized with the set of MSOs that corresponds to all the targeted 
miRNAs. After oligo annealing, mis-hybridized and non-hybridized oligos are 
washed way. A polymerase is then added, causing the MSO to undergo extension. 
Then a universal PCR is followed. The primer on the strand that is complementary to 
the array is fluorescently labelled. After PCR amplification, the labelled, single-
stranded product is prepared for hybridization to the bead on the array containing the 
complementary address sequence. The BeadArray Reader measures fluorescence 
intensity at each addressed bead location. The intensity of the signal corresponds to 
the quantity of respective miRNA in the original samples. Finally, the miRNA 
expression data are obtained from the scanned microarray images collected from the 
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Figure 3.2 The workflow of the microRNA microarray. Adapted from [346]. 
 
 
3.2.2.2 Quality control of Illumina microRNA microarray 
 
 
The built-in control set on the microarray showed that my array data were of good 
quality (Figure 3.3). The figure shows the signals for the seven built-in controls and 
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the average miRNA signal intensity. The negative controls consist of query oligos 
targeting 15 random sequences that do not appear in the human genome. Generally, 
the mean signal intensity of these probes defines the system background. The 
background is represented by both the imaging system background and by any signal 
resulting from cross-hybridization or non-specific binding of dye. The BeadStudio 
application uses the signals and signal standard deviation (STDEV) of these probes 
to establish gene expression detection limits. The average miRNA signal intensity of 
array samples was about ten times higher than that of the negative controls in my 
array, which indicated that the array was well probed and emitted strong fluorescent 
signals compared to the negative controls. Polyadenylation control oligos detect 
transcripts of a set of highly expressed housekeeping genes that already contain a 
stretch of poly-A sequence. These target sequences do not need a polyadenylation 
process to add poly-A sequence to their 3'-ends. Therefore, even without the 
polyadenylation process, these target sequences will show strong signals on the 
array. In contrast, microRNA target sequences need a successful polyadenylation 
process to add the poly-A sequence. If the polyadenylation process is ineffective, 
they will not be amplified and will not show signal. In my polyadenylation step (PAP) 
control, it was clear that successful polyadenylation of miRNA target sequences 
occurred yielding decent miRNA signals.  Annealing controls test the efficiency of 
annealing MSOs with different melting temperatures (Tms) to the same cDNA target. 
The MSO with higher Tm should always have a higher signal than the MSO with 
lower Tm. My array annealing controls were consistent with this. The internal single 
mismatch controls measure the specificity of extension in the second- strand cDNA 
synthesis step by comparing the signal intensity of perfectly matched oligos versus 
oligos with an internal mismatch. The extension controls (3' -mismatch) measure the 
specificity of extension in the second-strand cDNA synthesis step by comparing the 
signal intensity of perfectly matched oligos versus oligos with mismatch at the 3'-end. 
As expected, my mismatch controls and extension controls both showed that the 
perfectly matched query oligo had high signal while the mismatched oligo had 
dramatically decreased signal. The intensity of the positive control was much higher 
than that of the negative control in the contamination controls meaning my array 
wasn’t contaminated with mouse miRNA (Illumina has human and mouse miRNA 
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profiling panels). Hybridization controls are the positive controls for hybridizing 
PCR product to capture probes on the universal arrays. Both of my hybridization 




Figure 3.3 Summary of Illumina microRNA microarray control data. Negative Control: 
Determination of background signal; PAP Control: Control for polyadenylation step; Annealing 
Control: Control for MSO (miRNA specific oligo); Internal Single Mismatch: Stringency control; 
Extension Control: Positive and negative control for extension reaction; Contamination Control: 
Control for PCR contamination; Hybridization Control: Positive control for hybridization; miRNA 
Intensity: Average signal intensity of miRNA samples. 
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3.2.2.3 Data analysis of Illumina microRNA microarray 
 
The fundamental goal of microarray experiments is to identify genes that are 
differentially expressed in the conditions being studied. Comparison statistics can be 
used to help identify differential gene expression and cluster analysis can be used to 
identify patterns of gene expression and to segregate a subset of genes based on these 
patterns.  
 
Illumina miRNA microarray was used as a preliminary screen for differentially 
expressed miRNAs in certain stages of melanoma. To preserve as many differential 
miRNAs as possible my miRNA microarray raw data were not background 
subtracted and for calculation convenience it was also log2 transformed. The results 
of many DNA microarray experiments are fluorescence ratios. Ratio measurements 
are most naturally processed in log space. In log space (log2 for simplicity) the data 
points become 0, 1.0, -1.0. With these values, 2-fold up and 2-fold down expression 
changes are symmetric about 0. Although the raw data were not background 
subtracted, a filter [Detection P Value <0.01 in at least 80% of samples for each 
probe] was applied. Detection P Value is a statistical calculation that provides the 
probability that the signal from a given probe is greater than the average signal from 
the negative controls. The reason for using this filter instead of background 
subtraction is because there may be some miRNA signals lower than the background 
but still showing differences from negative controls. Among a total of 1,146 probes, 
862 (75.2%) passed through the filter. Thereafter, operated data were analyzed using 
R version 2.8.1 software and normalized using the Quantile method which is 
recommended to normalize miRNA data as it works best in reducing non-biological 
variations in miRNA expression values between array samples [347]. Quantile 
normalization is a method used to make the distribution, median and mean of probe 
intensities the same for every sample. Hierarchical clustering was performed using 
Cluster 3.0 software and the TreeView programme was used to give interactive 
graphical analysis of clustering results. In clustering array results, City block distance 
(Manhattan distance) and complete linkage clustering methods were selected to 
analyze log2-transformed data.  
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From the miRNA detection pilot experiment, miR-92 was chosen to be the internal 
control for the qRT-PCR assay because of its abundant and relatively constant 
expression in both melanoma cells and tissues. In the microarray, the summary of 
miR-92 average signal in different types of cell and FFPE samples is shown in 
Figure 3.4. The miR-92 average signal ranged between 19000 and 25000 for both 
cells and FFPE. Importantly, all but one group (Primary*) of FFPE samples showed 
equivalent average miR-92 signal intensities to the cell samples. The average signal 
of the Primary* group was 40% lower than the other FFPE groups. All nine samples 
in this group were prepared 2 years earlier and isolated with a different method 
relative to all the other samples. They were used in the pilot experiments (the six 
samples in Table 3.2 were from this group) and appeared in the microarray 
experimental quality control data. However, the data from this group were finally 
excluded from the data analysis because they were the source of many outliers in the 





Figure 3.4 miR-92 average signal intensities of all groups of cell and tissue samples on the 
microarray. The histogram shows the average fluorescent signal intensities ± SEM of miR-92 of all 
samples groups on the array.  Group Primary* represents nine old primary melanoma FFPE tissues 
where RNA was prepared by a different method.  
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3.2.2.4 Overview of hierarchical clustering  
 
miRNAs can be highly tissue-specific biomarkers [348-350] and have been linked to 
the development of specific malignancies [351]. Previous studies have shown them 
as promising candidates for the construction of a biologically driven classification 
algorithm for identifying cancer tissue of origin [275, 313, 322]. Although specimens 
in my array do not contain many different cancer types compared to the published 
studies, it was still of great interest to explore the internal relationships between cells 
and tissues of the same cancer, in particular the miRNA expression changes between 
melanocytic benign lesions and malignancies, comparisons between different 
melanoma cell lines and between derivatives of the same cell line. 
 
To identify patterns of miRNA expression, a cluster analysis was done on both cell 
lines and fixed tissues, except for the Primary* melanoma group. The entire 
clustering heatmap is shown in Appendix 2. Describing the miRNA based tissue 
classification on the whole data set is too complicated. Therefore, a simple example 
is shown here to make the main points. The selected part of the heatmap shows 
differentially expressed miRNAs in the EDMEL3 cell series relative to other samples 
(Figure 3.5). Basically, the shorter the distance between the samples in the analysis, 
the closer is their relationship. It is encouraging that the whole EDMEL3 cell series 
were close to each other in the same cluster. Figure 3.5 shows the best illustration of 
the EDMEL3 series cluster where the very high expression (yellow in the heatmap) 
of these 22 miRNAs in this cluster is easily distinguished from the lower expression 
in the other samples on the array. Generally, samples of the same origin were found 
in the same cluster or in closely related clusters: First, cell lines were clustered 
separately to FFPE tissues. Secondly, the EDMEL3 series were solely grouped in the 
same cluster and close to the other metastatic melanoma cell lines. Ovarian cancer 
cell lines were grouped in the same cluster, along with one metastatic melanoma cell 
line. The remaining melanoma cell lines were adjacent to the EDMEL3 cell series, 
but intermingled with two immortalised melanocytes lines. For tissues, the cluster 
patterns were more complicated. Benign naevi were all grouped together, except N5 
and N6, and were mixed with primary and metastatic melanomas. Moreover, the 
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metastatic melanoma tissue sample, ME (from where the EDMEL3 cell line was 
isolated), was clustered with other metastases rather than with the EDMEL3 cell 
series. However, it is clear from Figure 3.5 that expression in this group of 22 





Figure 3.5 Hierarchical clustering of microRNA expression patterns in the microarray. The 
clustering obtained for all 71 samples (19 cell lines and 52 FFPE specimens) is illustrated with 22 
selected miRNAs in the array expressed above the threshold level. A colour key is shown above each 
sample to identify the type of cell line or tissue sample. The selected heatmap of expression data for 
the 22 miRNAs is shown vertically below each sample. The red ellipses illustrate the similarity 
between the different members of the EDMEL3 melanoma cell line series and the ME metastasis from 
which the EDMEL3 cell line was derived. The bottom two keys: Coloured squares and a black arrow 
identify the types of sample. The blue-yellow colour log2 scale (0.0-14.0) depicts log2 expression 
level of the miRNAs on the heatmap. Naevi: Benign naevi. 
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3.2.2.5 Melanoma-specific microRNA expression profile  
 
It was impossible to do statistical analysis of cell lines to compare the miRNA 
expression differences between melanocytes and melanoma cell lines because only 
two immortalised melanocytes were available to go on the array. Moreover, since I 
have shown that robust expression profiles can be generated with miRNAs isolated 
from FFPE tissues and my clustering indicated major differences in expression 
patterns between FFPE samples and cultured cells, I concluded that it was preferable 
to analyze the FFPE data. Therefore, the following data analysis is only based on 
FFPE samples. Differential expression analysis between benign naevus, primary 
melanoma and metastatic melanoma groups was accomplished using R language. 
Single miRNA comparisons between groups were done using the t-test (P value) 
error model with adjusted P value used for multiple comparisons. The array contains 
470 well-annotated human miRNA sequences denoted with hsa-miR-# and 265 new 
identified miRNAs termed HS_ #. The rest are termed solexa-# as putative but as yet 
unconfirmed miRNAs.  
 
There were 82 well-annotated miRNAs (including HS and solexas the total was 113 
miRNAs) differentially expressed in the comparison between primary melanomas 
and benign naevi (adjusted P value <0.05). 28 of the 82 miRNAs were upregulated in 
primary melanomas. 
 
Comparing metastatic melanomas and benign naevi, 74 miRNAs (including HS and 
solexas the total was 97 miRNAs) were differentially expressed (adjusted P value 
<0.05). 30 of the 74 miRNAs were upregulated in metastatic melanomas. 
 
In the comparison between metastatic and primary melanomas, 22 miRNAs 
(including HS and solexas the total was 25 miRNAs) were differentially expressed 
(adjusted P value <0.05). The expression of 12 miRNAs was increased in the 
metastatic melanoma group. The full lists of the differentially expressed miRNAs in 
the three comparisons are shown in Appendix 3. 
 
 
Chapter 3: Expression screen for melanoma-specific microRNAs 
 in FFPE tissues 
100 
In the above comparisons, there were too many differentially expressed candidates to 
investigate further using qRT-PCR verification. Moreover, to investigate which 
miRNAs are essential to melanomagenesis through functional studies and by looking 
for miRNA target genes with the miRBase targets database is a big challenge 
because each miRNA potentially has hundreds of targets. So to narrow the candidate 
list, the more stringent criteria [log2 FC (fold change)>|2| and adjusted P value< 
0.001] were added. 20 miRNAs were now selected in the primary melanoma versus 
naevi comparison, 19 in the metastatic melanoma versus naevi comparison and only 
two miRNAs (miR-203, miR-205) remained in the metastatic versus primary 
melanoma comparison (Table 3.3 A-C). There was considerable overlap between 
these three selected miRNA candidate lists (Figure 3.6). In the primary melanoma 
versus benign naevi comparison, 7 miRNAs were increased and 13 miRNAs were 
reduced in the primary melanoma. In the metastatic melanoma versus benign naevus 
comparison, 7 miRNAs were upregulated and 12 miRNAs were downregulated in 
the metastatic melanoma. 
 
Only two miRNAs, miR-205 and miR-203 were present in all three comparisons and 
both were downregulated in melanomas. Their expression was decreased from the 
naevus through the primary melanoma and then to the metastatic melanoma group.  
 
All five members of miR-200 family, miR-200a, b, c and 141, 429 were decreased in 
the metastatic melanoma versus the benign naevus group and three of them (miR-
200a, b and 141) were also downregulated in the primary melanoma versus benign 
naevus group. Expression of miR-20b and miR-675 was increased in the melanomas 
in comparison of primary vs. benign naevi and metastatic vs. benign naevi. miR-211 
was differentially downregulated in metastatic melanomas relative to benign naevi, 
but was not in the top candidate lists (adjusted P value = 0.0087, log2FC = -2.4). 
Although it did not pass through the adjusted P value < 0.001 filter, it was also 
chosen for qPCR verification because of the huge expression difference detected 
between melanocytes and most melanoma cells in the pilot qRT-PCR study.  
 
 
Chapter 3: Expression screen for melanoma-specific microRNAs 
 in FFPE tissues 
101 
The signal intensity summary for miR-211 and eight of the above miRNAs (miR-429 
was not included because of its differential expression similarity but lower overall 
expression level compared to other miR-200 family members) is shown in Figure 3.7 
A-C. These nine miRNAs were then subjected to the qPCR verification. 
 
The limitations of the best current prognostic markers for melanoma, Breslow 
thickness and Clark level, drive the search for better molecular markers. I also looked 
to see whether there were any differentially expressed miRNAs between recurrent 
and non-recurrent primary melanomas. However, there were no significant 
differences of miRNA expression in the comparison of 10 pairs of age and sex 
matched recurrent and non-recurrent primary melanomas (adjusted P value> 0.05). 
 
(A) Primary melanoma vs. benign naevus 





1 miR-603 1.45E-12 5.06E-15 2.79 11.71 3342.96 
2 miR-663b 7.04E-10 4.90E-12 3.43 12.22 4759.02 
3 miR-1826 8.69E-10 7.06E-12 2.23 13.60 12453.11 
4 miR -200b* 1.26E-09 1.17E-11 -3.52 9.32 639.23 
5 miR -183 2.47E-09 3.15E-11 -3.06 8.96 497.90 
6 miR -149 5.13E-07 7.15E-09 -2.41 9.12 556.74 
7 miR -200a 1.55E-06 2.34E-08 -2.79 9.52 735.01 
8 miR -205 2.49E-06 4.05E-08 -2.44 11.34 2597.07 
9 miR -675 4.87E-06 9.04E-08 3.06 11.11 2203.52 
10 miR -99a 6.97E-06 1.39E-07 -2.03 11.84 3675.38 
11 miR -200b 6.97E-06 1.46E-07 -3.04 11.83 3636.42 
12 miR -455-5p 8.39E-06 1.95E-07 -2.45 9.60 774.70 
13 miR -182 1.76E-05 4.48E-07 -2.82 9.69 825.12 
14 miR -203 2.91E-05 7.75E-07 -2.62 10.88 1880.62 
15 miR -494 4.99E-05 1.39E-06 2.91 11.36 2636.98 
16 miR -455-3p 1.93E-04 6.03E-06 -2.13 12.51 5813.25 
17 miR -20b 2.55E-04 8.28E-06 2.43 11.16 2281.88 
18 miR -141 5.14E-04 1.91E-05 -2.16 10.03 1048.34 
19 miR -198 7.98E-04 3.15E-05 2.45 9.09 544.99 
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(B) Metastatic melanoma vs. benign naevus 
 





1 miR -205 3.88E-16 4.50E-19 -5.23 11.34 2597.07 
2 miR -203 2.06E-15 7.18E-18 -6.00 10.88 1880.62 
3 miR -183 6.41E-11 2.98E-13 -3.52 8.96 497.90 
4 miR -200b* 1.27E-10 9.28E-13 -3.78 9.32 639.23 
5 miR -200c 1.27E-10 1.03E-12 -3.13 13.04 8393.22 
6 miR -603 1.26E-09 1.17E-11 2.20 11.71 3342.96 
7 miR -200b 8.86E-08 1.14E-09 -3.67 11.83 3636.42 
8 miR -200a 8.86E-08 1.23E-09 -3.11 9.52 735.01 
9 miR -663b 9.07E-08 1.37E-09 2.81 12.22 4759.02 
10 miR -141 2.24E-06 4.42E-08 -2.92 10.03 1048.34 
11 miR -149 4.38E-06 9.14E-08 -2.15 9.12 556.74 
12 miR -429 1.91E-05 4.66E-07 -2.53 9.14 564.22 
13 miR -21* 2.42E-05 6.17E-07 2.12 9.86 927.24 
14 miR -224 3.06E-05 8.23E-07 -3.16 10.13 1123.36 
15 miR -182 3.06E-05 8.52E-07 -2.71 9.69 825.12 
16 miR -142-5p 1.02E-04 2.96E-06 2.26 9.50 723.46 
17 miR -20b 2.26E-04 7.09E-06 2.43 11.16 2281.88 
18 miR -675 2.90E-04 9.43E-06 2.40 11.11 2203.52 




(C) Metastatic vs. primary melanoma 
 





1 miR -205 4.42E-09 6.64E-12 -2.79 11.34 2597.07 
2 miR -203 4.42E-09 1.03E-11 -3.38 10.88 1880.62 
 
Table 3.3 Differentially expressed microRNAs in benign naevi, primary and metastatic 
melanoma FFPE tissues. (A) Top 20 differentially expressed miRNAs in primary melanoma vs. 
naevi comparison. (B) Top 19 differentially expressed miRNAs in metastatic melanoma vs. naevi 
comparison. (C) Top 2 differentially expressed miRNAs in metastatic vs. primary melanoma 
comparison. ID: miRNA. P value: from t-test. Adjusted P: adjusted P value is the way to correct for 
multiple testing. Log2 FC: Log2 fold change (In X vs. Y comparison, when Y>X, log2 FC is negative, 
when Y<X, log2 FC is positive. Only miRNAs with Log2 FC >|2| and adjusted P value< 0.001 are 
shown. Average Intensity: stands for the average signal intensity of all samples on the array for the 
particular miRNA.  
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Figure 3.6 Relationship between differentially expressed microRNAs shown in Table 3.3.  For 
each circle (X vs. Y comparison) a red number means upregulated miRNAs in X while a green 
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Figure 3.7 Expression of microRNAs in FFPE samples on the microarray. The histograms (A-C) 
show the average fluorescent signal intensities ± SEM for the top selected miRNAs in the microarray. 
(A) Expression of miR-203 and miR-205. (B) Expression of miR-200a, miR-200b, miR-200c, miR-
141 and miR-211. (C) Expression of miR-20b and miR-675. Group size: Naevus (n=11), Primary 
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3.2.3 TaqMan qRT-PCR verification 
 
3.2.3.1 Amplification efficiency of target microRNAs 
 
As described in Chapter 2, there are two major methods to quantify miRNA 
expression using qRT-PCR. I compared the standard curve method and the ΔΔCt 
method for determining the expression of a target miRNA relative to an internal 
control in a number of cell lines. An example comparison between reference gene 
miR-92 and target gene miR-211 gave excellent agreement (Table 3.4). Moreover, 
the validation of the ΔΔCt method for miRNA expression relative to miR-92 as 
endogenous control showed that the slopes of the relative efficiency plot between 
each individual target miRNA and reference miRNA miR-92 were all below 0.1, 
indicating that the ΔΔCt method was valid for comparing the expression of these 
miRNAs between sample groups. The amplification efficiency plots are shown in 
Appendix 4. Therefore, I decided to proceed using the ΔΔCt method. (Details of the 








Table 3.4 Comparison of the standard curve and the ΔΔCt method. To quantify miRNA 
expression, Ct values for miR-211 and the endogenous control miR-92 were determined by qRT-PCR 
on HER1, HER4, A375 and EDMEL3 cell lines. Ct results show average Ct values ± STDEV of once 
in a triplicate repeat. For the standard curve method, the absolute ratio of miR-211/miR-92 expression 
is shown along with expression normalized to HER1. For the ΔΔCt method the expression is shown 






	   HER1	   HER4	   A375	   EDMEL3	  
miR-­92	   22.6±0.3	   22.8±0.2	   22.2±0.2	   21.6±0.2	  
Ct	  
miR-­211	   22.2±0.5	   23.6±0.3	   36.2±0.5	   32.3±0.1	  
miR-­211/92	   0.95	   0.46	   0.000044	   0.00046	  Standard	  
Curve	   RQ	   1.00	   0.48	   0.000046	   0.00048	  
ΔΔCt	   RQ	   1.00	   0.48	   0.000032	   0.00069	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3.2.3.2 Verification of target microRNAs in FFPE melanocytic specimens 
 
Nine differentially expressed target miRNAs identified from the microarray have 
been verified by qRT-PCR. Another eight new benign naevi were added to the 
verification experiments to increase the sample set. In each case the qRT-PCR 
results were in accordance with that of the microarray. Seven miRNAs were 
downregulated while two were upregulated in melanoma compared to benign naevi 
(Figure 3.8). Four members of the miR-200 family (miR-200a, 200b, 200c, 141) 
showed significant decreased expression between benign and malignant tissues of 
between 15 and 200 fold (Figure 3.8-A). However, except for miR-141 (p< 0.01), 
there was no significant decrease between primaries and metastases.  Expression of 
miR-211 was decreased in both primary (4-fold) and metastatic melanoma (6-fold) 
compared to benign naevi (p<0.001), but again there was no significant difference 
between primaries and metastases. For both miR-203 and miR-205 there was a 
greater than 10-fold decrease from benign naevi to primary melanomas and a greater 
than 2000-fold decrease from benign naevi to metastatic melanomas. All the 
expression differences between groups were significant (Figure 3.8-B). The 
remaining two miRNAs, miR-20b and miR-675, were both significantly upregulated 
in tumours. Expression was 10-fold higher in malignancies than benign naevi for 
miR-20b and 20-fold higher for miR-675, although in each case there was no 
significant difference between primary and metastatic melanomas (Figure 3.8-C). 
 
Expression of these nine miRNAs between recurrent and non-recurrent primary 
melanomas was also compared. All seven miRNAs that were downregulated in 
metastatic compared to primary melanomas show a lower level trend in the recurrent 
compared to the non-recurrent samples. miR-20b which was upregulated in the 
metastatic melanomas compared to primary melanomas, seems present at higher 
level in recurrent than in the non-recurrent primary tumours. However, none of the 
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Figure 3.8 Different microRNA expression levels during melanoma progression. (A) 
Downregulated miRNAs miR-200a, miR-200b, miR-200c, miR-141 and miR-211. (B) Downregulated 
miRNAs miR-203 and miR-205. (C) Upregulated miRNAs miR-20b and miR-675. Expression was 
determined by qRT-PCR using the ΔΔCt method. Expression of each miRNA relative to miR-92 and 
normalized to the mean of the Naevus group is shown. Results represent average relative expression ± 
SEM. Group size: Naevus (n=12-17), Primary (n=20), Metastasis (n=14). Here the Naevus group 







Figure 3.9 microRNA expression levels between non-recurrent and recurrent primary 
melanoma samples. Expression was determined by qRT-PCR using the ΔΔCt method. Expression of 
each miRNA relative to miR-92 and normalized to the mean of the Non-recurrent group is shown. 




3.2.3.3 Expression of microRNAs in additional classes of melanocytic lesions  
 
Based around the miRNA expression differences that I had seen between benign 
naevi and melanomas I decided to investigate the ability of these miRNAs to 
distinguish between some of more complex types of melanocytic lesions. I used the 
TaqMan assay because of its ability to detect miRNAs in as little as 1ng of RNA, as 
such it is much more sensitive than microarray. 
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Previously, samples of benign naevi and metastatic melanomas were obtained from 
Ø2mm cores of FFPE tissue blocks, while macrodissection on 10µm sections was 
required to isolate the much smaller primary melanomas from adjacent non-tumour 
tissues. The smaller size of the Blue, Spitz and dysplastic naevi available meant that 
samples for RNA isolation were also obtained by macrodissection of 10µm sections. 
Total RNA of these FFPE samples was isolated using the same kit as for previous 
FFPE samples. In general, the yields of scrapings from macrodissection were smaller 
than that from the cores. The 260/280 ratios of these total RNAs were similar to the 
RNAs from the cores. The full yields and 260/280 ratios are shown in Appendix 1. 
 
TaqMan qPCR expression data for five miRNAs in the original benign naevi, 
primary and metastatic melanoma comparisons is shown in Figure 3.10, along with 
the new data on Blue, Spitz and dysplastic naevi. Interpretation is compromised by 
the small number of new samples assayed. However, for miR-203, miR-205 and 
miR-200c the Blue, Spitz and dysplastic naevi appeared to group with the tumour 
samples rather than with benign naevi. Expression of miR-203, 205 and 200c in 
Blues was significantly lower than that in benign naevi (p<0.05), while the 
expression difference between Blues and primary melanomas was not significant. 
For miR-211 the Blue naevi had higher expression and grouped with the benign 
naevi, while the Spitz and dysplastic naevi had lower expression closer to the 
melanomas. Expression of miR-20b in the Spitz and dysplastic naevi was closer to 
that in benign naevi than in melanomas. miR-20b expression was significantly higher 
in Blues than that in benign naevi, while the expression difference between Blues 
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Figure 3.10 Expression of microRNAs in various melanocytic lesions. Expression of miR-203, 
miR-205, miR-200c, miR-211 and miR-20b was determined by qRT-PCR using the ΔΔCt method. 
Expression of each miRNA relative to miR-92 and normalized to the mean of the Benign Naevus 
group is shown on a log10 scale. Horizontal lines in all graphs indicate the means for each lesion 
group. Individual data points for each sample in the group are also shown. Group size: Benign Naevus 
(n=12-17), Blue Naevus (n=2-4), Spitz Naevus (n=2), Dysplastic Naevus (n=2), Primary (n=20) and 
Metastasis (n=14). 
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To date, three principal methods have been used to measure expression levels of 
miRNAs: microarray hybridization, real-time PCR and next generation sequencing 
(NGS) [352]. Northern blotting analysis was also adopted to study the expression of 
miRNA genes [168, 353] and was used as a method for detecting miRNA expression 
in cancer cells [269]. Due to the increasing demands for high-throughput analyses, 
NGS, also known as high-throughput sequencing, is coming into wider use than 
Northern blotting. All three methods comprehensively analyze miRNA expression, 
with each option having advantages and disadvantages. The clear merit of NGS is its 
ability to identify novel miRNAs, while qPCR is better used as a validation rather 
than a discovery tool [352]. As with genomic DNA and RNA analysis, microarrays 
are still the best choice for a standarized genome-wide assay that is amenable to 
high-throughput applications. I believe the experimental strategy adopted in this 
chapter—a combination of microarray and qRT-PCR—is most appropriate to 
identify a reliable melanoma-specific miRNA expression profile.  
 
In performing experiments for miRNA quantification, variation in the amount of 
starting material, sample collection, RNA preparation and quality, and reverse 
transcription (RT) efficiency can all contribute to quantification errors. 
Normalization to an endogenous control is currently the most accurate method to 
correct for potential RNA input or RT efficiency biases. For TaqMan MicroRNA 
Assays, the chosen endogenous controls should share similar properties, such as 
RNA stability and size. Small nuclear RNA (snRNA) and small nucleolar RNA 
(snoRNA) are good choices as internal controls because their size is close to 
miRNAs and they show constitutive and abundant expression across a large number 
of tissues and cell lines. Undoubtedly, the consistency of expression should be 
confirmed under the specific conditions of the experiment. In addition to use of 
snRNA or snoRNA, some specific miRNAs themselves (including miR-92, 
especially in tissue samples) that demonstrate the least variability can be an 
alternative choice [354]. Therefore, given the evaluation of my pilot qRT-PCR 
experiments and of my microarray, miR-92 was regarded as a better endogenous 
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control than the commonly used snRNA, RNU6B, for its stability of expression 
across different types of melanocytic samples.  
 
An early miRNA expression study revealed that 129 miRNAs were able to classify 
human cancers into their tissue of origin solely on the basis of their miRNA 
expression profile [313]. In addition, the miRNA profile can also reflect the 
developmental lineage and differentiation state of tumours [355]. Analysing the 
cluster patterns of my array work without sophisticated raw-data correction, the cell 
lines and tissues were well separated although the classification within cell lines or 
tissues was not ideal. The closely related EDMEL3 series of melanoma cell lines 
were all classified in the same cluster and were adjacent to other metastatic 
melanoma cell lines. Naevus tissues were also mostly grouped together in the same 
cluster. However, the rest of the melanoma cell lines were intermingled with two 
melanocytes lines. For another example, primary and metastatic melanoma tissues 
did not cluster separately, but were mixed together along with some naevus tissues. It 
seems that the cluster analysis of my miRNA microarray data here is more useful as 
a tool in classifying tissue origin rather than in distinguishing melanomas from 
benign melanocytic lesions, or primary tumours from metastatses. To obtain better 
expression profiles, the following factors should be taken into account: tissue 
heterogeneity, quantity and quality of total RNA input, quality control of the array, 
heterozygosity of melanoma and using a panel containing all known and 
uncharacterised miRNAs. I think tissue hererogeneity is the most crucial factor that 
affects profiling results. Even under close supervision to ensure pure sample 
collection, tumour tissues still contain multiple cell types, each with its specific gene 
expression programme. Disease not only changes the expression programme of the 
affected cell type but also its cell type composition. Therefore, to best separate these 
effects in the profiling of heterogeneous tumour samples, it may be useful to profile 
tumour cell lines and individual cell types that may be present in one tumour sample, 
or define miRNA cellular localization by performing in situ hybridization (ISH). 
However, my Illumina microarray has still identified a number of miRNAs whose 
expression changes during melanoma progression. This conclusion is supported by 
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the verification results for the selected miRNAs from qRT-PCR, which were entirely 
consistent with the Illumina array data. 
 
The existence of unique miRNA expression profiles for different tumour histology 
types and subtypes, due largely to the tissue specificity of miRNAs, appears to be a 
useful adjuvant diagnostic tool when tumours cannot be accurately classified by 
morphology and immunophenotype. Besides the diagnostic value of miRNA, 
emerging evidence also manifests their role in cancer prognosis. Reduced let-7 and 
high expression of miR-155 in human lung cancers was associated with poor survival 
[270]. Aberrant miRNA expression features may reflect a tendency for early disease 
relapse. Tong et al. looked for differentially expressed miRNAs through miRNA 
expression profiling and qRT-PCR of 40 prostatectomy specimens from stage T2a/b, 
early relapse and non-relapse cancer patients, to better understand the relationship 
between miRNA dysregulation and prostate oncogenesis [356]. A > 40% difference 
in expression between the relapse and non-relapse subsets was observed for miR-
135b and miR-194, although this trend of differential expression did not attain 
statistical significance for the limited number of patients analyzed. I also looked for 
any differentially expressed miRNAs between recurrent and non-recurrent primary 
melanoma tissues. However, there were no miRNAs with significantly different 
expression between the two categories of primary melanoma. Considering the small 
number of highly differentially expressed miRNAs in the metastatic versus primary 
melanoma comparison, I realize that it may be unrealistic to expect to see differences 
between recurrent and non-recurrent primary melanomas in such a relatively small 
sample set. Interestingly, the reduction in seven downregulated miRNAs and 
elevation in two upregulated miRNAs verified by qRT-PCR (Figure 3.9) in recurrent 
compared to non-recurrent primaries is compatible with the sequential transition 
observed from benign naevus through primary to metastatic melanoma. It is possible 
that the number of samples was not big enough to reveal a significant difference 
between recurrent and non-recurrent primary melanomas. Looking for miRNAs with 
prognostic value should ideally consider the actual length of survival and not just 
whether or not the patients relapse. Some patients may still live a very long time with 
recurrent tumours. This was not accomplishable with my data because the full 
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clinical records of the cases were not readily available. Two research groups have 
studied melanoma survival associated with miRNA expression profiles. Segura’s 
group identified 18 miRNAs (See Table 3.5, Page 116) whose overexpression in 
melanoma metastases was significantly correlated with longer survival (≥ 18 months 
post-recurrence survival) compared to shorter survival (< 18 months post-recurrence 
survival) [357], such as miR-155 and miR-142-5p, which are upregulated in 
malignancies in my differentially expressed miRNA candidates. Furthermore, low 
expression of miR-191 and high expression of miR-193b in melanomas compared to 
melanocyte cells were associated with poor melanoma-specific survival [358]. 
 
Firm diagnostic criteria based on histological features alone are difficult to establish 
owing to the wide morphological range of melanocytic naevi and significant 
morphological overlap of benign lesions and malignant melanoma leading to both 
over-treatment as well as delayed treatment. Therefore, I decided to extend my study 
of miRNA expression changes during melanoma progression to an additional set of 
melanocytic lesions: Blue, Spitz and dysplastic naevi. However, the preliminary 
study using five of my candidate miRNAs on a very small set did not allow me to 
make any clear conclusions about miRNA expression patterns in these naevi. 
Analysis of more samples would be required before differences of any useful 
diagnostic miRNA between these expanded groups of melanocytic lesions could be 
estimated. However, such an approach could still be helpful diagnostically if large 
sample number could be linked to miRNA ISH to eliminate the need for RNA 
extraction from very small lesions such as in-situ melanoma. 
 
Up to ∼60% of human genes are putative targets of one or more miRNAs [359]. 
miRNAs play a role in all major biomolecular processes, including metabolism [360], 
cell proliferation [361], apoptosis [362], development and morphogenesis [363, 364], 
stem cell maintenance and tissue differentiation [365]. So any abnormality occurring 
in the above programmes could induce diseases including cancer. Therefore, when 
searching for biomarkers or looking for new treatment for cancers, it is important to 
look for tumour-specific miRNA candidates, especially if they can be linked to one 
or more key signalling pathway(s) in the cancer. Some miRNAs identified from my 
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array results have already been studied in some other cancers. For instance in breast 
cancer, miR-9 promotes metastases by directly targeting E-cadherin [366] and miR-
155 regulates cell survival, growth and chemosensitivity by targeting FOXO3a [367]. 
In another instance in hepatocellular carcinoma, let-7c induces apoptosis through 
inhibiting Bcl-xL [368] and miR-224 represses apoptosis by targeting the apoptosis 
inhibitor-5 [369].  
In melanoma miRNA research, besides my data other melanoma-specific miRNA 
expression patterns have now been identified, based on both cell lines and tissues. 
Table 3.5 summarises the miRNAs that are differentially expressed, either in 
melanoma cells relative to other cancer cells, or between normal and malignant 
cells/tissue samples from microarray profiling. The first two papers discussing 
miRNA profiles on the NCI-60 cell panel identified 17 significantly differentially 
expressed miRNAs in melanoma cell lines versus other cancer cell lines. 11 of these 
miRNAs (miR-182, 183, 203, 224, 200b*, 200a, 200c, 141, 211, 204, 335) 
overlapped with my full list of FFPE differentially expressed miRNAs and 8 of 11 
appear in the refined lists. In Mueller’s study, an overview of differentially expressed 
miRNAs with validated target genes and their impact on cellular functions in 
malignant melanoma was summarized. Five miRNAs (miR-137 and miR-182, miR-
141, miR-183 and miR-200c) discussed were differentially expressed in my FFPE 
array work. However, the above differentially expressed miRNAs from the literature 
were obtained either from cell-based microarray or from tissue analysis, but not from 
tissue profiling. Very few studies have systematically interpreted full miRNA 
expression profiles by microarray on melanocytic FFPE samples. Among the above 
profiles, only two studies (the last two in Table 3.5) included the different stages of 
melanocytic lesions between naevi and malignant melanomas as in my array samples. 
One of these two papers described 31 miRNAs (13 upregulated, 18 downregulated) 
that were differentially expressed in metastatic melanomas relative to benign naevi 
and 15 of them were verified by qRT-PCR [370]. The sample panel of this study 
contained only 8 benign naevi and 8 metastatic melanomas, but no primary 
melanomas. Another study correlating cell line-derived miRNA expression patterns 
with melanoma patients included 3 benign naevi, 5 primary and 7 metastatic 
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melanoma samples [371]. It was found that expression of selected miRNAs was 
inconsistent when comparing cell line–derived and patient-derived data. Some 
discrepancies were also detected when miRNA microarray data were correlated with 
qPCR-measured expression levels. Furthermore, they identified miRNA-200c to be 
consistently downregulated in melanocytes, melanoma cell lines, and patient 
samples, whereas miRNA-205 and miRNA-23b were markedly reduced only in 
patient samples. In contrast, miR-146a and miR-155 were upregulated in all analyzed 
patients but none of the cell lines. Both of these two papers used far fewer samples 
than mine. Comparing these two papers with my array results, some common 
differentially expressed miRNAs emerge including: some (not all) members of the 
miR-200 family, miR-203, miR-205, miR-193b, miR-125b, miR-211, miR-204, 
miR-20b, miR-183, miR-196a, let-7c. I conclude that my miRNA profiling study is 
the best melanoma-specific miRNA profile so far because it uses the most miRNA 
probes, has the most FFPE samples, contains complete stages in melanoma 
progression and is verified by qPCR.  
 
Literature Number Type Overlapping miRNAs in my array 
Gaur/ Blower, 2007 17 Cell miR-182, miR-183, mir-203, miR-224, miR-200b*, 
miR-200a, miR-200c, miR-141, miR-211, miR-
204, miR-335 (11) 
Mueller, 2009 22 Cell miR-141, miR-182, miR-183, miR-200c, miR-137 
(5) 
Segura, 2010 18 Tissue miR-455-3p, miR-145, miR-497, miR-155, miR-
342-5p, miR-193b, miR-142-5p (7) 
Caramuta, 2010 32 Cell let-7c, miR-211, miR-9, miR-196a (4) 
Chen, 2010 31 Tissue miR-193b, miR-211, miR-149, miR-200c, miR-
205, miR-203, miR-200b, miR-141, miR-204 (9) 
Philippidou, 2010 / Cell/ 
Tissue 
miR-155, miR-142-5p, miR-200c, miR-183, miR-
193b, miR-205, miR-203, miR-125b, miR-20b, 
miR-196a, let-7c (11) 
 
Table 3.5 Summary of overlapping miRNAs between the literature and my array results.  
Number represents differentially expressed miRNAs in the particular paper.  
 
I considered two different approaches before moving on to study the functional role 
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in melanoma of some of the differentially expressed miRNAs that I identified: 
choose miRNAs that have never been studied and explore their targets blindly, or 
select miRNAs with established connections in other cancers and with some known 
human targets. After studying the top selected miRNA candidates, I found that about 
10 have been shown to have roles in other cancers and so I chose the latter approach. 
First, all five members of the miRNA-200 family (miR-200a, 200b, 200c, 141, and 
429) were present in my refined lists of differentially expressed candidates. The 
miRNA-200 family regulates PDGF-δ-mediated epithelial to mesenchymal transition 
(EMT) in prostate cancer cells [372]. EMT facilitates tissue remodelling during 
embryonic development and is viewed as an essential early step in tumour metastasis. 
The role of the miRNA-200 family and miR-205 in EMT has been studied [373, 374] 
(For more information see Chapter 4.1.2 and 4.1.3). Decreased expression of miR-
203 was identified in prostate, bladder, gastric, and colorectal cancers [375-377]. Li 
et al. found overexpression of miR-203 significantly reduced cell proliferation and 
survival, and induced cell apoptosis in the p53-mutated colon cancer cells. Moreover, 
overexpressing miR-203 could increase the cytotoxic role of paclitaxel in the p53-
mutated colon cancer cells, but not in the p53 wild type cells [378].  Given the fact 
that miR-205 and miR-203, two downregulated miRNAs, appeared in all three of my 
comparisons, I verified them using qPCR as preparation for future functional study. 
miR-20b and miR-675 were found to be functional in modulating c-MYC and RB 
genes respectively [379, 380]. All the above miRNAs appear at the top of my 
selected comparisons.  
 
However, this doesn’t mean that the other differentially expressed miRNAs not in the 
top lists can be ignored. One such is miR-211 with its large expression difference 
between immortalised melanocytes and most of the malignant melanoma cell lines I 
examined. Other published papers also showed that miR-211 was downregulated in 
both melanoma tissues and melanoma cell lines compared to normal melanocytes 
[381-383]. However, overexpression of miR-211 was found to be involved in poor 
survival of oral carcinoma patients [384], indicating that there may be an oncogenic 
potential for miR-211 in some tissue-specific functions. This seems quite common 
with other miRNAs also having opposite expression patterns in different cancers. 
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There are also reports of the same miRNA having opposite expression patterns in the 
same cancer. For example, miR-182 was found downregulated in melanoma samples 
from my array results, whereas it was reported upregulated in other melanoma 
samples [385].  
 
The few functional studies reported on the role of these miRNAs in cutaneous 
melanoma are discussed in detail in Chapter 4 where I go on to describe the results of 
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Chapter 4: Functional studies of microRNAs  
in melanoma cells 
 
 
Chapter 4: Functional studies of microRNAs in melanoma cells 120 
4.1 Introduction 
 
Besides the use of miRNA as diagnostic and prognostic markers in cancer, they have 
important functional roles through their ability to regulate the expression of target 
genes by binding with perfect or imperfect complementarity to the 3' UTRs of their 
target mRNAs. About 61% of miRNA genes are located within intronic regions of 
protein-coding genes, but they are also found in exons themselves and in intergenic 
regions [355]. Moreover, more than 50% of miRNA genes can be found in cancer-
associated genomic regions or in fragile sites, suggesting that miRNAs play an 
extremely important role in the pathogenesis of neoplasias [250].  This has been 
confirmed by a great number of functional studies in various cancers. Generally, 
dysregulated miRNAs participate in carcinogenesis through altered expression of 
their targets, which are involved in cell proliferation, apoptosis and metastasis. 
 
 
4.1.1 Roles of microRNAs in cell proliferation and apoptosis 
 
Members of the Cip/Kip family of cyclin-dependent kinase inhibitors (CKIs) are well 
characterized for their role as negative regulators of G1-phase cell-cycle progression 
[386]. p21, p27 and p57 are members of this family. In gastric carcinogenesis, 
several miRNAs have been found to be involved in altering the expression of CDK 
inhibitors. Two clusters of miRNAs, miR-106b/93/25 and miR-221/222, are 
upregulated in gastric cancer tissues and have been reported to inhibit CKIs [387]. 
miR-25 directly targets p57, and miR-106b/93 target p21. They both control their 
targets through the 3' UTR, and subsequently induce cell proliferation. miR-221/222 
have been reported to suppress both p27 and p57. Ectopic expression of these two 
miRNAs enhances CDK2 activity and assists the G1-S transition. Enforced 
expression of the miR-221/222 cluster also promotes the growth of gastric cancer 
xenografts in nude mice. Furthermore, aberrant miRNAs have been shown to 
regulate apoptosis by changing the expression of Bcl-2 family members in gastric 
cancer as well. miR-15b, miR-16, miR-34 and miR-181b all directly target the 
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antiapoptotic protein Bcl-2. They are downregulated in gastric cancer cells and thus 
reduce apoptosis [388, 389]. 
 
Knockdown of miR-31 repressed lung cancer cell clonal growth and in vivo 
tumourigenicity. miR-31 could function as an oncomiR by directly repressing the 
tumour suppressors, large tumour suppressor homolog 2 (LATS2) and protein 
phosphatase 2 regulatory subunit B alpha isoform (PPP2R2A) [390]. miR-122, 
which accounts for 70% of the total liver miRNA population, was found to be 
frequently downregulated in hepatocellular carcinoma (HCC) and in all HCC-derived 
cell lines. miR-122 can suppress HCC cell growth by directly targeting cyclin G1 
expression [391], as well as reducing the invasive capability of HCC-derived cells 
[392].  
 
Figure 4.1 is adapted from a review that discusses the role of miRNAs in liver 
cancer. Interestingly, the figure represents an interacting network of the most 
common aberrant miRNAs and their target genes in a variety of different cancers. 
For example, similar functions of miR-106 and miR-93 mentioned above in gastric 
cancer also have been observed in liver cancer.  p21 is also a direct target of miR-
106b and miR-93 [393] that are overexpressed in HCC and may have critical roles in 
cell proliferation by regulating the G1-to-S cell cycle transition. Likewise, miR-
221/miR-222 can function as oncogenes in HCC by binding to target sites in the 3' 
UTR of p27 [394] and as well as directly interacting with p57 [395] at the post-
transcriptional level. By controlling these two CDK inhibitors, miR-221/222 
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Figure 4.1 The network of aberrant microRNAs and their target genes in cancer. Green miRNA: 
Downregulated in cancer. Red miRNA: Upregulated in cancer. Adapted from [396]. 
 
 
4.1.2 Roles of microRNAs in tumour metastasis 
 
The above examples are mostly relevant to roles of miRNAs in cell growth and 
apoptosis. A great number of miRNAs are also involved in tumour metastasis. 
Metastasis from primary tumours involves multiple steps and genes. Neoplastic cells 
need to dissociate from primary tumours and enter body cavities or more commonly, 
circulatory systems (lymphatics and/or blood vasculature), and survive during 
transportation until they arrest at discontiguous sites, exit the circulation and finally 
proliferate at ectopic sites (colonization) in response to local growth factors [397].  
Although primary tumour formation is a prerequisite to metastasis, tumourigenicity 
and metastasis are distinct phenotypes. Therefore, the question is whether there exist 
specific metastasis-regulatory miRNAs (metastamiRs). Many studies have found 
both metastasis-suppressing and metastasis-promoting metastamiRs, which have 
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been discovered in the metastatic cascade including cell growth, EMT, adhesion, 
migration, invasion, apoptosis and/or angiogenesis [279]. miR-10b was the first 
metastasis-promoting miRNA described that was highly expressed only in metastatic 
breast cancer cell lines [398]. miR-10b was found to enhance migration and invasion 
in vitro and metastasis in vivo. miR-10b expression was elevated by Twist homolog 1 
(TWIST1) and it directly targeted Homeobox protein Hox-D1 (HOXD1), leading to 
increased expression of RAS homolog gene family member C (RHOC).  
 
Members of the miR-200 family are very important metastasis-suppressing 
metastamiRs that particularly aroused my attention, as they were all present in my 
differentially expressed miRNA list. The miR-200 family was found to reverse the 
EMT process needed for metastasis by driving a mesenchymal to epithelial transition 
(MET) through directly targeting E-cadherin (CDH1) transcription repressors Zinc 
finger E-box binding homeobox1/2—ZEB1 (δEF1)/ ZEB2 (SIP1) in various cancers 
(Figure 4.2), including breast, pancreatic, colorectal and ovarian [399-404]. 
Moreover, miR-205, which also directly targeted both ZEB1 and ZEB2, was found 
downregulated in cancer cells that had undergone EMT. In addition, upregulation of 
the miR-200 family and miR-205 in EMT cell lines caused morphological change 
from a spindle-shaped, mesenchymal form to a rounded, epithelial-like form [399]. 
 
 
Figure 4.2 The schematic model for feedback loop between the miR-200 family and ZEB1/ZEB2 
in switching the EMT-MET process. In epithelial cells, a stable state is maintained by high levels of 
miR-200, which inhibits ZEB1/SIP1 and increases the expression of ZEB-repressed epithelial genes 
such as E-cadherin. The switch to a mesenchymal state can be induced by TGF-ß, which increases 
ZEB1-SIP1 levels. This in turn triggers and maintains a mesenchymal state through ZEB1-SIP1 
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binding to ZEB-type E-boxes within the miR-200 family promoter and repressing miR-200 
transcription. Together, this system forms a double-negative feedback loop, maintaining stable cellular 
states depending upon the relative levels of ZEB1-SIP1 and miR-200, yet retaining the ability to 
switch between these states, as exemplified by TGF-ß induced EMT. Figure is adapted from [401]. 
 
 
4.1.3 The miR-200 family, EMT and melanoma 
 
The miR-200 family comprises five members: miR-200a, b, c, 141 and 429, which 
are generated from two transcripts. Human miR-200a/b/429 are located on 
chromosome 1 and miR-200c/141 are located on chromosome 12. The members of 
this family are highly related in sequence, especially in the nucleotide 2-8 seed 
region (Table 4.1 and Figure 4.3) that determines target specification, indicating that 
they likely target a similar complement of mRNAs. Within the five members, miR-
200a and miR-141 have the same seed region, while the other three group together 
with a different common seed region (Table 4.1).  
 
EMT-like processes take place during embryonic development and wound healing 
[405] and in carcinogenesis, as well as when cancer cells undergo a change from a 
differentiated to a more invasive undifferentiated tumour [405, 406]. When an EMT-
like process is triggered, cells lose epithelial features and acquire mesenchymal 
signatures. Cells become more invasive by expressing proteases that allow them to 
pass through basement membrane and migrate. During EMT, cancer cells can 
express various transcription factors in response to stimulation with soluble factors 
that are present in the tumour environment, such as TGF-ß. The two E-box-binding 
transcription factors—ZEB1 and ZEB2 are important regulators because they 
negatively regulate the expression of E-cadherin and assist the EMT process [407-
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miR-200 Sequence 
miR-200a 5' UAACACUGUCUGGUAACGAUGU 3' 
miR-200b 5' UAAUACUGCCUGGUAAUGAUGA 3' 
miR-429 5' UAAUACUGUCUGGUAAAACCGU 3' 
miR-200c 5' UAAUACUGCCGGGUAAUGAUGG 3' 
miR-141 5' UAACACUGUCUGGUAAAGAUGG 3' 
 
Table 4.1 Sequence alignment of microRNAs of the miR-200 family. The seven –nucleotide seed 









Figure 4.4 The schematic model of ZEB1 binding sites for the miR-200c stem loop. The figure 
shows two ZEB1 binding sites to the miR-200c stem loop. The putative recognition sites are highly 
conserved among various species. Adapted from [403].  
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The NCI-60 panel contains nine different cancers that can be genetically divided into 
two major branches: subcluster 1 (SC1) cells have a mesenchymal gene signature 
and subcluster 2 (SC2) cells have an epithelial gene signature [410]. As it is known 
that E-cadherin is lost during cancer progression, Park et al. sorted all NCI-60 panel 
cell lines from highest to lowest E-cadherin/Vimentin ratio using western blot 
analysis [404]. Thus, NCI-60 cell lines were grouped into three: epithelial group 
(with high E-cadherin, low Vimentin), undefined (either equal expression or no 
expression of both) and mesenchymal group (with low E-cadherin, high Vimentin). 
Expression of the miR-200 family was positively correlated with E-cadherin, 
suggesting that the miR-200 family is a powerful marker for cell lines with an 
epithelial nature. More interestingly, seven of eight melanoma cell lines in the NCI-
60 panel belonged to the mesenchymal group and one was in the undefined group. 
This, combined with my microarray results, led me to ask whether the miR-200 
family plays the same role in melanoma metastasis. 
 
First, the question, whether EMT is relevant in melanoma needs, to be answered. 
Looking back to EMT during embryonic development, primary EMT (that which 
occurs in tissues that have never undergone a previous EMT) not only occurs at 
gastrulation but also at neural crest formation. This is the cell lineage that gives rise 
to melanocytes and changes in cadherin expression and cell-cell adhesion are crucial 
to neural crest delamination. Besides the roles of EMT in the origin of melanocytes, 
studies also identified a close relationship between EMT and melanoma. Melanoma 
constitutively produces TGF-ß and its expression may be related to tumour 
progression [411]. TGF-ß is involved in downregulation of E-cadherin in melanoma 
[412].  It was also found that N-cadherin was directly regulated by E-cadherin and 
loss of E-cadherin could induce NF-κB activity and N-cadherin expression in 
tumourigenic EMT [413]. A high-throughput study using cutaneous melanoma 
tissues suggested that EMT-related genes, including N-cadherin, contributed to the 
promotion of the metastatic phenotype by supporting specific adhesive, invasive and 
migratory properties [414]. In their study, increased N-cadherin was matched by loss 
of cadherin 10 expression, a type II cadherin with near-equivalent binding strength to 
that of E-cadherin [415]. To determine whether human melanoma cells have 
 
Chapter 4: Functional studies of microRNAs in melanoma cells 127 
decreased levels of E-cadherin, Tang et al. stained nine melanoma cell lines. Six of 
them showed negative staining and the remaining three (SK-MEL-1, 2 and 28) 
showed positive staining [416]. However, only SK-MEL-1 had E-cadherin at a 
similar level to normal melanocytes, while the other two showed decreased E-
cadherin levels. Another study also showed the loss of E-cadherin expression and 
high mesenchymal protein expression (N-cadherin, Vimentin and Fibronectin) in 
melanoma cell lines. Moreover, after cytokine treatment, these mesenchymal 
proteins were elevated further, indicating that malignant melanoma cell lines are 
susceptible to EMT after cytokine treatment [417]. However, there has been no 
report yet that focused on studying the relationship between the miR-200 family and 
EMT in melanoma metastasis. 
 
Chemotherapy-resistance is often observed in platinum-based chemotherapy, 
currently the main regimen in non-small cell lung cancer (NSCLC) treatment [418], 
and is a key cause of chemotherapeutic failure. A recent study investigated the 
expression of miR-200c in a panel of NSCLC cell lines and a strong inverse 
correlation with invasion was detected. Reintroduction of miR-200c into highly 
invasive/aggressive NSCLC cells induced a loss of the mesenchymal phenotype by 
restoring E-cadherin and reducing N-cadherin expression, and inhibited in vitro cell 
invasion as well as in vivo metastasis formation. Moreover, they found 
overexpression of miR-200c sensitized NCI-H1299 NSCLC cells to cisplatin and 
cetuximab treatment [419]. This study indicates that the loss of miR-200c expression 
can induce an aggressive, invasive, and chemoresistant phenotype. Therefore, 
increasing miR-200c expression level might contribute to anti-carcinogenesis and 
sensitize to chemotherapy. 
 
 
4.1.4 Roles of microRNAs in melanoma 
 
So far, studies of miRNAs related to melanoma have mainly involved two aspects: 
expression and functions of miRNAs, impacts of epigenetic regulation of miRNAs. 
The majority of the studies have focused on investigating aberrant miRNAs in 
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melanoma and their functions in melanomagenesis through studying their targets, 
because it is the most direct approach to identify potential biomarkers that have 
diagnostic and prognostic values, as well as to discover novel therapeutic targets. A 
small number of aberrant miRNAs that play a crucial role in melanoma pathogenesis 
have been identified through functional studies. These miRNAs were identified 
either from cell based work or tissue study, with or without a microarray screen. I 
summarise these human melanoma related miRNAs in Table 4.2. This summary does 
not consider epigenetic regulation of miRNAs or the subsequent impact on 
melanomagenesis.  
 




miR-137 Tumour suppressor MITF 
α-MSH1 
Cell (-) Bemis LT, 
2008 




miR-34 Tumour suppressor MET Cell (-) Migliore C, 
2008 
miR-340 Tumour suppressor MITF Cell (-) Goswami S, 
2010 
miR-196a Tumour suppressor HOX-B7 Cell (-) Braig M, 
2010 
miR-148 Tumour suppressor MITF Cell (-) Benedikta S, 
2010 





miR-205 Tumour suppressor E2F1, E2F5 Cell (-) Dar AA, 
2011 
miR-155 Tumour suppressor SKI Cell (-) Levati L, 
2011 
miR-125b2 Prognostic marker NA Tissue (-) Glud M, 
2010/11 
miR-182 OncomiR FOXO3, Cell+Tissue (-) Segura MF, 
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MITF 2009 
miR-15b2 Prognostic marker NA Cell+Tissue (-) Satzger I, 
2010 
miR-193b Tumour suppressor CCND1 Cell+Tissue Tissue (+) Chen J,  
2010 
miR-214 OncomiR TFAP2C Cell+Tissue (-) Penna E, 
2011 
miR-211 Tumour suppressor 1. KCNMA1 
 
2. TGFBR2,   























Table 4.2 Summary of melanoma related microRNAs. MET: MNNG HOS Transforming gene, 
HOX-B7: Homeobox B7, MARCKS: Myristoylated alanine-rich C-kinase substrate, MLC2: Myosin 
light chain 2, SKI: V-ski sarcoma viral oncogene homolog, FOXO3: Forkhead box O3, CCND1: 
Cyclin D1, TFAP2C: Transcription factor AP-2 gamma, KCNMA1: potassium large conductance 
calcium-activated channel, subfamily M, alpha, TGFBR2: transforming growth factor receptor II, 
NFAT5: nuclear factor of activated T-cells 5, BRN2: POU domain, class 3, transcription factor 2. NA: 
Not applicable.  In the miRNA Array column, Tissue (+)/Cell (+) means miRNA microarray data 
based on tissues or cells. α-MSH1 was found to regulate miR-137. miR-125b2/miR-15b2 act as 
prognostic markers involved in melanoma progression. 
 
In this Chapter, a series of assays have been performed to investigate potential 
functions of four miRNAs (miR-200c, 205, 211 and 20b) through manipulating their 
expression in a human malignant melanoma cell line—A375. To assay for functional 
miRNAs in melanomagenesis from the set of miRNA candidates identified in 
Chapter 3, transient transfection was used as it has been proved effective in many 
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4.2 Results 
 
4.2.1 Physiological expression levels of microRNAs in cell lines 
 
As described in Chapter 3, miR-200c, 205 and 211 were significantly decreased 
while miR-20b was significantly increased in melanoma FFPE samples compared to 
benign naevi.  The expression levels of miR-200c, miR-205 and miR-211 in 
immortalised melanocytes and several melanoma cell lines are shown in Figure 4.5.  
The expression levels of miR-200c and miR-205 were generally higher in melanoma 
cell lines (Figure 4.5-A) than in immortalised melanocytes. However, the expression 
of miR-211 was greatly decreased in melanoma cell lines relative to immortalised 
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Figure 4.5 Expression levels of selected miRNAs in cell lines.  Histograms show the expression of 
three miRNAs (A) miR-200c, miRNA-205 and (B) miR-211 that were downregulated in human 
melanoma samples. The expression levels were calculated using the ΔΔCt method relative to miR-92 




From Figure 4.5, it is clear that expression of miR-211 is downregulated in both 
melanoma samples and melanoma cell lines, whereas the expression patterns of miR-
200c and miR-205 are more complicated. In retrospect, it may have been preferable 
to compare normal rather than immortalised melanocytes with melanoma cells in 
vitro when considering the role of miRNA expression differences between benign 
naevi and malignant melanomas. However, neither normal nor immortalised 
melanocytes are appropriate in vitro representatives of the benign naevus in vivo as 
the some genetic features of melanocytes and naevi are not the same. For example, 
many naevi have mutated BRAF and may experience senescence, while normal and 
immortalised melanocytes do not show all of these features. Therefore, I think it is 
valid to overexpress levels of these miRNAs in melanoma cells to mimic the naevus-
like situation in vivo. I artificially increased miR-200c, 205 and 211 levels in A375 to 
study their function by comparing cell proliferation, apoptosis, colony formation in 
methylcellulose and invasion in the miRNA-transfected cells relative to controls. 
FACS cell cycle analysis, SRB cell proliferation assay, transwell migration assay and 
methylcellulose colony formation assay were all used. I also used the same assays to 
see whether there was any functional change after I decreased the expression of miR-
20b in A375 cells. For each assay, a negative control group (non-transfected A375 
cells), a scramble miRNA control group (A375 cells transfected with scrambled 
miRNA precursor or inhibitor) and an experimental group (A375 cells transfected 
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4.2.2 Optimization of transfection efficiency 
 
Prior to functional studies, to obtain the highest transfection efficiency various 
amount of transfection agents and fluorescently labelled small RNA oligos 
(precursor/ inhibitor scramble miRNA controls) were mixed and after 24 hours the 
successfully transfected fluorescently labelled cells were detected using FACS 
(Table. 4.3). Conditions G1 and G3 in Table 4.3-A showed the highest two 
efficiencies where about 50% of cells in the populations were transfected 
successfully with miRNA precursors. In Table 4.3-B, conditions G2, G3 and G6 
gave very high efficiencies (>90% of the cell populations) in miRNA inhibitor 
transfection assays. Given the need to obtain the best transfection efficiency with the 
least transfection agent, I chose condition G3 for gain-of-function experiments 











Table 4.3 Optimization of transfection conditions. The tables show the transfection efficiency with 
different input amounts of transfection agents and small RNA oligos after 24 hours as assessed using 
FACS to measure fluorescence from the labelled oligo. (A) Optimization in miRNA gain-of-function 
experiments. Pre-scramble represents a negative control for a miRNA precursor. (B) Optimization in 
inhibiting endogenous miRNA molecule experiments. Anti-scramble represents a negative control for 
a miRNA inhibitor. G: Group. NeoFx: Transfection agent. Pre-scramble/Anti-scramble (nM) 





 Control G1 G2 G3 G4 G5 
0 4 4 8 12 16 NeoFx (ul) 
Pre-scramble (nM) 0 50 30 30 30 30 
Efficiency (%) 0.3 47.8 29.1 56.3 41.1 29.2 
 Control G1 G2 G3 G4 G5 G6 
0 4 4 4 8 8 8 NeoFx (ul) 
Anti-scramble (nM) 0 10 50 100 10 50 100 
Efficiency (%) 0.3 11.8 91.9 95.2 39.2 89.6 97.8 
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4.2.3 Time course 
 
To confirm how long transfected miRNAs remain in the cells, the fluorescently 
labelled cell assay was assessed over a 3-day time course (Table 4.4). In the 
transfecting precursor assay (Table 4.4-A), the transfection efficiency was higher at 
24 hours (84%) compared to the optimization experiment (Table 4.3-A). For both 
precursor and inhibitor transfection, the frequencies of labelled cells dropped rapidly 
on subsequent days (Table 4.4). However, the reduction was more rapid in the 



















Table 4.4 Decay of transfected microRNAs over a three-day time course. The tables show the 
reduction in fluorescent signal from the transfected miRNA over 3 days. (A) Frequencies of labelled 
cells in miRNA gain-of-function experiments. Pre-scramble represents a negative control for a 
miRNA precursor. (B) Frequencies of labelled cells in inhibiting endogenous miRNA molecule 
experiments. Anti-scramble represents a negative control for a miRNA inhibitor. G: Group. NeoFx: 







 Control G 
0 8 NeoFx (ul) 
pre-scramble (nM) 0 30 
24hr 1.9 83.9 
48hr 0.2 43.9 Frequency (%) 
72hr 0.1 12.5 
 Control G 
0 4 NeoFx (ul) 
anti-scramble (nM) 0 100 
24hr 0.8 97.4 
48hr 0.4 23.9 Frequency (%) 
72hr 0.5 3.6 
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4.2.4 Functional studies for miR-200c and miR-205 
 
4.2.4.1 Expression level changes following transfection of miR-200c and miR-
205 precursors 
 
Expression of miR-200c and miR-205 were significantly reduced in melanomas 
compared to benign naevi as described in Chapter 3. Thus, precursors of both miR-
200c and miR-205 were transfected into A375 melanoma cells for functional studies. 
Expression of miR-200c and miR-205 were assayed daily for 3 days using qPCR (the 
same method as used in Chapter 3) after precursors of miR-200c and miR-205 were 
transfected. Levels of both miR-200c and miR-205 were dramatically increased in 
precursor transfected cell groups (pre-200c group and pre-205 group) on all three 
days compared to non-treated negative control and scramble control groups (Table 
4.5). The levels were highest at 24 hours and then dropped rapidly over the time 
course.  Phenotypic changes were not seen among the various groups of transfected 
and control cells (Figure 4.6). 
 
Because miRNA expression 24 hours after transfection was more than 106 fold 
increased relative to controls for miR-205, an extra experiment was carried out to 
investigate the possibility that the qRT-PCR assay was detecting the precursors 
themselves in addition to their mature miRNA products.  
 
0.015nmoles of miR-205 precursor were used per well of A375 cells transfected and 
the yield of total RNA recovered 24hours later was typically 1ug. 100ng of total 
RNA was used for cDNA synthesis in the qRT-PCR assay. Thus, if the transfection 
was 100% efficient, 100ng of input RNA in the qRT-PCR assay would contain 
0.0015nmoles of miR-205 precursor. When 100ng of non-transfected A375 cell 
RNA was spiked with 0.0015nmoles of miR-205 precursor and used in the same 
qPCR assay for quantifying miR-205, the miR-205 signal was 4x104-fold the A375 
control level. The equivalent signal for A375 cells transfected with miR-205 
precursor was > 106-fold the A375 control level. Therefore, although the qRT-PCR 
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assay does detect the miR-205 precursor, the great majority of the signal obtained is 
from mature miR-205 rather than its precursor. 
 
 
(A) Expression of miR-200c  
 
 Negative Scramble pre-200c 
24hr 1.00±0.23 3.71±2.33 21752±7810 
48hr 1.00±0.12 0.92±0.11 5983±2225 




(B) Expression of miR-205  
 
 Negative Scramble pre-205 
24hr 1.00±0.48 1.42±0.51 1392245±552660 
48hr 1.00±0.56 0.97±0.10 521964±142580 
72hr 1.00±0.34 1.50±0.59 179269±61807 
 
Table 4.5 Comparison of microRNA expression in negative control, scramble and miR-200c and 
miR-205 precursor transfected A375 melanoma cells.  The two tables compare target miRNA 
expression changes in negative control, scramble and miR-200c precursor (A) and miR-205 precursor 
(B) treated A375 cells over 3 days by qRT-PCR using the ΔΔCt method. Expression of each miRNA 
is shown relative to miR-92 and normalized to the mean of negative control group. Results represent 
average relative expression ± SEM from three independent determinations, each with triplicate 
samples. pre-200c: miR-200c precursor treated group, pre-205: miR-205 precursor treated group. The 
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Figure 4.6 Phenotypic comparison of negative control, scramble and miR-200c and miR-205 
precursor transfected A375 melanoma cells. The pictures show no phenotypic changes in precursor 




4.2.4.2 Cell cycle assay 
 
The cell cycle status of miRNA precursor transfected and control cells was 
determined post-transfection at 24-, 48- and 72-hours. No changes were seen 
between the groups for the pre-200c (Table 4.6-A), or the pre-205 (Table 4.6-B) 
experiments.  
 
(A) miR-200c  
 
 
(B) miR-205  
24hr (%) 48hr (%) 72hr (%)  
(-) Sr pre-205 (-) Sr pre-205 (-) Sr pre-205 
Sub G1 2.1 2.4 2.8 3.0 2.8 3.5 4.2 5.2 3.4 
G1 59.3 59.7 60.7 55.9 55.3 52.5 54.8 52.9 52.8 
S 20.0 20.1 18.8 22.1 21.8 22.3 20.8 21.6 22.6 
G2 18.6 17.8 17.7 19.0 20.1 21.7 20.2 20.3 21.2 
 
Table 4.6 Cell cycle comparison in negative control, scramble and miR-200c and miR-205 
precursor transfected A375 melanoma cells. Results represent percentage of cells in each phase of 
the cell cycle at 24 hours, 48 hours and 72 hours post-transfection determined by FACS from two 
individual experiments. (A) miR-200c precursor treatment and (B) miR-205 precursor treatment.  (-), 





24hr (%) 48hr (%) 72hr (%)  
(-) Sr pre-200c (-) Sr pre-200c (-) Sr pre-200c 
Sub G1 1.9 2.2 2.4 2.8 4.1 3.9 4.2 6.5 5.5 
G1 50.7 52.3 49.8 52.5 53.1 54.0 63.6 62.3 62.7 
S 23.3 22.4 24.3 21.9 22.5 20.3 16.8 16.3 17.3 
G2 24.1 23.1 23.5 22.8 20.3 21.8 15.4 14.9 14.5 
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4.2.4.3 Cell proliferation assay 
 
The SRB cell growth assay was used to assess cell proliferation of miRNA precursor 
transfected and control cells over a 4-day time course. The assay started immediately 
post-transfection of precursors of miR-200c and miR-205 (Day0). The same timing 
was used for migration and colony formation assays. The results were consistent with 
the cell cycle assay in that no changes were observed between the pre-200c and pre-
205 transfected groups and their control groups (Figure 4.7).  
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Figure 4.7 Comparison of cell growth in negative control, scramble and miR-200c and miR-205 
precursor transfected A375 melanoma cells. The graphs compare cell growth over 4 days. Y-axis 
represents OD 540 for SRB dye extracted from stained wells as an indirect measure of cell number. 
Results show average OD values ± SEM of once in a 16-replicate for each time point. (A) miR-200c 
precursor treatment and (B) miR-205 precursor treatment. Note that error bars are present for all data 
points, but are often too small to be visible. This experiment was repeated two times with the same 
result. The above result is from one individual experiment. 
 
 
4.2.4.4 Transwell migration assay 
 
To determine whether elevated levels of miR-200c and miR-205 influence invasive 
ability of A375 melanoma cells, the transwell migration assay was performed and 
migration was analysed on Day 5. For all three experimental groups, pre-200c, pre-
205 and pre (200c+205), relative cell numbers at the 40um-layer seem lower than 
those of both scramble and negative controls (Figure 4.8). However, the differences 
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(B) 
   
 
Figure 4.8 Comparison of invasive ability in negative control, scramble and miR-200c and miR-
205 precursor transfected A375 melanoma cells. The two figures compare the invasive ability using 
the transwell inverse invasive assay. (A) Cells migrating through matrigel after 5 days were quantified 
at the 40um-layer. The relative cell number was measured for each group using the ratio of the cell 
number at the 40um-layer/ that at bottom layer (0um). Results represent average ratios ± SEM of five 
microscope fields of one individual experiment. The ratio for each group was normalized to the 
negative control group. (B) Stacked pictures are confocal microscopic pictures from the bottom layer 
(0um) to the tenth layer (90um). Each layer is 10um thick. The 40um-layer indicated in red was used 
to quantify relative cell number. This experiment was repeated three times. The above result is from 
one individual experiment. 
 
 
4.2.4.5 Methylcellulose colony formation assay 
 
To determine whether elevated levels of miR-200c and miR-205 affect 
tumourigenicity of A375 cells, the colony forming ability in methylcellulose was 
assayed. Colony size was used to evaluate the capacity for colony formation and was 
measured on Day1, Day3, Day6. Images of entire wells were taken on Day12 and the 
colony number was counted using Gel doc software with a size threshold parameter 
set at 3.1 to exclude single cells and very small colonies. 
 
Colony size measured on Day 1, Day 3 and Day 6 is shown in Figure 4.9 (A-C). It is 
clear from Figure 4.9-A, where each group on Day 1 contains predominantly single 
cells that all groups were equivalent at the start. There was no difference of colony 
size on Day 3 between the groups (Figure 4.9-B). However, the colony size was 
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significantly smaller on Day 6 for all the experimental groups compared to their 
controls (Figure 4.9- C). The pre-200c group showed a smaller colony size than the 
pre-205 group, but there was no indication of an additive effect in the pre-
(200c+205) group.  
 
Colony numbers on Day12 for negative control, scramble control, pre-200c, pre-205 
and pre-(200c+205) were 433, 492, 341, 396 and 315. In Figure 4.9-D, a decreased 
colony number was observed in each experimental group compared to the controls, 
and the colony size also looked smaller in experimental groups, consistent with the 
measurements made on Day6. The colony size was not measured at this stage 




(A-1)                                                                               (A-2)                                 
     
 
 
(B-1)                                                                               (B-2) 
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(C-1)                                                                               (C-2) 





Figure 4.9 Comparison of colony formation in negative control, scramble and miR-200c and 
miR-205 precursor transfected A375 melanoma cells. The three histograms compare the average 
colony size in the methylcellulose assay on Day 1, Day 3 and Day 6 (A-1, B-1, C-1). Results represent 
the average colony size ± SEM of 30 colonies and each group was normalized to the negative control 
group. Images of colony size of each group are also shown (A-2, B-2, C-2). (C-1) One asterisk: 
p<0.05, three asterisks: p<0.001. (D) Images show the colony number in each entire well of a plate on 
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4.2.4.6 Study of miR-200c and miR-205 target genes  
 
ZEB1 and ZEB2 are predicted targets of both miR-200c and miR-205 and this has 
been demonstrated experimentally in some epithelial cell cancers such as breast and 
prostate cancer [399, 420]. On the Diana Lab webpage for miRNA target prediction, 
ZEB2 ranks as the No.1 target of miR-200c (http://diana.cslab.ece.ntua.gr/microT/). 
Moreover, as described in Section 4.1, E-cadherin is negatively regulated by ZEB2. 
Therefore, mRNA and protein levels of ZEB2 and E-cadherin were detected using 
qPCR and western blotting in transfected A375 melanoma cells with elevated levels 
of miR-200c and miR-205. N-cadherin expression was also detected due to the 
inverse correlation of E-cadherin and N-cadherin expression in the EMT process. 
 
 
4.2.4.6.1 Validation experiment on qPCR assays for ZEB2, E-cadherin and N-
cadherin mRNAs 
 
As described in Chapter 2, when analyzing qPCR results using the ΔΔCt method, 
validation experiments first need to be done to evaluate whether the amplification 
efficiencies of target and reference are equal. For mRNA qPCR, beta-actin was used 
as the internal control. The slopes of the relative efficiency plots between each 
individual target mRNA and reference mRNA, beta-actin, were all below 0.1 
(Figures are shown in Appendix 5), indicating that the ΔΔCt method was valid. 
 
 
4.2.4.6.2 ZEB2, E-cadherin and N-cadherin mRNA levels changes 
 
mRNA level changes of ZEB2, E-cadherin and N-cadherin were assayed daily in 
A375 cells for a 3-day time course post-transfection. ZEB2 expression was 
downregulated in the pre-200c group for all 3 days, and the reduction was significant 
on Day1 (4.5-fold) and Day2 (2-fold) compared to the scramble control, indicating 
that the inhibitory effect was reduced over the time course (Figure 4.10-A). The 
expression level of ZEB2 was also reduced in the pre-205 group on Day1 but the 
reduction was not significant (p=0.066) compared to the scramble control (Figure 
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4.10-B). ZEB2 expression was also decreased in the pre-(200c+205) group on Day1 
and Day2, and was significant at Day2 compared to the scramble control (Figure 
4.10-C). Consistent with the results of the methylcellulose colony formation assay, 
there was no indication of an additive effect in the pre-(200c+205) group on the 
reduction of ZEB2 mRNA levels. Again, in line with the rapid decline of miR-200c 
and miR-205 levels post-transfection, their effect on ZEB2 mRNA was most marked 
24 hours post-transfection. 
 
Subsequently, E-cadherin gene expression was only assayed in miR-200c elevated 
cells as ZEB2 expression was significantly reduced by miR-200c, but not by miR-
205 overexpression. E-cadherin gene expression was increased in the pre-200c group 
on all three days compared to the controls and the elevation effect was significant on 
Day1 (3-fold) and Day2 (4-fold) (Figure 4.11-A). This was compatible with the 
observed reduction in ZEB2 mRNA on the same days. However, there were no N-
cadherin gene expression changes in the pre-200c group relative to the controls 
(Figure 4.11-B), suggesting that expression changes of ZEB2 and E-cadherin caused 
by miR-200c overexpression failed to trigger the expected subsequent reduction of 


















Figure 4.10 Comparison of ZEB2 expression in negative control, scramble and miR-200c and 
miR-205 precursor transfected A375 melanoma cells. The series of histograms compare the 
expression of ZEB2 mRNA in negative control, scramble and miR-200c precursor (A), miR-205 
precursor (B) and miR-(200c+205) precursors (C) treated A375 cells by qRT-PCR using the ΔΔCt 
method. Expression of ZEB2 mRNA relative to beta-actin is shown and is normalized to the mean of 
the negative control group. (A-C) Data represent average relative expression of ZEB2 ± SEM from 
















Figure 4.11 Comparison of E-cadherin and N-cadherin expression in negative control, scramble 
and miR-200c precursor transfected A375 melanoma cells. The histograms compare the 
expression of E-cadherin and N-cadherin relative to beta-actin in A375 melanoma cells by qRT-PCR 
using the ΔΔCt method. (A) E-cadherin expression results were normalized to the mean of the 
negative control group. Data represent average relative expression ± SEM from three individual 
experiments. One-asterisk: p<0.05. (B) N-cadherin expression results were also normalized to the 
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4.2.4.6.3 E-cadherin protein level changes 
 
Upregulation of miR-200c in A375 melanoma cells negatively regulated ZEB2 gene 
expression, resulting in upregulation of E-cadherin gene expression. Thus, western 
blotting was used to establish whether there were corresponding E-cadherin protein 
level changes. E-cadherin protein was not detectable in any of the A375 samples 
tested (negative control, scramble or pre-200c groups), but it was detectable in the 
immortalised melanocyte cell line, HER1 (Figure 4.12-A). As the mRNA level of E-
cadherin in melanocytes  (average Ct value was 27.3) was much higher (~100 fold) 
than that in untreated A375 melanoma cells (average Ct value was higher than 34), 
any upregulation of E-cadherin protein level in the pre-200c group, equivalent to the 
observed 4-fold increase in mRNA levels, would probably not to be detectable. I 
considered using another melanoma cell line instead of A375 for these experiments. 
Of the five other melanoma cell lines assayed, it turned out that E-cadherin protein 
was only detectable in G361 (Figure 4.12-A). However, the E-cadherin protein level 
in G361 was higher than that in HER1 (Figure 4.12, B and C). For this reason G361 
was considered unsuitable to demonstrate increased levels of E-cadherin proteins 
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(C) 
 
Figure 4.12 E-cadherin protein levels in melanoma cells and melanocytes. (A) Detection of E-
cadherin protein in various melanoma cell lines. HER1: an immortalised melanocyte cell line taken as 
the positive control. (B) E-cadherin protein level changes in two input amounts of cell proteins (20ug 
and 200ug). (C) The histogram shows the relative protein quantity of E-cadherin over beta-actin for 
the western blotting shown in (B). Each group was normalised to the HER1 (20ug) group. The 
western blot experiment was repeated twice with the same result. 
 
 
4.2.4.7     Effects of miR-200c overexpression on sensitivity of melanoma cells to 
cisplatin 
 
To assess whether upregulated miR-200c could sensitize A375 melanoma cells to 
cisplatin, five concentrations of cisplatin were added to negative, scramble and pre-
200c groups and cell survival data were obtained at Day 5 post-transfection. Cells 
with increased miR-200c levels showed a slightly reduced survival rate compared to 
control groups when treated with 0.1uM and 0.3uM cisplatin (Figure 4.13).  
However, when cisplatin was increased to more toxic concentrations, the cell 
survival rate was indistinguishable between the groups with an IC50 for cisplatin in 
all three groups of 0.44uM. 
 
 0 uM 0.1uM 0.3uM 0.6uM 1uM 3uM 
Negative (%) 100±8.3 97.9±4.1 74.5±6.5 31.9±7.0 12.3±1.4 4.6±0.9 
Scramble (%) 100±1.1 92.3±2.0 71.7±4.1 28.7±1.3 13.2±0.2 5.4±1.2 
pre-200c (%) 100±1.2 88.5±0.7 65.9±0.2 31.1±1.9 14.0±0.4 5.7±1.5 
 
 




Figure 4.13 Cisplatin sensitivity of negative control, scramble and miR-200c precursor 
transfected A375 melanoma cells. The table shows cell survival rate of different groups treated with 
various concentrations of cisplatin for 5 days. Results were normalized to untreated controls and 
represent average cell survival ± SEM from two individual experiments. Every group of each 
experiment contained 8 replicates. X-axis: Concentration of cisplatin. Y-axis: Cell survival rate. Note 
that error bars are present for all data points, but are often too small to be visible. 
 
 
4.2.5 Functional studies for miR-211 
 
4.2.5.1 Expression level changes following transfection of miR-211 precursor 
 
The expression of miR-211 was significantly reduced in melanoma cells as described 
in Chapter 3. Therefore, miR-211 precursor was used to increase its expression in 
A375 melanoma cells for miR-211 functional studies. The expression of miR-211 
was tremendously increased compared to negative and scramble controls for the 3 
days assayed following transfection of precursor miR-211 (Table 4.7). The 
increasing level is comparable to the difference between immortalised melanocytes 
and melanoma cell lines (see Figure 4.5B), which suggests that the miR-211 
expression level manipulation in vitro may well reflect the situation in vivo. miR-211 
levels decreased over time, but not so rapidly as for miR-200c and miR-205. 
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 Negative Scramble pre-211 
24hr 1.00±0.26 0.71±0.22 1828710±665240 
48hr 1.00±0.24 1.72±0.67 1597780±108000 
72hr 1.00±0.11 0.99±0.47 934060±270440 
 
Table 4.7 Comparison of microRNA expression in negative control, scramble and miR-211 
precursor transfected A375 melanoma cells.  The table compares expression changes of miR-211 in 
negative control, scramble and miR-211 precursor treated A375 cells over 3 days by qRT-PCR using 
the ΔΔCt method. Expression of each miRNA is shown relative to miR-92 and normalized to the 
mean of the negative control group. Results represent average relative expression ± SEM two times in 
a triplicate repeat. pre-211: miR-211 precursor treated group.  
 
 
4.2.5.2 Cell cycle assay 
 
The cell cycle status of miRNA precursor transfected and control cells was 
determined post-transfection at 24-, 48- and 72-hours. No changes were seen 
between the groups for the pre-211 experiment (Table 4.8). 
 
 
Table 4.8 Cell cycle comparison in negative control, scramble and miR-211 precursor 
transfected A375 melanoma cells. Results represent percentage of cells in each phase of the cell 
cycle at 24 hours, 48 hours and 72 hours post-transfection determined by FACS. The above data are 
the average results of two individual experiments. 
 
 
4.2.5.3 Cell proliferation assay 
 
The SRB cell growth assay was used to assess cell proliferation of miR-211 
precursor transfected and control cells over a 4-day time course. The assay started 
immediately post-transfection of the miR-211 precursor (Day0). The same timing 
was used for migration and colony formation assay. The results were consistent with 
24hr (%) 48hr (%) 72hr (%)  
(-) Sr pre-211 (-) Sr pre-211 (-) Sr pre-211 
Sub G1 2.4 4.7 4.3 6.8 6.9 6.7 1.3 1.4 1.8 
G1 49.4 48.7 48.3 52.6 53.6 51.1 68.1 64.2 65.9 
S 26.5 25.8 25.8 19.0 18.2 18.5 15.0 17.5 16.9 
G2 21.7 20.8 21.6 21.6 21.3 23.7 15.6 16.9 15.4 
 
Chapter 4: Functional studies of microRNAs in melanoma cells 150 
the cell cycle assay in that no changes were observed between the pre-211 
transfected group and their control groups (Figure 4.14). 
 
 
Figure 4.14 Comparison of cell growth in negative control, scramble and miR-211 precursor 
transfected A375 melanoma cells. The graphs compare cell growth over 4 days. Y-axis represents 
OD 540 for SRB dye extracted from stained wells as an indirect measure of cell number. Results show 
average OD values ± SEM of once in a 16-replicate for each time point. Note that error bars are 
present for all data points, but are often too small to be visible. The experiment was repeated twice 
with the same result. The above result is from one experiment. 
 
 
4.2.5.4 Transwell migration assay 
 
Transwell migration assays were performed and migration was analysed on Day 5 in 
order to determine whether elevated levels of miR-211 influence invasive ability of 
A375 melanoma cells. The relative cell number of the pre-211 group was 
significantly lower than both the scramble and negative control groups at the 40um-
layer (Figure 4.15-A). The reduced invasion of the pre-211 group compared to the 
other two showed up clearly in the stacked pictures taken through the matrigel 
(Figure 4.15-B), and particularly in the enlarged images of the bottom layer and 















     
Figure 4.15 Comparison of invasive ability in negative control, scramble and miR-211 precursor 
transfected A375 melanoma cells. The three figures compare the invasive ability using the transwell 
inverse invasive assay. (A) Cells migrating through matrigel after 5 days were quantified at the 40um- 
layer. The relative cell number was measured for each group using the ratio of the cell number at the 
40um-layer/ that at the bottom layer (0um). Results represent average ratios ± SEM of six microscope 
fields of one individual experiment. The ratio for each group was normalized to the negative control 
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group. (B) Stacked pictures are confocal microscopic pictures from the bottom layer (0um) to the 
tenth layer (90um). Each layer is 10um thick. The 40um-layer indicated in red was used to quantify 
relative cell number. The 60um-layer indicated in red is illustrated in enlarged images in (C). (C) 
Three images (Upper row—0um) represent the bottom layers for the three groups, another three 
images (Lower row—60um) represent the sixth layers for the three groups. The experiment was 
repeated three times with the same result. The above result is from one individual experiment. 
 
 
4.2.5.5 Methylcellulose colony formation assay 
 
To determine whether elevated levels of miR-211 affect tumourigenicity of A375 
cells, the colony forming ability in methylcellulose was assayed after transfection. 
Colony size was used to evaluate the capacity of colony formation and was measured 
on Day1, Day3, Day6. Images of entire wells were taken on Day12 and colony 
number was counted using Gel doc software with a threshold parameter set at 3.1 to 
exclude single cells and very small colonies. 
 
Colony size measured on Day1, Day3 and Day6 is shown in Figure 4.16 (A-C). It is 
clear from Figure 4.16-A, where each group on Day1 contains mainly single cells 
that all groups were equivalent at the start. There was no difference of colony size on 
Day3 between the groups (Figure 4.16-B). However, the colony size was 
significantly smaller on Day6 for all the experimental groups compared to their 
controls (Figure 4.16-C). The difference between negative and scramble was not 
significant (P > 0.05). 
 
Colony numbers on Day12 for negative control, scramble control, pre-211 were 770, 
547 and 305, respectively. In Figure 4.16-D, a decreased colony number was 
observed in each experimental group compared to the controls. The colony size was 
not measured at this stage because the colonies were much bigger on Day12 and 
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(A-1)                                                                        (A-2) 
     
 
 




(C-1)                                                                       (C-2) 













Figure 4.16 Comparison of colony formation in negative control, scramble and miR-211 
precursor transfected A375 melanoma cells. The three histograms compare the average colony size 
in the methylcellulose assay on Day 1, Day 3 and Day 6 (A-1, B-1, C-1). Results represent the average 
colony size ± SEM of 30 colonies and each group was normalized to the negative control group. 
Images of colony size of each group are also shown (A-2, B-2, C-2). (C-1) One asterisk: p<0.05. (D) 
Images show the colony number in each entire well of a plate on Day12. The experiment was repeated 
three times. The above result is from one individual experiment. 
 
 
4.2.6 Functional studies for miR-20b 
 
4.2.6.1 Expression level changes following transfection of miR-20b inhibitor  
 
Expression of miR-20b was significantly increased in melanomas compared to 
benign naevi as described in Chapter 3. Therefore, miR-20b inhibitor was transfected 
into A375 melanoma cells to decrease its expression for functional studies.  
 
Expression of miR-20b was significantly decreased at 24 hours (5 fold) and 48 hours 
(2 fold) compared to the scramble controls (p<0.05) (Table 4.9). The reduction effect 
diminished rapidly over time. It is also clear that inhibiting expression of miRNAs 
using inhibitors is not as efficient as increasing expression of miRNAs using 
precursors, as the inhibitory effect on miR-20b was much smaller than the elevating 
effect observed earlier on miR-200c, miR-205 and miR-211.  
 
 Negative Scramble anti-20b 
24hr 1.00±0.14 1.21±0.30 0.23±0.04 
48hr 1.00±0.20 0.91±0.06 0.45±0.06 
72hr 1.00±0.20 0.91±0.28 0.96±0.19 
 






Table 4.9 Comparison of microRNA expression in negative control, scramble and miR-20b 
inhibitor transfected A375 melanoma cells.  The table compares miR-20b expression changes in 
negative control, scramble and miR-20b inhibitor treated A375 cells by qRT-PCR using the ΔΔCt 
method. Expression of miR-20b relative to miR-92 is shown and is normalized to the mean of the 
negative control group. Results represent average relative expression ± SEM three times in a triplicate 
repeat. Anti-20b: miR-20b inhibitor treated group. 
 
 
4.2.6.2 Cell cycle assay 
 
The cell cycle status of miRNA inhibitor transfected and control cells was 
determined post-transfection at 24-, 48- and 72-hours. No changes were seen 
between the groups for the anti-20b experiment (Table 4.10). 
 
24hr (%) 48hr (%) 72hr (%)  
(-) Sr anti-20b (-) Sr anti-20b (-) Sr anti-20b 
Sub G1 3.3 4.0 3.9 3.2 2.9 3.2 2.2 1.9 2.1 
G1 52.2 53.7 53.5 59.3 59.8 59.4 59.4 58.3 59.2 
S 24.3 23.8 23.4 21.4 20.7 20.0 20.4 21.0 20.4 
G2 20.2 18.5 19.2 16.1 16.6 17.4 18.0 18.8 18.3 
 
Table 4.10 Cell cycle comparison in negative control, scramble and miR-20b inhibitor 
transfected A375 melanoma cells. Results represent percentage of cells in each phase of the cell 
cycle at 24 hours, 48 hours and 72 hours post-transfection determined by FACS. The above data are 
the average results of two individual experiments. 
 
 
4.2.6.3 Cell proliferation assay 
 
The SRB cell growth assay was used to assess cell proliferation of miR-20b inhibitor 
transfected and control cells over a 4-day time course. The assay started immediately 
post-transfection of the miR-20b inhibitor (Day0). The same timing was also used for 
the migration and colony formation assays. The results were consistent with the cell 
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cycle assay in that no changes were observed between the anti-20b group and their 




Figure 4.17 Comparison of cell growth in negative control, scramble and miR-20b inhibitor 
transfected A375 melanoma cells. The graphs compare cell growth over 4 days. Y-axis represents 
OD 540 for SRB dye extracted from stained wells as an indirect measure of cell number. Results show 
average OD values ± SEM of once in a 16-replicate for each time point. Note that error bars are 
present for all data points, but are often too small to be visible. The experiment was repeated twice 
with the same result. The above figure shows one of the individual experments. 
 
 
4.2.6.4 Transwell migration assay 
 
Transwell migration assays were also performed for the miR-20b experiment and 
migration was analysed on Day 5 in order to determine whether decreased levels of 
miR-20b influence invasive ability of A375 melanoma cells. There was no difference 





















Figure 4.18 Comparison of invasive ability in negative control, scramble and miR-20b inhibitor 
transfected A375 melanoma cells. The two figures compare the invasive ability using the transwell 
inverse invasive assay. (A) Cells migrating through matrigel after 5 days were quantified at the 40um-
layer. The relative cell number was measured for each group using the ratio of the cell number at the 
40um-layer/ that at the bottom layer (0um). Results represent average ratios ± SEM of five 
microscope fields of one individual experiment. The ratio for each group was normalized to the 
negative control group. (B) Stacked pictures are confocal microscopic pictures from the bottom layer 
(0um) to the tenth layer (90um). Each layer is 10um thick. The 40um-layer indicated in red was used 
to quantify relative cell number. The experiment was repeated twice with the same result. The above 
result is from one experiment. 
 
 
4.2.6.5 Methylcellulose colony formation assay 
 
The colony forming ability in methylcellulose was also assayed in anti-20b 
experiment. Colony size was used to evaluate the capacity for colony formation and 
was measured on Day1, Day3, Day6.  
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Colony size measured on Day1, Day3 and Day6 is shown in Figure 4.19 (A-C). It is 
clear that from Figure 4.19-A, where each group on Day 1 contains mainly single 
cells that all groups were equivalent at the start. There was no difference of colony 
size on both Day3 and on Day6 between the groups (Figure 4.19-B, C).  
 
 
(A-1)                                                         (A-2) 
    
 
 
(B-1)           (B-2) 
    
 
 
(C-1)                 (C-2) 
 
    
 
Figure 4.19 Comparison of colony formation in negative control, scramble and miR-20b 
inhibitor transfected A375 melanoma cells. The three histograms compare the average colony size 
in the methylcellulose assay on Day 1, Day 3 and Day 6 (A-1, B-1, C-1). Results represent the average 
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colony size ± SEM of 30 colonies and each group was normalized to the negative control group. 
Images of colony size of each group are also shown (A-2, B-2, C-2). The experiment was repeated 






It has been identified in my array work that miR-200c was greatly reduced in 
melanomas relative to benign naevi, which is consistent with the results of two other 
studies [370, 371]. Moreover, miR-200c was significantly downregulated in 
metastatic melanoma compared to primary melanoma from the array, although it 
wasn’t in the top list in the metastasis vs. primary comparison. Given the above facts, 
the role of the miR-200 family in other cancers, and target prediction results for miR-
200c from the Diana Lab web source, it was chosen first from the miR-200 family 
for functional studies.  
 
Many research groups have shown that miR-200 family members inhibit cancer cell 
migration through inhibiting the EMT process rather than influencing cell growth 
[399, 400, 403, 404]. In my study, there were no changes in cell proliferation, cell 
cycle status or apoptosis in melanoma cells with upregulated miR-200c. However, 
there was a significant reduction in both colony size and number in the 
methylcellulose assay, which is an in vitro surrogate assay for tumourigenecity. 
Migration inhibition was not observed in my transwell migration assay, but a good 
explanation for this comes from other studies on the invasive behaviour of melanoma 
cells. It has been discovered that melanoma cell invasion in vivo is affected by cell 
morphology and switching between different modes of invasion [421, 422]. The 
assays of migration on rigid 2D substrates, or transwell migration assays as used in 
my study, cannot reproduce the rounded “amoeboid” form of movement seen in vivo 
[423, 424]. Interestingly, it was found that expression of miR-200c in melanoma 
cells drives the rounded-amoeboid form of cell migration, while miR-200a drives the 
elongated form or mesenchymal-type of invasion using a refined 3D assay with a 
thick deformable collagen-I matrix [425]. They found both miR-200a and miR-200c 
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can enhance invasion in some melanoma cell lines using the 3D assay. Thus, the 
failure to see inhibition of migration in melanoma cells with increased levels of miR-
200c in my transwell migration assay is consistent with recent published results.  
 
For the miR-200c target study, I took advantage of the report that the miR-200 
family directly target ZEB1 and ZEB2 in other cancers. Therefore, I detected 
expression of ZEB2 without using a luciferase report system. I detected significant 
ZEB2 repression at the transcriptional level one day after transfection with the miR-
200c precursor and this was accompanied by a significant increase of E-cadherin 
gene expression. Both effects reduced over time, most likely because the miR-200c 
upregulating effect was transient. The expression of N-cadherin was not changed, 
perhaps because the observation time was not long enough, or the increased E-
cadherin level was not sufficient to trigger the changes of N-cadherin. I conclude that 
elevating expression of miR-200c in melanoma cells can inhibit tumourigenicity 
through repressing colony forming ability in methylcellulose.  Further studies would 
be needed to see if this results in smaller melanoma size in vivo. Additionally, 
although I was not able to evaluate E-cadherin protein level changes in miR-200c 
increased melanoma cells, it is possible that EMT in melanoma may be reversed to 
MET through upregulating miR-200c. 
 
As mentioned in the introduction of this Chapter, miR-200c could sensitize NSCLC 
cells to cisplatin treatment [419]. To investigate whether miR-200c expression is 
correlated to chemoresistance in melanoma cells, a cell survival assay following 
cisplatin treatment was performed. No significant change in the IC50 for cisplatin 
was observed in miR-200c increased melanoma cells. On the contrary, a recent paper 
has shown significantly increased miR-200c expression in cisplatin-resistant 
oesophageal cancer cells compared with their parent cells [426]. Knockdown of miR-
200c expression resulted in reduced phosphorylation of AKT, indicating 
overexpression of miR-200c induces cisplatin resistance through activating the AKT 
signalling pathway. The above results indicate that the relationship between miR-
200c and chemoresistance is complicated and may be tissue-specific. 
For miR-205, the results of functional studies were quite similar to miR-200c. No 
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changes occurred in cell proliferation or apoptosis post-transfection of the miR-205 
precursor. Melanoma cells with overexpressed miR-205 showed slight inhibition in 
migration assay, although the inhibition was not significant. Whether miR-205 has 
the same effects on invasive behaviour as that of miR-200c needs to be studied. 
Likewise, increased expression of miR-205 may also decrease melanoma size in vivo 
as there was a significant reduction of colony size and colony number in the 
methylcellulose assay. miR-205 and the miR-200 family share the common targets, 
ZEB1 and ZEB2. However, unlike the inhibition of ZEB2 mRNA observed in 
melanoma cells with increased miR-200c, no inhibition was observed in cells with 
elevated miR-205. Moreover, upregulating miR-205 and miR-200c simultaneously 
did not have a stronger effect than miR-200c alone, indicating that they do not 
cooperate with each other. A very recent study identified that E2F1 and E2F5 were 
direct targets of miR-205. It also elucidated that miR-205 negatively regulates the 
AKT pathway through targeting these two transcription factors in C8161.9 
melanoma cells [427]. Moreover, miR-205 were also involved in inhibiting cell 
proliferation, inducing apoptosis and reducing colony formation in both transient and 
stable miR-205 elevated C8161.9 melanoma cells. The inconsistency between the 
results of the above study and my work is probably because of the different 
melanoma cell lines used. 
 
Another important miRNA—miR-211, showed a significant reduction in melanomas 
compared to naevi. Notably, it also showed a thousand fold decrease in most of the 
melanoma cell lines examined compared to immortalised melanocytes. In my 
functional studies of miR-211, I found that ectopic expression of miR-211 
significantly decreased colony forming ability in methylcellulose and inhibited cell 
migration in melanoma cells. However, cell proliferation changes in normal media 
were not observed. Three papers have been published recently that discussed the role 
of miR-211 in melanomagenesis. There are both consistencies and inconsistencies 
with my results.  
 
The consistency is that the same expression pattern in both cells and tissues implies 
miR-211 definitely acts as a tumour suppressor. The question is how? Mazer et al. 
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revealed that miR-211 inversely regulates KCNMA1 at both transcription and 
protein levels. KCNMA1 encodes a component of a K+ exporting channel whose 
function is modulated by Ca2+. It has been linked to tumour cell proliferation in 
prostate cancer [428], cell migration in glioma [429], and antineoplastic drug 
resistance in melanoma cells [430]. Levy et al. found that transforming growth factor 
receptor II (TGFBR2) and nuclear factor of activated T-cells 5 (NFAT5) are the 
direct targets of miR-211. Boyle et al. reported that BRN2 is the direct target of miR-
211. However, the discrepancy is that in Mazer et al.’s study, overexpression of miR-
211 inhibited both cell proliferation and migration of melanoma cells, while the other 
two groups only showed changes in migration, which is consistent with my results. 
 
Intriguingly, miR-211 is encoded within the sixth intron of TRPM1 (melastatin), a 
candidate suppressor of melanoma metastasis. MITF is the transcription factor for 
TRPM1. MITF coodinately regulates both miR-211 and TRPM1 expression [381]. 
High levels of MITF inhibit melanoma invasiveness and this is likely due to its 
effects on miR-211 independent of melastatin, indicating that TRPM1 is not itself a 
tumour suppressor, but is rather a marker of expression of the true melanoma tumour 
suppressor at this locus, miR-211 [382, 383].  
 
miR-20b was upregulated in melanoma tissues compared to the other three miRNAs 
that I also conducted functional studies on. It has been reported to accumulate in 
tumour cells and act as an oncogene in human T-cell leukemia and mouse breast 
tumours [379, 431]. My functional studies for miR-20b did not show any changes in 
melanoma cells with reduced miR-20b levels. A possible explanation could be that 
the miR-20b reduction was too small to show significant functional differences, or 
miR-20b functions in other carcinogenetic processes that were not assayed in my 
work.  
 
The roles of miR-20b in tumourigenesis are quite complicated. Two papers discussed 
the role of miRNAs in angiogenesis under hypoxic condition, whereas none of my 
studies were relevant to tumour angiogenesis. miR-20b was confirmed to regulate 
oxygenation and two angiogenesis related regulators (hypoxia inducible factor 1 α 
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subunit—HIF-1α and vascular endothelial growth factor—VEGF) in several mouse 
tumour cell lines, including  a melanoma mouse cell line—B16 [432]. Both HIF-1α 
and VEGF are the direct targets of miR-20b [432, 433] and HIF-1α can also 
inversely regulate miR-20b expression [432]. Furthermore, VEGF can be 
transcriptionally activated by HIF-1α [434]. Zhang et al. found differentially low 
expression of miR-20b in hypoxia compared to the normoxic condition. Combined 
with the fact that overexpression of HIF-1α leads to a decrease in the level of miR-
20b, it could explain why upregulation of miR-20b was established in my melanoma 
tissues but the inhibition of cell growth was not seen after downregulation of miR-
20b in my cell based study. My hypothesis is: when tumour cells proliferate in 
normoxia, the low level of HIF-1α regulates miR-20b and upregulation of miR-20b 
is seen. When tumour cell proliferation reaches a hypoxic condition, HIF-1α 
becomes upregulated and thus miR-20b becomes downregulated and low miR-20b 
keeps high levels of HIF-1α until VEGF is upregulated to continue tumour 
progression. The multiple relationship among miR-20b, HIF-1α and VEGF implies 
their reciprocal action in allowing tumour cells to adapt to different oxygen 
concentration and angiogenesis for survival. Therefore, oxygen condition should be 
taken into account in functional studies on miR-20b.  
 
Four miRNAs of the miRNA microarray profile were further studied through 
functional assays. In this Chapter, it was found that expression of both miR-200c and 
miR-205 reduced colony forming ability in methylcellulose. This Chapter also first 
reported that miR-200c negatively regulated expression of ZEB2 and resulted in 
upregulated E-cadherin at the transcriptional level in melanoma, indicating miR-200c 
may contribute to the MET process through overexpression of E-cadherin. For miR-
211, ectopic expression inhibited colony formation and tumour cell migration. None 
of these miRNAs influenced cell growth in normal culture conditions. To conclude, 
miR-200c, miR-205 and miR-211 act as tumour suppressors in melanoma 
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5.1 Introduction 
 
Cutaneous melanoma is 10 times more frequently seen in white populations than in 
black individuals, which indicates a protective role for melanin pigment [435]. The 
major role of melanin is to protect against the harmful actions of solar radiation. 
UVR represents a fraction of the solar radiation but it is responsible for the majority 
of its carcinogenic effect. UVR is divided into UVC (200-280nm), UVB (280-
320nm) and UVA (320-400nm) [436]. The UVC spectrum rarely reaches the earth’s 
surface while UVA and UVB wavelength represent 95% and 5% of the UV spectrum 
reaching the earth’s surface. UVB is more efficiently absorbed by cellular molecules, 
although it is about 20-fold less abundant than UVA [435]. The interaction of UVB 
with DNA results in 6-4PP and CPD between adjacent pyrimidine sites. If 6-4PPs 
and CPDs are not repaired, they can induce mutations in many genes. The most 
abundant mutations after UVB are C to T and CC to TT transitions at bipyrimidine 
sites or pyrimidine runs, called “UVB fingerprint mutations” [437]. UVB can also 
induce reactive oxygen species (ROS). Recent studies reported that UVA is also an 
important factor involved in photocarcinogenesis but through different mechanisms 
to UVB [437].  UVA induces DNA damage indirectly through the absorption of 
UVA photons by other cellular structures, such as chromophores, with formation of 
ROS (H2O2). This can transfer the UVA energy to DNA via mutagenic oxidative 
intermediates, such as 8-hydroxydeoxyguanosine. DNA damage by UVA radiation 
typically consists of T to G transversions, called “UVA fingerprints”. It was found 
that irradiation of melanocytes with UVA or UVB leads to alterations of different 
intracellular proteins, indicating that UVA and UVB may trigger initiation of 
melanoma via separate intracellular pathways [438]. 
 
The BRAF gene is a member of the RAF family which comprises three members: 
ARAF, BRAF and CRAF. It encodes a serine-threonine protein kinase [439]. RAS is 
a small G protein that is embedded in the plasma membrane of cells and is activated 
downstream of growth factor receptor tyrosine kinases, cytokines and hormones. 
RAF is activated following its recruitment to the plasma membrane by RAS and then 
triggers the MAPK pathway, which regulates cell proliferation, differentiation, 
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senescence and survival [439]. 
 
BRAF is the only RAF protein to be frequently mutated in cancer. No ARAF 
mutations have been identified so far [440, 441]. CRAF mutations are only rarely 
found [440, 442], but the gene is overexpressed in some ovarian and pulmonary 
carcinomas, indicating that CRAF can act as an oncogene [443]. Besides BRAF 
mutations, NRAS mutations are found in all subtypes of melanoma, although the 
overall mutation frequency (15-30%) is lower than that of BRAF. Generally, BRAF 
and RAS (N, H, or K) mutations are mutually exclusive with only few exceptions. 
Mutations in cKIT are most common in mucosal, acral or chronically sun-damaged 
skin melanomas [131, 444, 445]. CCND1 is amplified most commonly in melanomas 
without BRAF or RAS mutations, whereas melanomas with mutation in either of the 
latter two genes display elevated Cyclin D1 levels [446, 447]. CDK4 amplifications 
are more common in acral and mucosal melanomas and are also inversely correlated 
with BRAF or RAS mutations or CCND1 amplifications [447]. From the above 
evidence, it is clear that constitutive activation of the RAS/MEK/ERK pathway, by 
oncogenic lesions in one of the pathway’s components, is an important step in 
melanoma development. However, BRAF mutation is the most common among all 
these mutations and aberrant gene expressions. 
	  
	  
More than 30 different BRAF mutations have been identified in a number of 
malignancies including thyroid, ovarian, lung and colon cancer as well as melanoma 
[448]. Among human cancers, BRAF mutations are most common in melanoma. The 
prevalence of BRAF mutations varies substantially among the different types of 
melanoma. The highest frequency (50% to 60%) is found in cutaneous melanoma 
[447]. It is rare in mucosal, acral and conjunctival melanomas, and virtually absent 
from uveal melanomas. Furthermore, within the group of cutaneous melanomas, 
BRAF mutations are highest on sites of intermittently sun-exposed skin, rather than 
on chronically sun-damaged or completely unexposed skin [447]. Cutaneous 
melanomas on sites of chronically sun-damaged skin harbour wild type BRAF and 
arise later in life [447, 449]. More intriguingly, the high frequency of BRAF 
mutations is also seen in melanocytic naevi [450]. Within the BRAF mutations, the 
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most common one, which accounts for more than 90% of total BRAF mutations [77] 
corresponds to a T>A transversion at position 1799, resulting in the substitution of 
Valine by Glutamine at codon 600 (V600E BRAF mutation). The BRAF V600E 
mutation displays increased kinase activity relative to the wild type protein and has 
transforming capacity [77]. Cell lines expressing the BRAF V600E are dependent on 
it for proliferation and survival [451-453] and most do not require RAS for 
proliferation [77].  
 
Cutaneous melanoma can vary significantly in clinical and histopathological 
appearance, which has led to the development and refinement of morphologically 
based classification systems. The standard classification for melanoma uses the 
current World Health Organization (WHO) classification that distinguishes four main 
types of melanoma as described in Chapter 1 (See Page 6). These distinctions are 
related to clinical features such as anatomic site of the primary tumour, pace of 
tumour evolution and the patient age. However, clinical management based only on 
the above classifications is difficult. For example, a number of melanomas are 
differentially classified by different observers, or classified as “ambiguous” because 
these classifications are defined by multiple criteria [454]. On the other hand, genetic 
alterations can serve as biomarkers for classification purposes even though the 
complete profile of genetic factors is still not available. Viros et al. described that 
combining the morphological appearance and the genetic changes could be clinically 
useful for therapy stratification and for retrospective study of clinical trial data. They 
found BRAF mutation status is strongly related to some phenotypic features such as 
pigmentation, cell shape, size, and nesting of primary melanomas, which implies that 
refined morphological classification of primary melanomas can be used to improve 
existing melanoma classifications by integrating genetic and morphologic features 
[455].   
 
In our group, about 150 melanoma samples were available from a TMA panel 
constructed by Dr Ewan Brown, containing primary and metastatic melanoma 
samples with clinicopathological records. We have also developed a mature method 
to genotype the BRAF V600E mutation. Potentially, we are able to perceive new 
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insights into the role of the BRAF mutation in melanomagenesis and melanoma 
classifications by investigating the relationship between BRAF mutation status and 
the clinicopathological signatures in our sample cohort. Moreover, we can also 
associate BRAF mutation to patient survival. 
 
Therefore, the objectives of this Chapter were: to genotype BRAF V600E mutations 
in FFPE melanoma tissues from our TMA cohort; to identify the correlation between 
the BRAF V600E mutation and the clinicopathological features; to assess the 





5.2.1 BRAF V600E mutation frequency in melanoma tissues 
 
5.2.1.1 BRAF V600E mutation assay 
 
Genetic analysis by restriction fragment length polymorphism (RFLP) allows the 
examination of nucleic acids for the presence of known sequence variants. A 
segment that is to be searched for a mutation is amplified from genomic DNA, 
digested by the appropriate restriction enzyme, and then separated by agarose gel 
electrophoroesis. Although RFLP analysis is highly sensitive and relatively easy to 
perform, many polymorphisms are the result of single-base substitutions that fail to 
create or remove a restriction site and therefore cannot be genotyped by simple PCR 
and RFLP analysis. A mismatch PCR primer can be used to overcome this as it 
artificially creates a restriction site in the amplified product to allow the detection of 
the presence of a base substitution by RFLP.  
 
In order to associate the presence of the BRAF V600E mutation with history of UV 
exposure and other available clinicopathological characteristics, an assay was 
developed for detection of this mutation in melanoma samples. The assay used PCR 
with a mismatch PCR primer and an XbaI RFLP, which is a method originally 
 
Chapter 5: Role of the BRAF V600E mutation in melanomagenesis 169 
reported by Hayashida et al. [456]. DNA extracted from FFPE specimens is often 
fragmented and PCR is difficult when amplifying products greater than 100bp in 
length. In order to increase the efficiency of the PCR on DNA isolated from FFPE 
tissues, a nested PCR was also used which was developed by Dr Jim Selfridge. 










XbaI (fwd): TAAAAATAGGTGATTTTGGTCTAGCTCTAG 
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(C) 
 
Fig 5.1 BRAF PCR RFLP analysis. (A) Schematic diagram showing position of primers used for 
BRAF nested PCR. The site of the transversion mutation T1799A is marked with a black bar. (B) 
Sequence of genomic DNA (exon 15) containing coding sequence in blue and primers indicated with 
red line and black texts. Mismatched primer nucleotides are in bold and underlined in blue. The site of 
the T1799A mutation is in red bold. The nested PCR primers are: BRAF TAQ (fwd) and BRAF Rev5 
(Nested 1); BRAF XbaI (fwd) and BRAF REV (Nested 2). (C) Strategy underlying the PCR-RFLP 
method for detection of BRAF T1799A mutation. DNA was amplified by PCR using a mismatched 
forward primer AC to CT (where the wildtype AC was changed to CT). The Amplified products were 
digested with XbaI. In this case only mutant DNA products can be cut by XbaI, as shown in red. 
 
 
5.2.1.2 Sensitivity of genotyping method         
 
Although the TMA cores were taken from areas that were rich in tumour cells it was 
likely that the cores still contained some non-tumour material. So heterozygous 
BRAF mutant and wild type cultured cells were used to elucidate the sensitivity of 
the assay, by determining the lowest frequency of mutant cells that could be detected 
in the presence of wild type cells in the TMA core samples.  Different ratios of 
mutant and non-mutant containing DNA were made up and subjected to PCR and 
digestion as described above. The sensitivity results are shown in Figure 5.2.  A band 
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of 105bp identified the presence of the BRAF V600E mutation. In this figure, a very 
faint band at 105bp is seen in Lane 3, indicating that the sensitivity of the assay is 
10%. This suggested that the assay could detect mutant BRAF V600E if it was 
present in at least 10% of cells isolated from the TMA cores. Moreover, 
heterozygous and homozygous BRAF mutant samples of primary melanoma tissues 




Figure 5.2 BRAF V600E RFLP assay. Lanes 2 to 6 are sample mixtures of BRAF V600E wild type 
(WT) and mutant type (MT) of DNA in the indicated ratios. In each case the total amount of DNA 
used for PCR was the same (1ug). Lane 7 and Lane 8 are two individual primary melanoma samples 
with heterozygous and homozygous BRAF V600E mutations, respectively. M: Marker, WT: Wild 
type, MT: Mutant. The assay used nested PCR for BRAF exon 15. 134bp is the size of the nested PCR 
product, while 105bp is this size if the PCR product contains the mutation and is restricted by XbaI. 
 
 
5.2.1.3 Frequency of the BRAF V600E mutation in melanoma samples 
 
Cores were available from 115 primary and 29 metastatic melanoma tissues and 
BRAF V600E mutation results were observed from all of them. The frequency of 
BRAF V600E mutation was 20% in primary melanoma tissues, and 69% in 
metastases (Table 5.1). In addition, examples of homozygous mutants were also seen 
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 Primary Melanoma Metastatic Melanoma 
BRAF V600E Heterozygous MT 21 17 
BRAF V600E Homozygous MT 2 3 
Wild type 92 9 
BRAF mutation frequency (%) 23/115 (20%) 20/29 (69%) 
 
Table 5.1 BRAF V600E mutational status in melanoma samples. The table shows the frequency of 
the BRAF V600E mutation in tumour samples from both primary and metastatic melanoma patients 
and the status of heterozygous and homozygous mutant types. MT: Mutant type. 
 
 
5.2.2 Statistical analysis of the BRAF V600E mutation in primary melanoma  
 
I have correlated the BRAF V600E mutation to age, gender, Breslow thickness, 
ulceration, solar elastosis (SE) and pigmentation using either Chi-square or Fisher’s 
exact test. 
 
Two sets of available records were not analysed statistically: anatomic sites (sun-
exposed, sun-protected, acral) and histo-type. For site records, patients with BRAF 
mutations accounted for 6.7% (1/15) sun-exposed, 20.6% (20/97) sun-protected and 
66.7% (2/3) acral samples. However, the numbers in some subgroups were too small 
for analysis and SE was a better indicator to quantify UV exposure. For histo-type 
records of the cohort, 25% LLM (2/8), 20% SSM (17/87), 16.7% NM (3/18) and 
50% (1/2) ALM patients had BRAF V600E mutations. Sample size of some of the 
subgroups was also too small and so multivariate analysis was not used in this study. 
 
 
5.2.2.1 BRAF V600E mutation and age 
 
In 115 primary melanoma patients, the median and mean ages at diagnosis were 
54.8yrs and 54.87yrs. Previous studies of the correlation between BRAF mutation 
and age have used different age cutoffs. So far, three common age cutoffs were used 
(45yrs [457], 55yrs [455], 60yrs [458]) and it was found that BRAF mutations were 
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more common  in the younger age group. However, there was no correlation between 
BRAF mutation and age in our cohort using any of the three cutoffs. 
 
(A) 
 Age ≤ 45 Age > 45 Total 
BRAF (+) 7 (6.1%) 16 (13.9%) 23 (20%) 
BRAF (-) 31 (27.0%) 61 (53.0%) 92 (80%) 
Total 38 (33.1%) 77 (66.9%) 115 (100%) 
p value p=0.77 
 
(B) 
 Age ≤ 55 Age > 55 Total 
BRAF (+) 11 (9.6%) 12 (10.4%) 23 (20%) 
BRAF (-) 47 (40.9%) 45 (39.1%) 92 (80%) 
Total 58 (50.5%) 57 (49.5%) 115 (100%) 
p value p=0.78 
 
(C) 
 Age ≤ 60 Age > 60 Total 
BRAF (+) 13 (11.3%) 10 (8.7%) 23 (20%) 
BRAF (-) 55 (47.8%) 37 (32.2%) 92 (80%) 
Total 68 (59.1%) 47 (40.9%) 115 (100%) 
p value p=0.78 
 
Table 5.2 Comparison of the BRAF V600E mutation and age in primary melanoma patients. 
Patients were divided into young and old groups. The Chi-square test was used for all three tables. 
Numbers in brackets in this and in the following tables in this chapter, represent the percentage of 
patients in each category.  
 
 
5.2.2.2 BRAF V600E mutation and gender 
 
In the cohort, males and females accounted for 44.3% and 55.7%, respectively. 
29.4% male patients possessed the BRAF V600E mutation, whereas only 12.5% 
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females had the mutation. The statistical test that showed the mutation was present at 
significantly higher frequency in male relative to female patients (Table 5.3).   
 
 Male Female Total 
BRAF (+) 15 (13.0%) 8 (7.0%) 23 (20%) 
BRAF (-) 36 (31.3%) 56 (48.7%) 92 (80%) 
Total 51 (44.3%) 64 (55.7%) 115 (100%) 
p value p=0.024 
 
Table 5.3 Comparison of the BRAF V600E mutation and gender in primary melanoma patients. 
The Chi-square test was used. 
 
 
5.2.2.3 BRAF V600E mutation and Breslow thickness 
 
When correlating to Breslow thickness, BRAF V600E mutation frequencies of 
13.5%, 17.4%, 44.4% and 20% were identified in the four subgroups of the Breslow 
system, respectively (Table 5.4, A). When the subgroups were combined into bigger 
groups, the results were interesting. In Table 5.4-B, the data were divided into thin 
and thick groups with a cutoff at 1mm thick. This result did not reach statistical 
significance for correlating BRAF mutation and tumour thickness. However, when 
the cutoff was set at 2mm thick, the BRAF V600E mutation was significantly 
correlated to thicker tumour lesions (Table 5.4, C). The correlation was significant 
when the Bonferroni correlation for multiple tests was applied. (In this case the 
significance cutoff was 0.05/2 = 0.025). 
 
(A) 
  ≤ 1mm 1.01-2.0mm 2.01-4.0mm > 4.0mm Total 
BRAF (+) 8 4 8 3 23 
BRAF (-) 51 19 10 12 92 





















Table 5.4 Comparison of the BRAF V600E mutation and melanoma lesion thickness in primary 
melanoma patients. Melanoma lesion thickness was evaluated using the Breslow system. Table (A) 
shows number of BRAF V600E positive and negative tumours in different melanoma lesion thickness 
groups according to the Breslow thickness. Table (B) correlates BRAF mutation status with thin 
lesion (≤ 1mm) or thick lesion (>1mm) groups. Table (C) correlates BRAF mutation status with thin 
lesion (≤ 2mm) or thick lesion (>2mm) groups. The Chi-square test was used. 
 
 
5.2.2.4 BRAF V600E mutation and ulceration 
 
For correlation analysis between the BRAF V600E mutation and ulceration, the 
Ulceration unknown group was removed.  The Incipient group, which represents 
those tissues with very early signs of ulceration, was added to the Yes group. In this 





 Yes No Incipient Unknown Total 
BRAF (+) 10 10 2 1 23 
BRAF (-) 26 49 13 4 92 
Total 36 59 15 5 115 
 ≤ 1mm > 1mm Total 
BRAF (+) 8 (7.0%) 15 (13.0%) 23 (20%) 
BRAF (-) 51 (44.3%) 41 (35.7%) 92 (80%) 
Total 59 (51.3%) 56 (48.7%) 115 (100%) 
p value p=0.076 
 ≤ 2mm > 2mm Total 
BRAF (+) 12 (10.4%) 11 (9.6%) 23 (20%) 
BRAF (-) 70 (60.9%) 22 (19.1%) 92 (80%) 
Total 82 (71.3%) 33 (28.7%) 115 (100%) 
p value p=0.023 
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(B)              
 
 Yes No Total 
BRAF (+) 12 (10.9%) 10 (9.1%) 22 (20%) 
BRAF (-) 39 (35.5%) 49 (44.5%) 88 (80%) 
Total 51 (46.4%) 59 (53.6%) 110 (100%) 
p value p=0.39 
 
Table 5.5 Comparison of the BRAF V600E mutation and ulceration in primary melanoma 
patients. Ulceration was divided into four groups as shown in table (A). The Incipient group was 
added into the Yes group and the Unknown group was removed for analysis. Table (B) analyzed the 
correlation between the BRAF V600E mutation and ulceration. The Chi-square test was used. 
 
 
5.2.2.5 BRAF V600E mutation and solar elastosis 
 
Solar elastosis (SE) is a histological indicator of chronic sun-induced damage (CSD). 
The degree of SE in the dermis of each primary melanoma sample was scored 
according to a method reported by Landi et al. [459]. The aim was to provide a 
quantitative assessment of sun damage in the skin in which the melanoma arose. The 
scores (0-11) took account of both amount and distribution of the elastosis seen. The 
SE scoring was performed on H&E stained sections by Dr Tamasin Doig. It was 
divided into two groups: low group (score 0-6) and high group (score 7-11). 10 
samples had no SE records. The frequency of BRAF mutation patients in the low SE 
group was 21.7%, with only 7.7% in the high SE group. However, the statistical 










 SE ≤ 6 SE > 6 Total 
BRAF (+) 20 (19.0%) 1 (1.0%) 21 (20%) 
BRAF (-) 72 (68.6%) 12 (11.4%) 84 (80%) 
Total 92 (87.6%) 13 (12.4%) 105 (100%) 
p value p=0.46 
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Table 5.6 Comparison of the BRAF V600E mutation and solar elastosis in primary melanoma 
patients. SE scores were divided into low (0-6) or high (7-11) [459]. Fisher’s exact test was used. 
 
 
5.2.2.6 BRAF V600E mutation and pigmentation 
 
Pigmentation was scored according to a described method [455]. It was defined as 
the degree of melanin accumulation within the constituent melanocytes and was 
scored on a five-point scale (0-4). The scoring method was: 0, (absent) no pigment 
discernible even at high power; 1, (faint) pigmentation barely visible at low power. 
At high power, melanocytes showed a faint diffuse melanin pigment or a few 
pigment granules. 2, (moderate) pigmentation visible at low power with translucent 
cytoplasm that is significantly lighter than the hematoxylin stained nuclei; 3, (high) 
pigmentation easily visible at low power with the cytoplasmic pigmentation reaching 
an intensity approximating that of the nucleus; 4, (very high) cytoplasm strikingly 
pigmented making it difficult to identify nuclei. 
 
Scores 0-2 were put into the low pigment group, while scores 3-4 were put into the 
high pigment group. The H&E slide of one primary sample was not available for 
scoring. A 14.7% BRAF mutation frequency was seen in the low pigment group 
while 47.4% was seen in the high pigment group. The Fisher’s exact test showed 
significant correlation (p=0.003) between the BRAF V600E mutation and 
pigmentation, indicating that the presence of BRAF V600E mutation was associated 
with pigmentation. 
 
 Pigmentation ≤ 2 Pigmentation > 2 Total 
BRAF (+) 14 (12.3%) 9 (7.9%) 23 (20.2%) 
BRAF (-) 81 (71.0%) 10 (8.8%) 91 (79.8%) 
Total 95 (83.3%) 19 (16.7%) 114 (100%) 
p value p=0.003 
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Table 5.7 Comparison of the BRAF V600E mutation and pigmentation in primary melanoma 




5.2.3 Prognostic evaluation of the BRAF V600E mutation  
 
In assessing whether the BRAF V600E mutation affects patient survival and 
melanoma relapse, two cases were excluded as they had no follow-up records. For 
two survival analyses, the endpoint was death. For time to melanoma relapse, the 
endpoint was relapse. Table 5.8 summarises the number of cases that were put into 
the analyses. The following three Kaplan-Meier analyses were based on the data in 
this table. 
 
 Overall Survival Melanoma Specific Survival Relapse 
 
          Yes         No Yes         No Yes         No 
BRAF (+)           14            9 17            6 9            14 
BRAF (-)           68          22 76           14           15          75 
Total	   	  	  	  	  	  	  	  	  	  	  	  82	  	  	  	  	  	  	  	  	  	  	  31	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  93	  	  	  	  	  	  	  	  	  	  	  20	   	  	  	  	  	  	  	  	  	  	  	  24	  	  	  	  	  	  	  	  	  	  	  89	  
 
Table 5.8 Data for survival and time to relapse analysis.  
 
 
5.2.3.1 Survival analysis 
 
To evaluate whether the BRAF V600E mutation correlated with prognosis in patients 
with primary melanoma, Kaplan-Meier survival curves were constructed using 
overall and melanoma-specific survival (Figure 5.3 and Figure 5.4). Patients with the 
BRAF V600E mutation had no significant difference in overall and melanoma-
specific survival (log-rank test =0.1981 and 0.25, respectively) compared to patients 
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5.2.3.2 Time to melanoma relapse 
 
Using Kaplan Meier analyses, the BRAF V600E mutation was found to correlate 
with time to melanoma relapse in our cohort, although the presence of the BRAF 
V600E mutation seems to be having no effect on overall and melanoma-specific 
survival (Figure 5.5). The result suggested that patients with BRAF V600E mutation 
would have melanoma relapse earlier than those without this mutation. The hazard 




                                                                                                           
 
Figure 5.3 Comparison of the BRAF V600E mutation and overall survival in melanoma 
patients. The Kaplan-Meier survival analysis shows the relationship between the BRAF V600E 
mutation and overall survival in melanoma patients (year since diagnosis). The key in the graph 
includes p value, hazard ratio and 95% CI of hazard ratio. 
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Figure 5.4 Comparison of the BRAF V600E mutation and melanoma specific survival in 
melanoma patients. The Kaplan-Meier survival analysis shows the relationship between the BRAF 
V600E mutation and melanoma specific survival in melanoma patients (year since diagnosis). The key 





Figure 5.5 Comparison of the BRAF V600E mutation and melanoma relapse. The Kaplan-Meier 
melanoma relapse analysis shows the relationship between the BRAF V600E mutation and time to 
melanoma relapse in melanoma patients (year since diagnosis). The key in the graph includes p value, 
hazard ratio and 95% CI of hazard ratio.   
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5.3 Discussion 
  
In this Chapter, I showed that the frequency of the BRAF V600E mutation was 20% 
using nested PCR-RFLP method in a 115-case primary melanoma cohort. The 
frequency was 69% in metastatic melanoma samples. The presence of the BRAF 
mutation was associated with gender and pigmentation. It was related to Breslow 
thickness when the lesion was thicker than 2mm. In assessing the BRAF mutation’s 
prognostic value, patients with BRAF V600E mutations seem to have melanoma 
relapse earlier than those without the mutation. However, there was no evidence that 
there was a correlation between the BRAF mutation and overall and melanoma-
specific survival in our sample panel. 
 
To compare my results to others, I summarised the frequencies of the BRAF V600E 
mutation in primary melanoma tissues from a number of published papers (Table 
5.9). The prevalence of the BRAF V600E mutation observed in this study in 
metastatic melanoma is consistent with reported frequencies in Pollock’s study [460], 
while the frequency in primary melanomas was lower than in many published 
reports, but was similar to that in most other large sample number studies (No.5, 12, 
14 in Table 5.9). The reported incidence of the BRAF V600E mutation varies 
between 20-80% in primary melanoma samples. The reasons why it varies so greatly 
probably depend on the different types of samples analysed, the sample size and the 
genotyping method used. BRAF mutations are more prevalent in superficial 
spreading and nodular melanoma than in other types. Most of the published papers 
did not mention the sensitivity of the genotyping assay. However, I showed that our 
assay sensitivity is able to detect the mutation in small tumours when the cores 
contain up to 90% non-tumour tissue.  
 
Interestingly, there were two examples of homozygous BRAF mutation in primary 
samples which is rare and has not been reported in other papers, although there is one 
report of a possible homozygous mutation of BRAF in melanocytic lesions (benign 
and atypical naevi) [461] .  
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No. Frequency (%) Detection method Sensitivity Reference 
1 6/9 (66.7%)    Sequencing ND Davies H, 2002 
2 37/71 (52.1%) SSCP/Sequencing ND Omholt K, 2003 
3 4/5 (80.0%) AS-PCR ND Pollock PM, 2003 
4 14/25 (56%) PCR-RFLP/Sequencing ND Uribe P, 2003 
5 28/97 (28.9%) Sequencing ND Yazdi AS, 2003 
6 24/32 (75.0%) Sequencing ND Maldonado JL, 2003 
7 10/35 (28.6%) SSCP/Sequencing ND Kumar R, 2003 
8 17/59 (28.8%) SSCP/Sequencing ND Masaru S, 2004 
9 13/51 (25.5%) SSCP/Sequencing ND Akslen L, 2005 
10 20/36 (55.6%) PCR/RFLP ND Goydos JS, 2005 
11 33/58 (56.9%) AS-PCR ND Goel VK, 2006 
12 19/81 (23.5%) ND ND Poynter JN, 2006 
13 112/251 (44.6%) AS-PCR 2% Liu W, 2007 
14 60/214 (28.0%) SSCP/Sequencing ND Thomas NE, 2007 
15 30/69 (43.4%) Sequencing ND Kannengiesser C, 2008 
16 4/18 (22.2%) Sequencing ND Dadzie OE, 2008 
17 23/115 (20.0%) PCR-RFLP 10% This thesis 
 
Table 5.9 Summary of primary melanoma BRAF V600E mutation frequencies in publications. 
The table summarizes published data of BRAF V600E mutation frequencies for the last ten years with 
detection method and sensitivity of the assay. ND: Not described. AS-PCR: Allele specific PCR; 
SSCP: Single-strand conformational polymorphism. 
 
 
In correlation analyses of BRAF mutation and clinicopathological signatures, there 
seems no agreement either. Although the age cutoff may be not the same, some 
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research results showed that the BRAF mutation was more common in younger 
patients [455, 457, 458, 462]. In Viros’ paper, age at diagnosis < 55yrs was described 
as the single most predictive factor for BRAF mutation and the mutation showed a 
significant decrease in survival when stratified by this age cutoff. However, this was 
not seen in my study. BRAF mutation was correlated to male patients in our cohort, 
which is consistent with the report from Uribe et al, indicating that mutation 
frequencies may be related to hormonal influences in melanocyte biology [461]. 
Generally, the presence of the BRAF mutation has not been correlated to the key 
prognostic indicator, Breslow thickness, except for Liu’s study that reported a 
correlation with lower thickness [462]. However, my data indicated that BRAF 
mutation was related to higher thickness when the cutoff was 2mm, which is 
opposite to their results. Interestingly, both of our results showed significant 
correlation between BRAF mutation and more frequent pigment production, which 
was also seen in Viros’s study [455]. This evidence supports the finding that mutant 
BRAF V600E activates the MAPK pathway and modulates MITF function and 
melanocytes’ differentiation [462]. A relationship between BRAF mutation and 
ulceration is rarely seen, but Akslen et al. reported that primary tumours with BRAF 
mutation were more often ulcerated than wild type tumours [463].  
 
Solar elastosis (SE) reflects cumulative UV exposure. Many studies showed an 
inverse relationship between BRAF mutation and SE [449, 455, 457, 459, 462]. 
However, there was no correlation between SE and BRAF mutation in my study, 
perhaps due to the small sample size. It still needs to be determined whether UVR 
causes BRAF mutations since there are both arguments against and for this 
association.  
 
The arguments against the association are: first, the most common BRAF V600E 
mutation results from a single base-pair substitution (T>A) while the typical 
mutations caused by UVR are C>T/CC>TT; secondly, the BRAF mutation also 
occurs frequently in other cancers, such as thyroid, ovarian and colon cancer, which 
arise in the absence of UVR [448]. 
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On the other hand, there are arguments that support the association that the BRAF 
mutation is the result of UVR. It was proposed that T>A mutation could arise from 
error-prone replication of UV-damaged DNA [458]. BRAF mutation is often seen in 
cutaneous melanoma but not in uveal and mucosal melanomas indicating that it is 
related to UVR. Moreover, BRAF mutation is common in sites that receive 
intermittent UVR (trunk and extremities), whereas it is rarely seen in locations that 
receive the lowest (mucosa) and highest (face) sun exposure. Other theories are: 
BRAF mutations may result from reactive oxygen species, which may be produced 
as a by-product of melanomagenesis or by pheomelanin absorption of UVA [458]; 
BRAF mutation is linked to inflammation that may result from sunburn; the fact that 
melanocytic lesions have a high frequency of BRAF mutation may be explained by 
UVR triggering a stronger proliferative response in melanocytes with an activating 
BRAF mutation than in neighbouring cells with wild type BRAF, further promoting 
melanoma progression in UV-exposed sites [464, 465].  
 
Prior to my study, some studies correlated BRAF mutation to Clark level, a previous 
prognostic marker. However, there was no evidence showing that the presence of 
BRAF mutation affects survival [461, 466]. Using Kaplan Meier survival analysis, 
my results showed melanoma patients with BRAF mutation had shorter trends of 
overall survival and melanoma survival compared to patients without BRAF 
mutation, although the difference was not significant. The analysis also showed that 
patients with BRAF V600E mutation had significantly shorter melanoma-recurrence 
free times than patients without BRAF mutation. However, if the patient survival had 
been monitored over a longer period then the presence of the BRAF mutation may 
have become significant. 
 
As mentioned in Chapter 1, personalised therapy has become the hope for curing 
cancer. Several strategies for inhibiting MAPK signalling, including RAF kinase 
inhibitors and MEK inhibitors, are now being evaluated clinically in melanoma 
therapy. The limited activity of sorafenib in tumours with BRAF mutation prompted 
the development of second-generation RAF inhibitors with greater selectivity for 
mutant BRAF. Vemurafinib (PLX4032) is a potent inhibitor of mutated BRAF. It has 
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marked antitumour effects against melanoma cell lines with the BRAF V600E 
mutation, but not against cells with wild type BRAF [467]. Phase 1 and 2 clinical 
trials with Vemurafinib have shown response rates of more than 50% in patients with 
metastatic melanoma with the BRAF V600E mutation. A very recent report of the 
drug in a Phase 3 trial showed that Vemurafinib improved rates of overall and 
progression-free survival in patients with previously untreated melanoma with BRAF 
V600E mutation compared to the Dacarbazine group [467]. Besides the most 
common adverse events such as arthralgia, fatigue and photosensitive skin reactions 
of grade 2 or 3 that were seen in 12% of the patients, 18% of patients developed at 
least one squamous cell carcinoma of the skin or keratoacanthoma. One of the 
suggested mechanisms was linked to the observation that drugs that selectively 
inhibit BRAF drive RAS-dependent BRAF binding to CRAF and CRAF activation 
and MEK-ERK signalling when BRAF is inhibited in the presence of oncogenic 
RAS. Another problem that needs to be clarified is that melanomas become resistant 
to Vemurafinib. Studies from several groups have indicated that the MAPK pathway 
can be reactivated in resistant tumours, although the precise mechanisms of 
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Chapter 6: Summary 
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6.1 General discussion 
 
My work presented in this thesis focused on two types of molecules: melanoma-
specific miRNAs and oncogenic BRAF. In Chapter 3, a melanoma-specific miRNA 
expression profile was established and miRNA biomarker candidates were verified. 
Studies in Chapter 4 identified three miRNAs acting as tumour suppressors in 
melanomagenesis. The work in Chapter 5 determined the prevalence of BRAF 
mutation based on our TMA panel and correlated it with clinicopathological 
signatures and melanoma patient survival. The investigation of these key non-coding 
and coding genes improves our understanding of the molecular pathogenesis of 
cutaneous melanoma, identifies novel miRNA biomarker candidates in both 
diagnosis and prognosis, and may help us to develop more effective therapeutic 
interventions for cutaneous melanoma.   
 
miRNAs are highly conserved, indicating their important roles in basic cellular 
processes. miRNA alterations have been observed in all forms of cancer. High 
throughput analyses identified specific miRNA expression patterns in various 
cancers, suggesting that miRNA expression profiles are tissue-specific and possess 
diagnostic value.  Additionally, miRNA expression profiling can be utilized to 
determine cancer prognosis. More importantly for studies on melanoma where access 
to fresh frozen tissue is limited, reproducible miRNA expression profiles from FFPE 
samples can be obtained that are comparable to those from fresh frozen samples. 
Against this background, I carried out a miRNA microarray study. I consider my 
miRNA profiling study to be the best melanoma-specific miRNA profile so far 
because it detects the most miRNA probes, has the most FFPE samples, contains 
complete stages in melanoma progression and is verified by qPCR. Through this, I 
obtained a melanoma-specific miRNA expression profile based on FFPE samples. 
This profile established a number of miRNAs that were differentially expressed 
between benign naevi and melanomas and showed high potential in melanoma 
diagnosis, where morphological separation is particularly difficult for certain types of 
melanocytic lesion. Therefore, in a further study of miRNA diagnostic roles in 
melanoma, expression of five miRNAs was determined using qRT-PCR in FFPE 
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samples of additional types of these melanocytic lesions, including Blue naevus, 
Spitz naevus and dysplastic naevus. Possibly due to the limitation of very small 
sample size, I did not identify a miRNA that can separate the different melanocytic 
lesions clearly. However, I believe that such an approach could still be helpful 
diagnostically if large sample numbers are used and the use of miRNA in-situ 
hybridization (ISH) for miRNA detection can be developed to eliminate the need for 
RNA extraction from very small lesions such as in-situ melanoma. Moreover, in an 
attempt to identify miRNAs with prognostic value, a comparison between non-
recurrent and recurrent primary melanoma was performed. Again, increasing sample 
numbers will be needed to identify differentially expressed miRNAs. In addition, 
retrieving the detailed survival records of the primary melanoma patients would be 
needed for further analysis to correlate differentially expressed miRNAs with patient 
survival.  
 
One of the most important mechanisms of miRNA action is to stimulate mRNA 
cleavage resulting in mRNA degradation. miRNAs have been shown to target both 
tumour suppressors and oncogenes to influence cancer development. Some miRNAs 
can have opposite effects in different cancers, or can switch between these two 
functions and act as a tumour suppressor at one time and an oncogene at another 
time. Thus, altering miRNA expression could to be a novel treatment for cancers.  
 
23 miRNAs were identified as candidates for follow on functional studies from the 
differentially expressed miRNAs between benign naevi and malignancies. Nine 
miRNAs from the 23 candidates were verified by qRT-PCR and four of them were 
taken on into functional assays. Interestingly, ectopic overexpression of miR-200c 
and miR-205 in melanoma cells inhibited anchorage independent colony forming 
ability. Moreover, elevation of miR-200c resulted in increased expression levels of 
E-cadherin through negative regulation of the ZEB2 gene. Ectopic overexpression of 
miR-211 in melanoma cells repressed both colony formation and migratory ability. 
These findings indicate that miR-200c, miR-205 and miR-211 may act as tumour 
suppressors in melanomagenesis, which could make these miRNAs potential targets 
for melanoma therapy. Further studies, such as investigating more melanoma cell 
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lines, constructing stable cell lines with ectopic expression of these miRNAs, and 
animal models would be needed to confirm the above association between these 
miRNAs and melanomagenesis, and would be useful to address additional questions 
that I have not been able to answer. For example, in my transient expression assays, 
mRNA level changes of N-cadherin were not observed and there was difficulty in 
detecting a change in E-cadherin protein levels. However, using miR-200c precursor 
transfected stable cell lines it may be possible to see decreased mRNA and protein 
levels of N-cadherin, which would suggest that miR-200c influences the EMT 
process through both mRNA and protein level changes of E-cadherin. 
 
Oncogenic BRAF, which activates the MAPK pathway and results in tumour 
development, has been well studied in recent years. BRAF mutations are common in 
benign melanocytic naevi, primary and metastatic melanomas. The BRAF V600E 
mutation accounts for the majority of BRAF mutations. Based on the samples from 
our TMA panel, 20% and 69% BRAF V600E mutations were found in primary and 
metastatic melanoma, respectively. The correlation between BRAF mutation and 
clinicopathological features varies according to different reports. In our study, the 
presence of BRAF mutation was associated with gender and pigmentation. It was 
related to Breslow thickness when the lesion was thicker than 2mm. In assessing the 
BRAF mutation’s prognostic value, patients with BRAF V600E mutations have 
melanoma relapse earlier than those without the mutation. However, no evidence 
showing that there was correlation between BRAF mutations and overall survival 
and melanoma-specific survival was found in our sample panel. This additional study 
is a useful supplement to further understanding of the role of the BRAF mutation in 
melanoma. 
 
In Caramuta’s study, miRNA expression profiles were associated with clinical 
characteristics, patient survival, and mutational status for BRAF and NRAS [358]. 
Therefore, it would have been interesting to investigate whether there were 
expression level differences for the melanoma-specific miRNAs I identified between 
patients with mutated BRAF and patients with wild type BRAF and whether such 
differences affected survival. However, there were only a very few samples in 
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common between the miRNA and BRAF project and so no such analysis was 
possible.  This did not reflect bad experimental design, but rather that insufficient 
material was available from the large number of thin primary melanomas in the TMA 




6.2 Future work 
 
Following on from the work described in the thesis, especially for the miRNA 
project, there remains a need for further research. First is to develop and use miRNA 
ISH on our melanoma TMA panel. miRCURY LNA™  detection probes have been 
successfully used in various types of samples, including FFPE tissues [468], although 
it is a difficult work technically. I believe that miRNAs can be used in conjunction 
with conventional histology to facilitate the diagnosis of melanocytic lesions. 
Applying ISH on conventional FFPE patient samples to the best miRNA markers I 
have identified by microarray and qRT-PCR is a feasible approach to achieve the 
goal. Using miRNA ISH, it may be able to answer the questions: whether the 
miRNA expression patterns I obtained by microarray and verified by qPCR are 
supported by miRNA ISH expression patterns; whether using miRNA ISH can 
discriminate between various type of melanocytic lesions; whether the best miRNA 
biomarker candidates detected by miRNA ISH can be used as a routine diagnostic 
tool clinically.  
 
Secondly, functional studies using stable cell lines and research experiments in vivo 
are necessary. The tumour suppressor functions of the two most interesting miRNAs, 
miR-200c and miR-211, can be verified and further investigated using stable cell 
lines transfected with miR-200c and miR-211 vectors. Long-term observations can 
be made using the anchorage independent colony formation assay. Moreover, tumour 
growth can be measured after stable cells are injected subcutaneously into nude mice. 
miRNA target studies at both the mRNA and protein level can also be carried out for 
longer time courses with a coupled luciferase assay that can confirm direct targets. 
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The above work would be valuable and necessary to establish the case for using 
miRNAs as future treatments for melanoma. 
 
The studies I presented in the thesis were mostly directed to the downstream effects 
of miRNAs. However, miRNA regulation is an important topic, which is crucial in 
carcinogenesis. Epigenetic alterations are widely described as essential players in 
cancer progression. Such epigenetic modification mainly results in aberrant gene 
expression due to DNA methylation or histone deacetylation. Mis-expression of 
miRNAs is partially dependent on epigenetic regulation. Therefore, it would be 
essential to study methylation or histone deacetylation status of the miRNA gene 
candidates from my miRNA expression profile. A most recent paper reported that the 
miR-200 family, especially miR-200c and miR-205 loci, are specifically silenced and 
gain promoter hypermethylation and repressive chromatin marks in muscle invasive 
bladder tumours and undifferentiated bladder cell lines [469]. The questions of 
whether these miRNA genes are silenced and methylated in melanoma and whether 
correcting this is required for cure of melanoma need to be answered. 
 
Other work would involve: target studies of aberrant miRNAs using gene expression 
array or protein array on cells with ectopic miRNA expression; functional studies of 
miR-675, miR-203 or other differentially expressed miRNAs; and further study on 
miR-20b under different oxygen conditions. Moreover, it was found that miRNAs 
are present in the circulation of humans and other animals [470]. miRNAs can be 
used as biomarkers in blood and other biofluids, and the potential role of detecting 
miRNA expression in body fluids could be an important non-invasive tool for early 
cancer detection [471].  
 
In conclusion, the investigation of both non-coding and coding genes improves our 
understanding in cutaneous melanomagenesis. Established miRNA biomarker 
candidates would be useful clinically in both diagnosis and prognosis. Finally, the 
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                           (A) 
Naevus ID Yield (ng) 260/280 Ratio 
67955 1287 1.90 
70975 996 1.78 
67936 2176 1.91 
68519 2838 2.06 
68641 2285 2.02 
59981 5748 2.06 
68554 512 1.58 
68555 698 1.88 
67773 775 2.00 
68623 944 1.85 
64554 1350 1.59 
64337 1453 1.82 
64403 1215 1.88 
64196 1361 1.90 
64240 1876 1.85 
64878 2967 1.91 
64880 1148 1.81 
64442 1576 1.88 
 
 
                           (B) 
Primary ID Yield (ng) 260/280 Ratio 
RG1 818 2.06 
RG2 1973 2.03 
RG3 2185 2.03 
RG4 1831 2.03 
RG5 727 2.02 
RG6 1167 2.08 
RG7 2305 1.87 
RG8 1822 2.05 
RG9 1275 1.97 
Non 
 
RG10 1162 1.96 
RG11 1916 2.07 
RG12 1949 2.04 
RG13 1224 2.00 
RG14 1403 2.00 
RG15 567 2.07 
RG16 1647 2.06 
RG17 2169 2.01 
 
Re 
RG18 1633 2.06 
 
 228 
RG19 2188 2.07  
RG20 1768 2.05 
 
 
                          (C) 
Metastatic ID Yield (ng) 260/280 Ratio 
07117 2297 2.00 
M4 6008 1.91 
M5 5428 2.02 
M6 1670 2.04 
M7 1133 2.01 
M11 1190 1.82 
M17 2407 2.01 
M29 5607 2.04 
M31 1612 1.89 
M33 657.5 1.75 
M34 4915 1.96 
M36 4970 1.96 
M38 833 1.86 
M39 690 1.59 
M41 1185 1.94 
M42 1340 1.73 
M44 2095 1.98 
M48 4050 1.96 
M53 2608 1.78 
M54 2020 1.93 
M57 1423 1.93 
 
 
                          (D) 
Other naevus ID Yield (ng) 260/280 Ratio 
Blue-07619 350 1.98 
Blue-03401 216 1.76 
Blue-03390 484 1.73 
Blue-18434 359 1.88 
Spitz-08007 437 1.59 
Spitz-27937 1563 1.75 
Dysplastic-14013 1381 1.71 
Dysplastic-14568 1116 1.73 
 
The FFPE samples used in microarray and qPCR. The four tables list the yields and 260/280 ratios 
of all FFPE tissues: (A) Naevi; (B) Primary melanomas (Non: non-recurrent melanoma, Re: recurrent 
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The clustering heatmap for all the microRNAs on all the samples on the microarray. Horizontal: 











          (A) Comparison between primary melanoma and naevi 




1 solexa-2580-353 3.52E-13 4.08E-16 -2.67 8.51 
2 solexa-8048-104 1.45E-12 4.51E-15 3.72 13.27 
3 hsa-miR-603 1.45E-12 5.06E-15 2.79 11.71 
4 solexa-2683-338 5.33E-12 2.47E-14 4.05 11.83 
5 HS_29 9.76E-11 5.66E-13 3.86 12.90 
6 hsa-miR-663b 7.04E-10 4.90E-12 3.43 12.22 
7 hsa-miR-1826 8.69E-10 7.06E-12 2.23 13.60 
8 hsa-miR-200b* 1.26E-09 1.17E-11 -3.52 9.32 
9 hsa-miR-1308 1.69E-09 1.76E-11 0.81 14.56 
10 solexa-578-1915 2.47E-09 3.10E-11 3.50 11.78 
11 hsa-miR-183 2.47E-09 3.15E-11 -3.06 8.96 
12 hsa-miR-149 5.13E-07 7.15E-09 -2.41 9.12 
13 hsa-miR-200a 1.55E-06 2.34E-08 -2.79 9.52 
14 hsa-miR-205 2.49E-06 4.05E-08 -2.44 11.34 
15 HS_22.1 4.35E-06 7.57E-08 2.28 13.07 
16 hsa-miR-675 4.87E-06 9.04E-08 3.06 11.11 
17 hsa-miR-99a 6.97E-06 1.39E-07 -2.03 11.84 
18 hsa-miR-200b 6.97E-06 1.46E-07 -3.04 11.83 
19 HS_33 7.20E-06 1.59E-07 1.87 10.44 
20 hsa-miR-455-5p 8.39E-06 1.95E-07 -2.45 9.60 
21 HS_263.1 1.10E-05 2.68E-07 1.12 13.78 
22 hsa-miR-182 1.76E-05 4.48E-07 -2.82 9.69 
23 hsa-miR-203 2.91E-05 7.75E-07 -2.62 10.88 
24 hsa-miR-494 4.99E-05 1.39E-06 2.91 11.36 
25 hsa-miR-145 8.96E-05 2.60E-06 -0.91 13.85 
26 HS_35 1.42E-04 4.27E-06 2.76 9.23 
27 hsa-miR-455-3p 1.93E-04 6.03E-06 -2.13 12.51 
28 hsa-miR-20b 2.55E-04 8.28E-06 2.43 11.16 
29 hsa-miR-95 3.54E-04 1.19E-05 1.40 13.50 
30 hsa-miR-888 3.97E-04 1.38E-05 -1.86 8.85 
31 hsa-miR-891b 4.72E-04 1.70E-05 -1.34 8.12 
32 hsa-miR-141 5.14E-04 1.91E-05 -2.16 10.03 
33 hsa-miR-519e* 6.76E-04 2.59E-05 1.88 8.92 
34 hsa-miR-198 7.98E-04 3.15E-05 2.45 9.09 
35 hsa-miR-195 9.29E-04 3.77E-05 -1.80 12.92 
36 hsa-miR-923 9.86E-04 4.16E-05 0.88 14.11 
37 hsa-miR-224 9.86E-04 4.23E-05 -2.54 10.13 
38 hsa-miR-378 1.02E-03 4.50E-05 -2.02 12.21 
39 HS_43.1 1.30E-03 5.86E-05 1.09 8.92 
40 hsa-miR-1285 1.32E-03 6.12E-05 2.65 12.37 
41 hsa-miR-1273 1.41E-03 6.72E-05 2.89 11.67 
42 HS_143 1.48E-03 7.21E-05 2.05 10.69 
43 hsa-miR-154 1.98E-03 9.87E-05 -1.63 8.58 
44 hsa-miR-200c 2.12E-03 1.08E-04 -1.41 13.04 
45 hsa-miR-30c-1* 2.55E-03 1.33E-04 1.76 13.84 
46 hsa-miR-876-3p 2.68E-03 1.43E-04 -1.90 9.48 
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47 solexa-3927-221 2.97E-03 1.62E-04 0.58 14.29 
48 hsa-miR-139-5p 3.85E-03 2.14E-04 -1.79 10.41 
49 hsa-miR-1274a 4.02E-03 2.34E-04 0.47 14.65 
50 hsa-miR-429 4.02E-03 2.34E-04 -1.75 9.14 
51 hsa-miR-1248 4.02E-03 2.38E-04 2.36 10.94 
52 hsa-miR-497 4.65E-03 2.81E-04 -1.78 10.14 
53 hsa-miR-29b-2* 5.05E-03 3.11E-04 -1.07 8.39 
54 HS_78 5.06E-03 3.20E-04 0.99 9.33 
55 HS_40 5.06E-03 3.29E-04 -0.87 9.59 
56 hsa-miR-125b 5.06E-03 3.29E-04 -0.59 14.39 
57 hsa-miR-885-5p 5.42E-03 3.58E-04 -1.07 8.25 
58 hsa-miR-27b* 5.53E-03 3.72E-04 -1.18 9.94 
59 hsa-miR-204 5.58E-03 3.82E-04 -1.52 11.18 
60 HS_100 5.69E-03 3.96E-04 0.26 14.55 
61 hsa-miR-140-3p 6.57E-03 4.69E-04 -1.19 12.83 
62 hsa-miR-1300 6.57E-03 4.73E-04 1.51 9.77 
63 hsa-miR-27a* 7.44E-03 5.44E-04 -1.09 9.41 
64 hsa-miR-1249 8.38E-03 6.22E-04 -1.59 11.76 
65 hsa-miR-431 8.51E-03 6.41E-04 -1.15 8.85 
66 hsa-miR-1290 8.66E-03 6.63E-04 -1.82 10.12 
67 hsa-miR-189:9.1 8.71E-03 6.77E-04 -1.14 10.82 
68 hsa-miR-365 8.91E-03 7.03E-04 -1.15 11.23 
69 solexa-2952-306 1.12E-02 9.02E-04 0.32 14.28 
70 solexa-5620-151 1.12E-02 9.07E-04 1.67 9.22 
71 hsa-miR-567 1.16E-02 9.67E-04 -0.52 8.39 
72 solexa-826-1288 1.16E-02 9.72E-04 1.90 10.26 
73 solexa-15-44487 1.34E-02 1.14E-03 0.92 10.32 
74 solexa-8211-102 1.36E-02 1.17E-03 1.47 13.46 
75 solexa-555-1991 1.37E-02 1.19E-03 0.74 13.34 
76 hsa-miR-127-3p 1.84E-02 1.63E-03 -1.06 8.74 
77 hsa-miR-639 1.84E-02 1.64E-03 1.38 8.60 
78 hsa-miR-565:9.1 1.88E-02 1.70E-03 0.63 14.07 
79 HS_112 2.16E-02 1.98E-03 1.03 8.29 
80 hsa-miR-576-3p 2.19E-02 2.03E-03 1.12 9.11 
81 HS_241.1 2.34E-02 2.20E-03 1.47 10.45 
82 hsa-miR-125b-2* 2.38E-02 2.26E-03 -1.25 8.51 
83 hsa-miR-199a*:9.1 2.43E-02 2.34E-03 -0.89 13.36 
84 hsa-miR-9* 2.67E-02 2.60E-03 1.33 10.89 
85 HS_126 2.82E-02 2.78E-03 0.96 8.61 
86 hsa-miR-1228* 2.89E-02 2.89E-03 0.48 13.89 
87 solexa-4793-177 3.15E-02 3.21E-03 1.16 12.26 
88 hsa-miR-140-5p 3.15E-02 3.22E-03 -1.53 10.87 
89 HS_186 3.21E-02 3.31E-03 -0.82 9.65 
90 hsa-miR-25* 3.29E-02 3.43E-03 0.80 9.97 
91 hsa-miR-9 3.59E-02 3.85E-03 1.87 10.76 
92 hsa-miR-218 3.59E-02 3.85E-03 -1.49 10.61 
93 hsa-miR-342-5p 3.59E-02 3.87E-03 -1.25 11.40 
94 hsa-miR-591 3.86E-02 4.24E-03 0.81 9.49 
95 HS_196.1 3.86E-02 4.26E-03 1.11 8.55 
96 HS_188 4.15E-02 4.70E-03 1.42 10.95 
97 hsa-miR-100 4.15E-02 4.71E-03 -0.86 13.64 
98 hsa-miR-335 4.15E-02 4.72E-03 0.90 11.76 
99 hsa-miR-196a* 4.29E-02 4.95E-03 0.83 8.34 
100 hsa-miR-28-3p 4.29E-02 4.97E-03 -1.03 12.42 
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101 HS_31.1 4.40E-02 5.19E-03 1.05 9.40 
102 hsa-miR-181a-2* 4.40E-02 5.20E-03 -1.44 10.97 
103 hsa-miR-139-3p 4.60E-02 5.52E-03 -0.69 8.42 
104 hsa-miR-744* 4.60E-02 5.55E-03 -0.36 8.34 
105 hsa-miR-921 4.91E-02 6.10E-03 -0.73 8.46 
106 hsa-miR-875-5p 4.91E-02 6.11E-03 -0.56 8.87 
107 hsa-miR-664 4.91E-02 6.11E-03 0.65 13.49 
108 hsa-miR-767-5p 4.91E-02 6.19E-03 1.21 10.43 
109 HS_116 4.91E-02 6.30E-03 1.66 10.65 
111 hsa-miR-147b 4.91E-02 6.33E-03 -0.99 9.06 
112 hsa-miR-335* 4.91E-02 6.35E-03 -1.13 8.90 
113 hsa-miR-873 4.91E-02 6.40E-03 -1.31 9.33 
 
 
          (B) Comparison between metastatic melanoma and naevi 




1 hsa-miR-205 3.88E-16 4.50E-19 -5.23 11.34 
2 solexa-2580-353 8.42E-16 1.95E-18 -3.03 8.51 
3 hsa-miR-203 2.06E-15 7.18E-18 -6.00 10.88 
4 hsa-miR-183 6.41E-11 2.98E-13 -3.52 8.96 
5 solexa-2683-338 1.19E-10 6.93E-13 3.65 11.83 
6 hsa-miR-200b* 1.27E-10 9.28E-13 -3.78 9.32 
7 hsa-miR-200c 1.27E-10 1.03E-12 -3.13 13.04 
8 hsa-miR-603 1.26E-09 1.17E-11 2.20 11.71 
9 solexa-8048-104 4.64E-09 4.85E-11 2.78 13.27 
10 hsa-miR-1308 2.38E-08 2.76E-10 0.73 14.56 
11 hsa-miR-200b 8.86E-08 1.14E-09 -3.67 11.83 
12 hsa-miR-200a 8.86E-08 1.23E-09 -3.11 9.52 
13 hsa-miR-663b 9.07E-08 1.37E-09 2.81 12.22 
14 HS_29 1.03E-07 1.67E-09 2.93 12.90 
15 solexa-578-1915 4.56E-07 7.94E-09 2.84 11.78 
16 hsa-miR-1826 6.26E-07 1.16E-08 1.70 13.60 
17 hsa-miR-141 2.24E-06 4.42E-08 -2.92 10.03 
18 hsa-miR-149 4.38E-06 9.14E-08 -2.15 9.12 
19 solexa-555-1991 9.09E-06 2.00E-07 1.28 13.34 
20 hsa-miR-95 9.86E-06 2.29E-07 1.71 13.50 
21 hsa-miR-429 1.91E-05 4.66E-07 -2.53 9.14 
22 hsa-miR-21* 2.42E-05 6.17E-07 2.12 9.86 
23 hsa-miR-224 3.06E-05 8.23E-07 -3.16 10.13 
24 hsa-miR-182 3.06E-05 8.52E-07 -2.71 9.69 
25 hsa-miR-142-5p 1.02E-04 2.96E-06 2.26 9.50 
26 hsa-miR-923 2.11E-04 6.36E-06 0.98 14.11 
27 hsa-miR-20b 2.26E-04 7.09E-06 2.43 11.16 
28 hsa-miR-675 2.90E-04 9.43E-06 2.40 11.11 
29 hsa-miR-891b 4.47E-04 1.54E-05 -1.33 8.12 
30 hsa-miR-888 4.47E-04 1.56E-05 -1.83 8.85 
31 hsa-miR-9 5.51E-04 1.98E-05 2.88 10.76 
32 hsa-miR-455-5p 6.04E-04 2.24E-05 -1.89 9.60 
33 hsa-let-7c 8.37E-04 3.21E-05 -0.90 13.81 
34 hsa-miR-9* 1.02E-03 4.00E-05 1.88 10.89 
35 hsa-miR-155 1.02E-03 4.14E-05 1.31 13.28 
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36 HS_100 1.46E-03 6.21E-05 0.29 14.55 
37 hsa-miR-455-3p 1.46E-03 6.44E-05 -1.82 12.51 
38 hsa-miR-873 1.46E-03 6.46E-05 -1.99 9.33 
39 hsa-miR-876-3p 1.57E-03 7.12E-05 -1.98 9.48 
40 hsa-miR-139-5p 1.92E-03 8.90E-05 -1.89 10.41 
41 hsa-miR-548d-5p 2.01E-03 9.58E-05 -1.08 9.71 
42 hsa-miR-1300 2.29E-03 1.12E-04 1.67 9.77 
43 hsa-miR-204 2.58E-03 1.29E-04 -1.64 11.18 
44 HS_264.1 2.85E-03 1.45E-04 0.76 8.56 
45 hsa-miR-567 3.21E-03 1.67E-04 -0.60 8.39 
46 solexa-3927-221 3.42E-03 1.82E-04 0.57 14.29 
47 hsa-miR-1274a 3.45E-03 1.89E-04 0.47 14.65 
48 hsa-miR-365 3.45E-03 1.92E-04 -1.27 11.23 
49 hsa-miR-1321 4.05E-03 2.30E-04 0.45 8.41 
50 HS_108.1 4.26E-03 2.47E-04 -2.18 11.17 
51 hsa-miR-1248 4.67E-03 2.77E-04 2.32 10.94 
52 solexa-826-1288 4.71E-03 2.84E-04 2.09 10.26 
53 hsa-miR-193b 4.96E-03 3.05E-04 -1.62 12.93 
54 solexa-15-44487 6.83E-03 4.28E-04 1.00 10.32 
55 HS_33 7.55E-03 4.87E-04 1.14 10.44 
56 HS_114 7.55E-03 4.90E-04 -0.62 8.94 
57 hsa-miR-1290 8.11E-03 5.51E-04 -1.84 10.12 
58 hsa-miR-142-3p 8.11E-03 5.52E-04 1.55 12.74 
59 hsa-miR-508-3p 8.11E-03 5.55E-04 -2.56 12.66 
60 hsa-miR-99a 8.14E-03 5.67E-04 -1.21 11.84 
61 hsa-miR-10a* 8.14E-03 5.76E-04 1.32 10.40 
62 hsa-miR-211 8.75E-03 6.29E-04 -2.37 12.93 
63 hsa-miR-23b* 9.27E-03 6.77E-04 -1.40 8.93 
64 HS_75.1 9.70E-03 7.20E-04 -1.07 8.69 
65 hsa-miR-767-5p 9.91E-03 7.47E-04 1.51 10.43 
66 HS_93 1.02E-02 7.84E-04 0.77 8.81 
67 HS_43.1 1.02E-02 7.94E-04 0.88 8.92 
68 HS_78 1.02E-02 8.07E-04 0.91 9.33 
69 hsa-miR-449a 1.02E-02 8.20E-04 -1.69 8.93 
70 hsa-miR-513:9.1 1.16E-02 9.46E-04 -2.10 9.97 
71 hsa-miR-509-3p 1.24E-02 1.02E-03 -2.31 13.39 
72 hsa-miR-27a* 1.24E-02 1.04E-03 -1.02 9.41 
73 HS_194 1.25E-02 1.06E-03 -1.00 8.20 
74 hsa-miR-154 1.30E-02 1.12E-03 -1.32 8.58 
75 hsa-miR-506 1.32E-02 1.15E-03 -2.39 12.17 
76 hsa-miR-542-3p 1.37E-02 1.21E-03 1.12 9.52 
77 hsa-miR-137 1.38E-02 1.23E-03 0.95 10.32 
78 HS_263.1 1.39E-02 1.26E-03 0.64 13.78 
79 hsa-miR-618 1.41E-02 1.29E-03 0.76 9.33 
80 HS_40 1.46E-02 1.35E-03 -0.76 9.59 
81 HS_22.1 1.57E-02 1.47E-03 1.21 13.07 
82 hsa-miR-146b-3p 1.62E-02 1.54E-03 0.50 8.71 
83 hsa-miR-105 1.63E-02 1.57E-03 1.14 10.81 
84 hsa-miR-189:9.1 1.70E-02 1.66E-03 -1.04 10.82 
85 hsa-miR-513a-5p 1.95E-02 1.92E-03 -1.55 11.46 
86 hsa-miR-196a 2.03E-02 2.03E-03 1.43 13.41 
87 hsa-miR-1249 2.11E-02 2.14E-03 -1.40 11.76 
88 hsa-miR-27b 2.11E-02 2.16E-03 -0.86 13.49 
89 hsa-miR-664 2.79E-02 2.88E-03 0.71 13.49 
90 hsa-miR-885-5p 3.13E-02 3.28E-03 -0.86 8.25 
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91 hsa-miR-1202 3.13E-02 3.31E-03 0.44 8.40 
92 HS_241.1 3.24E-02 3.46E-03 1.39 10.45 
93 hsa-miR-16-1* 3.38E-02 3.65E-03 0.83 10.12 
94 hsa-miR-801:9.1 3.81E-02 4.15E-03 0.70 8.69 
95 hsa-miR-513c 4.08E-02 4.50E-03 -1.58 9.62 
96 hsa-miR-199a*:9.1 4.17E-02 4.64E-03 -0.81 13.36 
97 hsa-miR-147b 4.94E-02 5.56E-03 -0.99 9.06 
 
 
          (C) Comparison between metastatic and primary melanoma 




1 hsa-miR-205 4.42E-09 6.64E-12 -2.79 11.34 
2 hsa-miR-203 4.42E-09 1.03E-11 -3.38 10.88 
3 hsa-miR-145 4.16E-06 1.45E-08 0.97 13.85 
4 hsa-miR-200c 2.71E-05 1.26E-07 -1.72 13.04 
5 hsa-miR-142-5p 7.14E-04 4.14E-06 1.86 9.50 
6 hsa-miR-519e* 2.11E-03 1.47E-05 -1.62 8.92 
7 hsa-miR-198 5.06E-03 4.11E-05 -2.00 9.09 
8 hsa-miR-21* 1.22E-02 1.19E-04 1.30 9.86 
9 hsa-miR-452 1.22E-02 1.27E-04 -1.24 9.52 
10 hsa-miR-1296 1.96E-02 2.28E-04 1.77 9.60 
11 hsa-miR-509-3p 2.11E-02 2.76E-04 -2.17 13.39 
12 hsa-miR-150 2.11E-02 3.10E-04 1.01 14.05 
13 hsa-miR-19a 2.11E-02 3.19E-04 1.41 10.40 
14 hsa-miR-22 3.42E-02 5.55E-04 0.74 12.69 
15 hsa-miR-506 4.46E-02 7.76E-04 -2.09 12.17 
16 hsa-miR-542-5p 4.49E-02 8.77E-04 1.53 9.70 
17 HS_22.1 4.49E-02 8.95E-04 -1.07 13.07 
18 HS_143 4.49E-02 9.39E-04 -1.39 10.69 
19 hsa-miR-558 4.79E-02 1.15E-03 1.31 9.80 
20 hsa-miR-29c 4.79E-02 1.22E-03 1.14 13.03 
21 hsa-miR-28-3p 4.79E-02 1.27E-03 0.99 12.42 
22 HS_132.1 4.79E-02 1.32E-03 -1.28 9.60 
23 hsa-miR-514 4.79E-02 1.32E-03 -2.47 12.60 
24 hsa-miR-494 4.79E-02 1.33E-03 -1.51 11.36 
25 hsa-miR-140-3p 4.79E-02 1.39E-03 0.89 12.83 
 
Differentially expressed miRNAs in three comparisons. The three tables list all the differentially 
expressed miRNAs: (A) Primary melanoma versus naevi; (B) Metastatic melanoma versus naevi; (C) 
Metastatic versus primary melanoma. P value: from t-test. Adjusted P: adjusted P value is the way to 
correct for multiple testing. Log2 FC: Log2 Fold Changes (In X vs. Y comparison, when Y>X, log2 FC 
is negative, when Y<X, log2 FC is positive. Average Intensity: stands for the average signal intensity 
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Validation of ΔΔCt method for miRNA expression relative to miR-92 as endogenous control. 
Relative efficiency plots: (A) miR-203 vs. miR-92; (B) miR-205 vs. miR-92; (C) miR-200b vs. miR-
92; (D) miR-200c vs. miR-92; (E) miR-211 vs. miR-92; (F) miR-20b vs. miR-92; (G) miR-675 vs. 
miR-92. Using the ΔΔCt method for quantification, a validation experiment was performed on RNA 
extracted from either A375 or HER1 to demonstrate that the PCR efficiencies of target and reference 
were approximately equal. The approach is considered valid if the absolute value of the slope of log 
(dilution factor) vs. ΔCt is <0.1. The slopes obtained for each miRNA indicate that the method used to 
quantify and compare miRNA expression relative to the miR-92 control is valid. X-axis: log10 of 
dilution factor, Y-axis: value of ΔCt ± STDEV. The standard deviation (STDEV) of the quotient here 
is calculated from the standard deviations of target miRNA values and internal control miR-92 values 
using the following formula: STDEVC =  (C: Comparative Method, T: Target, 




























Validation of the ΔΔCt method for mRNA expression relative to beta-actin. Relative efficiency 
plots: (A) ZEB2 vs. Beta-actin; (B) E-cadherin vs. Beta-actin and (C) N-cadherin vs. Beta-actin. 
Using the ΔΔCt method for quantification, a validation experiment was performed on RNA extracted 
from A375 melanoma cells to demonstrate that the PCR efficiencies of target and reference were 
approximately equal. The approach is considered valid if the absolute value of the slope of log10 
(dilution factor) vs. ΔCt is <0.1. X-axis: log10 of dilution factor, Y-axis: value of ΔCt ± STDEV. The 
STDEV of the quotient here is calculated from the standard deviations of mRNA values and internal 
control beta-actin values using the following formula: STDEVC =  (C: 
Comparative Method, T: Target, R: Reference) [316]. 
 
